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ABSTRACT

Laminitis is a crippling disease of horses that can result in chronic lameness and
debilitation, and sometimes warrants euthanasia. It is a complication of inflammatory conditions
such as gastrointestinal disease, and also occurs in obese, insulin-resistant horses with Equine
Metabolic Syndrome (EMS). Inflammation and insulin resistance are risk factors for laminitis,
and these mechanisms might converge to induce laminitis in susceptible animals.
Systemic inflammation is often attributed to endotoxemia, although circulating endotoxin
concentrations are not commonly measured in the clinical setting. Although a theoretic basis
exists for endotoxemia in the pathogenesis of laminitis, administration of endotoxin alone does
not induce the condition. This could be related to differences between experimental models and
naturally occurring disease.
Studies presented in this dissertation address the overall hypothesis that systemic
inflammation causes laminitis and new experimental models can be developed to better represent
clinical disease.

Associations between systemic inflammation and laminitis were first

established by measuring blood inflammatory cytokine expression during a laminitis induction
model. A clinically relevant endotoxin model that induced laminitis was then sought, but
endotoxin administration alone was insufficient to cause laminitis and endotoxin tolerance
developed. Endotoxemia was therefore evaluated in conjunction with predisposing factors such
as obesity. In horses with EMS, endotoxin infusion caused exaggerated inflammatory responses,
and derangements in glucose homeostasis were more pronounced. Laminitis, however, did not
develop. Repeated inflammatory events are implicated in the pathogenesis of sepsis-associated
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organ failure, so a final study was performed to test whether preexisting endotoxemia increased
the risk of laminitis during subsequent carbohydrate overload-induced systemic inflammation.
This did not occur, however systemic inflammation was more pronounced in horses that
developed laminitis compared to non-responders, and tissues rather than circulating leukocytes
appeared to be the major source of inflammatory mediators.
Our results do not support a role for endotoxin as the causal agent of laminitis, even when
combined with predisposing factors. Tissues appear to be an important source of inflammatory
mediators, therefore their role in laminitis should be further characterized. Additionally, future
investigations should determine whether exaggerated inflammatory responses and loss of
glycemic control increase the risk of laminitis in horses with EMS.

Keywords: horse, laminitis, systemic inflammation, endotoxemia, Equine Metabolic Syndrome,
insulin resistance
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CHAPTER 1
Literature Review

Laminitis is a crippling disease of horses that affects 2% of the U.S. horse population, or
180,000 animals, each year.1,2 This condition can result in chronic lameness and debilitation,
and sometimes warrants euthanasia for humane reasons.

Laminitis is a complication of

inflammatory conditions such as gastrointestinal (GI) disease,3 and occurs in conjunction with
obesity, insulin resistance (IR), and endocrine disorders such as Equine Metabolic Syndrome
(EMS) and pituitary pars intermedia dysfunction (PPID).4,5

This review will examine

inflammation and IR as risk factors for laminitis, and will explore how these mechanisms might
converge to induce laminitis in susceptible animals.

1.1 Inflammation

1.1.1 Role of Inflammation in Host Defense Against Pathogens

The inflammatory response is present to protect the body from invasion by pathogens.
Inflammation is a major component of innate immunity and can be thought of as a rapidresponse system that protects the organism from infection until a more specific adaptive immune
response is orchestrated.6-8 Invading pathogens must first breach defenses such as an intact
epithelium, antimicrobial peptides on body surfaces, commensal flora that inhibit pathogen
survival, and secreted antibodies such as immunoglobulin A.8 If successful, the pathogen will
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next encounter a rapid generalized inflammatory response. For simplicity, consider a bacterium.
Once it, or portions of it such as cell wall, gain access to the host, they encounter sentinel cells of
the immune system, including reticuloendothelial cells, mast cells, and neutrophils.9 Other cell
types, such as endothelial cells, are also capable of recognizing and responding to pathogens.10
These cells possess pattern recognition receptors (PRRs), which include toll-like receptors
(TLRs), nucleotide-binding and oligomerization domain-like receptors, and others.11 Pattern
recognition receptors are highly conserved phylogenetically, and recognize molecules called
pathogen associated molecular patterns (PAMPs) that are not found in the host, but are common
to pathogens.12,13 For example, glycolipids such as lipopolysaccharide (LPS) and lipoteichoic
acid are not found in mammals, but are common in bacteria.14 Double stranded ribonucleic acid
(RNA) is also absent in mammals, but found in viruses.15 Pattern recognition receptors may be
at the cell surface or intracellular, depending on the optimal location to recognize their particular
ligand.8,11 Some PRRs also recognize alarmins, which are molecules such as high mobility
group box 1 protein that are produced by distressed host cells.16,17 Pattern recognition receptors
then trigger inflammatory signaling cascades leading to transcription of genes involved in killing
the invading pathogen.11 For example, many of the cytokines produced by nuclear factor κB
(NFκB) activation, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, and IL8, are essential for the innate immune response.18,19

Most cytokines have pleotropic and

redundant functions, and usually work in combinations to elicit responses from target cells. 20
Responses elicited by pro-inflammatory mediators include 1) leukocyte attachment, rolling, and
extravasation from the vasculature into tissues through expression of leukocyte and endothelial
cell surface adhesion molecules, 2) enhancement of neutrophil and macrophage respiratory burst
and phagocytic activity, 3) enhancement of macrophage and dendritic cell antigen presentation,
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4) acute-phase protein production, 5) activation of coagulation that helps to sequester the
infection, and 6) activation of complement components that neutralize invaders through
agglutination, opsonization by phagocytic cells, and lysis via membrane attack complexes.8
The specific PRRs stimulated by a pathogen dictate the cytokine expression profile
induced in an antigen-presenting cell, causing activated cells such as macrophages to begin
secreting cytokines accordingly to the type of pathogen encountered.6,7 The specific cytokine
profile then determines the adaptive immune response by directing lymphocyte development. 6,7
The initial innate immune response is activated very rapidly and is therefore invaluable to
clearing pathogens.8 Its major limitation is that the response is the same regardless of the
inciting source. This lack of specificity towards the antigen or microbe can ultimately become
detrimental, as with sepsis and organ failure, because a massive inflammatory response can
damages organs to the point that death occurs.21,22 Innate immune responses are designed to
clear pathogens rapidly, or at least to hold them at bay until the adaptive immune response can
develop.
The adaptive immune response is centered around lymphocytes.23 Macrophages and
other host cells that have encountered an antigen or pathogen present it on their surfaces in
association with major histocompatibility molecules (MHCs).23 Class I MHC is present on all
nucleated cells, whereas class II is only present on antigen presenting cells. Interaction of a
lymphocyte with MHC-associated antigen on an antigen presenting cell, in conjunction with costimulatory signals received in the form of secreted cytokines, influences lymphocyte
development and clonal expansion. Both B-lymphocyte and T-lymphocyte lineages have the
capacity to develop into either effector or memory cells.23 In the case of B-lymphocytes, effector
cells secrete antibodies with specificity towards the target antigen. T-lymphocytes also become
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either memory cells or effector cells, and include cluster of differentiation (CD) 8+ cytotoxic Tcells and CD4+ T-helper cells. These T-cells also have specificity towards the target antigen.
Cytotoxic T-cells are responsible for directly killing cells such as infected host cells, while Thelper cells secrete cytokines that enhance either B-cell or cytotoxic T-cell function.
Overall, this later adaptive immune response is characterized by activation of the optimal
cells to combat a particular pathogen.6,7 T-helper cells also secrete cytokines involved in downregulation of the initial inflammatory response.24 In the case of severe sepsis, this mechanism of
checks and balances does not occur.19,25 There are two key areas of dysregulation. First, the
initial inflammatory response may be overwhelming, resulting in massive damage to host
tissues.26-28 Second, secretion of anti-inflammatory mediators such as IL-10 and glucocorticoids,
as well as macrophage and neutrophil tolerance during the later phases of sepsis, results in
immunosuppression and death due to secondary infection.27,29-32

1.1.2 Deleterious Effects of Inflammation

On a whole-organism level, activation of the inflammatory cascade leads to the
production of mediators that can damage the endothelium.33-35 A number of clotting factors and
mediators such as plasminogen activator inhibitor-1, which inhibits fibrinolysis and promotes
coagulation, are acute-phase proteins.36

A smooth, undamaged endothelium is largely

responsible for preventing thrombosis under normal conditions.36,37 When activated or damaged,
the endothelium fails to secrete antithrombotic mediators such as antithrombin, Proteins S and C,
and tissue factor pathway inhibitor.35-37 It also expresses abundant tissue factor and adhesion
molecules,35,38,39 leading to a prothrombotic condition in which thrombosis, or disseminated
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intravascular coagulation in severe cases, results in tissue hypoxia.22,25,40-43 Maintenance of
smooth laminar blood flow is important to reduce coagulation in normal vessels.44,45
Inflammation upregulates the activity of enzymes such as phospholipase A2, cyclooxygenase-2
(COX-2), and lipoxygenase.22 Vasoactive lipid derivatives generated by these enzymes include
prostaglandins and thromboxanes that both regulate vascular tone and promote platelet
activation.8,43 Prostaglandins that are upregulated by inflammation alter vascular tone, which
creates turbulent blood flow and promotes coagulation.33,34 Activated neutrophils also contribute
to platelet activation by secreting factors such as cathepsin G.46-48
Vasoactive mediators such as nitric oxide (NO), which is generated by inducible nitric
oxide synthase (iNOS), are responsible for the widespread vasodilation seen in sepsis.43,49
Peripheral vasoconstriction occurs in an attempt to maintain blood pressure, resulting in regional
hypoperfusion and tissue hypoxia.50

Endothelin-mediated vasoconstriction initially helps

maintain blood pressure as well, however excessive endothelin-1 (ET-1) production eventually
induces profound vasoconstriction and contributes to hypoperfusion of tissues.51,52 Also, direct
myocardial suppression occurs during sepsis and further exacerbates microcirculatory perfusion
abnormalities in tissues.53 All of these events can lead to hypoxic damage, which increases cell
stress,

promotes

mitochondrial

dysfunction,

and

further

intensifies

inflammation.54

Reestablishment of blood flow can also lead to reperfusion injury, which is characterized by the
generation of reactive oxygen species (ROS), mitochondrial stress, and subsequent cell
apoptosis.55-57 In addition, complement activation and endothelial cell stimulation increases
vascular permeability and leads to edema.35,58,59
Tissue damage also results from cytokine secretion and subsequent activation of
endothelial cells and neutrophils, either locally due to localized infection or more universally
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with multi-organ failure.21,22 Endothelial cells and neutrophils express adhesion molecules,
including intercellular adhesion molecules, vascular cell adhesion molecules, and integrins.22
Adhesion molecules on both the endothelial cells and neutrophils bind to their integrin ligand
counterparts, causing neutrophils to roll, slow down, and eventually adhere tightly to the vascular
wall.21 Once a tight attachment has formed, neutrophils squeeze through the vessel wall and
enter the tissue. Neutrophils secrete proteases that digest the extracellular matrix and facilitate
movement into tissues.21

They then follow chemotactic factors such as IL-8, complement

component C5a, and bacterial chemoattractants along concentration gradients into tissues.19,60
Once at the site of infection or inflammation, neutrophils begin to phagocytize pathogens and
debris, and generate reactive oxygen and nitrogen species in a process known as the respiratory
burst.8 They also secrete proteolytic enzymes to kill microbial invaders. Unfortunately, these
enzymes are not specific to pathogens, and also kill surrounding host cells. Depending on the
duration of inflammation, macrophages follow a slower progression into tissues, where they
phagocytize necrotic cells and dead neutrophils in an effort to minimize damage to the host. 8
Extensive damage to the tissues can result in organ failure.

1.1.3 Structure of Endotoxin

Lipopolysaccharide, or endotoxin, is a major component of the outer cell membrane of
Gram-negative bacteria, and influences permeability properties that are essential to cell
survival.61 Lipopolysaccharide is a complex glycolipid composed of a hydrophobic lipid A
moiety that anchors the molecule to the outer membrane, a core oligosaccharide chain, and an O-
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antigen polysaccharide chain. The core oligosaccharide and the O-antigen chain are variable,
while the lipid A moiety is more highly conserved among bacterial species.62
The O-antigen polysaccharide is composed of linear or branched homopolymeric or
heteropolymeric glycosyl residues, with a highly variable structural across different bacterial
species and strains.9,62 The O-antigen is not required for bacterial growth in culture, but prevents
phagocytosis and complement-mediated lysis in vivo.9 The core oligosaccharide is more highly
conserved than the O-antigen and is composed of an outer core connected to the O-antigen
region and an inner core that connects to lipid A. Within the core region, the inner core is less
variable, and consists of 3-deoxy-D-manno-octulosonic acid and L-glycero-D-manno-heptose,
while the outer core contains oligosaccharides of 3-deoxy-D-manno-octulosonic acid, L-glyceroD-manno-heptose, D-glucose, and D-galactose.9,62
Lipid A is a unique phosphoglycolipid that is synthesized from UDP-Nacetylglucosamine.9,63

Its structure is highly conserved among Gram-negative species, but

modifications exist that allow bacteria to evade recognition by host innate immune receptors and
resist host-derived antimicrobial peptides and exogenous antibiotics.62 The basic structure is a
phosphorylated (β1-6) homo- or heterodimer of 2,3-diamino-2,3-dideoxy-D-glucose that is
linked to a variable number of 12- to 14-carbon fatty acid chains. However, the degree of
phosphorylation, type of hexosamine incorporated into the disaccharide backbone, and number,
position, and chain length of the fatty acid groups may vary considerably among bacterial
species.9 The most biologically active lipid A configuration consists of two D-gluco-configured
hexosamine residues, two phosphoryl groups, and 6 fatty acid residues.9,64 Lipopolysaccharides
derived from some bacterial species are poorly recognized by the immune system,62 so LPS from
different bacterial strains stimulates different inflammatory mediator profiles.65 Lipid A derived
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from Escherichia coli is a potent activator of innate immune responses in many species,
including the horse.66

1.1.4 Endotoxin Recognition and Intracellular Signaling

Endotoxin is liberated from the outer cell membrane of Gram-negative bacteria as they
proliferate or die and undergo lysis.9 Host innate immune defenses recognize PAMPs such as
the lipid A moiety of LPS that are not found in the host, but are conserved among pathogenic
organisms.12,13 A wide array of host cells recognize LPS, including cells of the immune system
such as monocytes, macrophages, dendritic cells, and granulocytes, as well as endothelial cells
and smooth muscle cells.9 Lipid A represents the toxic component of LPS, and stimulates the
host’s innate immune response (Figure 1.1).67 Lipopolysaccharide from most bacterial species
is recognized by TLR4 in conjunction with cluster of differentiation antigen 14 (CD14) and the
adaptor protein myeloid differentiation factor-2 (MD-2).67-70 Circulating lipopolysaccharide
binding protein (LBP) recognizes the lipid A moiety, forms a high-affinity complex, and
transports LPS to cells that express TLR4, including sentinel cells of the immune system.67,71
Intracellular signaling occurs through a variety of adaptor proteins and culminates with
activation of transcription factors including NFκB, activator protein-1 (AP-1), and interferon
regulatory factor-3 (IRF-3), leading to increased transcription of pro-inflammatory cytokines
and mediators.67,70
Binding of LPS to the TLR4/CD14/MD-2 complex causes the intracytoplasmic toll/IL-1
receptor (TIR) domain of TLR4 to associate with either the adaptor protein myeloid
differentiation factor 88 (MyD88) or an adaptor called TIR-domain-containing adaptor protein
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Figure 1.1 Lipopolysaccharide from most bacterial species is recognized by the TLR4 complex.
Toll-like receptor 4 signaling through the MyD88-dependent and MyD88-independent/TRIF
pathways activates transcription factors and leads to the production of pro-inflammatory
cytokines.

Negative feedback mechanisms, including production of the anti-inflammatory

cytokine IL-10 and the regulatory molecules SOCS3 and BCL3, are also activated. Signaling
cascade components are shaded in light grey, transcription factors are shaded in dark grey, and
negative regulators are shaded in blue. From Biswas SK, Lopez-Collazo E. Endotoxin tolerance:
new mechanisms, molecules and clinical significance. Trends Immunol 2009;30:475-487.
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inducing interferon-β (TRIF).11,12,70,72,73 These diverging pathways are referred to as either
MyD88-dependent or MyD88-independent, and both are capable of capable of upregulating
transcription factors including NFκB because cross-talk occurs between them. However, the
MyD88-dependent arm is responsible for most of the early increase in pro-inflammatory gene
transcription, while the MyD88-independent pathway is concerned with the production of
interferon-β (IFN-β) and late-phase upregulation of cytokines such as TNF-α,12,73,74 as well as
the induction of endotoxin tolerance.70,74-76

The MyD88-independent pathway promotes

endotoxin tolerance by upregulating expression of IL-10 and enhancing production of regulatory
proteins of the MyD88-dependent pathway, including IL-1 receptor-associated kinase (IRAK)M, inhibitor of κB (IκB), B-cell CLL/lymphoma 3 (BCL3), and suppressor of cytokine signaling
(SOCS) proteins.
The MyD88-dependent pathway proceeds from MyD88 through IRAK-4, a serine kinase
which then phosphorylates IRAK-1.12,70,72,73

Interleukin-1 receptor-associated kinase-4

associates with, and activates, TNF receptor-associated factor 6 (TRAF6), which then activates a
complex called transforming growth factor-β activated kinase-1. This leads to activation of 1)
mitogen activated protein kinases (MAPKs) such as c-jun N-terminal kinase (JNK),
extracellular signal-regulated kinase (ERK), or p38 MAPK that ultimately activate the
transcription factor AP-1, or 2) activation of the inhibitor of κB kinase (IKK), which then
phosphorylates IκB.12,70,72,73,77,78 Inhibitor of κB is bound to the transcription factor NFκB, and
when phosphorylated, releases NFκB before being ubiquinated and destroyed. Nuclear factor κB
then dimerizes to form either the active p50/p65 heterodimer or inactive dimers such as the
p50/p50 homodimer, and then translocates to the nucleus where it promotes the expression of
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over 150 genes, many of them inflammatory mediators such as cytokines, iNOS, or inducible
COX-2.
Activation of NFκB induces expression of pro-inflammatory cytokines.79 Receptors for
several of these mediators, including IL-1β and TNF-α, utilize signal transduction cascades very
similar to that of TLR4, and therefore the inflammatory cycle is further perpetuated.8,80-82 Type
1 cytokine receptors, such as the IL-10 receptor, employ Janus Kinase - Signal Transducer and
Activator of Transcription (JAK-STAT) signaling, which also relies on tyrosine phosphorylation
of pathway intermediates.8,83

This pathway ultimately leads to the formation of Signal

Transducer and Activator of Transcription (STAT) dimers that function as nuclear transcription
factors. Communication exists between JAK-STAT and MyD88-dependent pathways. For
example, IFN-β and IL-10 signal through JAK-STAT pathways, upregulating the expression of
interferon-inducible genes, SOCS, and BCL3.

While some of the genes induced are pro-

inflammatory, SOCS and BCL3 provide negative feedback inhibition to both JAK-STAT and
MyD88-dependent signaling pathways.70,74-76

1.1.5 Inflammation and Insulin Resistance

Cross-talk between the insulin signaling cascade and inflammatory signaling cascades
occurs on many levels. Insulin resistance results from inappropriate serine phosphorylation of
insulin receptor substrates (IRSs) or the insulin receptor itself.84

Signaling by the insulin

receptor, as well as TLR4 and cytokine receptors, relies on phosphorylation of
intermediates.67,70,85,86 The residue on which the intermediate is phosphorylated determines
whether the signal is propagated or terminated. With regard to the insulin signaling pathway, the
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insulin receptor is a tyrosine kinase that autophosphorylates itself as well as IRSs, while later
members of the pathway, such as protein kinase B (PKB/Akt) are serine kinases.87
Many of the kinases activated by cytokine receptors and TLRs during inflammation are
serine kinases, the most important to IR being IKK, JNK, and protein kinase C (PKC).82,88-92
Serine kinases phosphorylate insulin signaling pathway components such as IRSs on serine
residues rather than on tyrosine, resulting in inhibition of insulin signaling. Isoforms of PKC are
activated by TRAF6 in inflammatory signaling pathways, diacylglycerol (DAG)-dependent
signaling pathways that are initiated by epinephrine, and during insulin signaling.82,90,93,94 In
addition to direct serine phosphorylation of insulin signaling pathway intermediates, certain PKC
isoforms also activate NFκB and JNK, further promoting inflammation and exacerbating
IR.88,95,96 In addition, SOCS molecules induce IR through one of two mechanisms. Classically,
SOCS proteins bind to IRSs and cause them to be ubiquinated and destroyed,97 but they can also
bind to IRSs and directly inhibit their association with the insulin receptor.98 The inflammatory
cytokine IL-1β exerts additional effects by down-regulating IRS gene and protein expression.99
Glucocorticoids are released as part of the counterregulatory response to inflammation and
sepsis, and induce IR by down-regulating the expression of proteins involved in the
phosphoinositide 3-kinase (PI3-kinase) signaling cascade100,101 and also by interfering with the
function of the PI3-kinase p85 regulatory subunit.102 Glucocorticoids reduce cellular IRS-1 and
PKB/Akt concentrations in adipocytes100,101 and inhibition of glucose transporter (GLUT) 4
translocation to the plasma membrane has been demonstrated.103
Obesity, which is frequently associated with IR, can be regarded as an inflammatory
condition. Pro-inflammatory cytokines are produced by adipose104-106 and liver107-109 tissues of
obese individuals. Abnormalities of the GI flora and reduced hepatic Kupffer cell function in
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obese individuals might also result in higher LPS concentrations in the systemic circulation,
further promoting inflammation.110-112

Also, glucotoxicity91 and higher pro-inflammatory

cytokine concentrations113 promote ROS formation and mitochondrial stress, which further
exacerbate inflammation and activate serine kinases such as IKK and JNK.88-90,114 Mitochondrial
dysfunction in obese individuals may also inhibit oxidation of fatty acids, leading to
accumulation of lipid intermediates such as DAG that activate PKC.55,82,90

1.1.6 Hypothalamic-pituitary axis activation

Activation of hypothalamic-pituitary axis (HPA) occurs as part of the inflammatory
response. Neurons of the paraventricular nuclei of the hypothalamus secrete corticotrophinreleasing hormone, which stimulates the release of adrenocorticotropic hormone (ACTH) from
corticotrophs of the pars distalis.115 Adrenocorticotropic hormone exerts its greatest effect on the
zona fasciculata of the adrenal gland, where it increases the production and release of
glucocorticoids.116 Normally, 67-87% of cortisol is inactive and bound to corticosteroid-binding
globulin, 7-19% is bound to proteins such as albumin, and the remaining 6-14% unbound
hormone is active.117 Neutrophil elastase also liberates biologically active free cortisol from
corticosteroid-binding globulin locally to increase tissue concentrations at sites of
inflammation.118,119

Glucocorticoids affect physiologic processes in most tissues, and the

importance of an appropriate increase in glucocorticoid concentrations during sepsis is illustrated
by the fact that relative adrenal insufficiency has been associated with nonsurvival in several
species, including the horse.120-123 One major role of these hormones is to provide the body with
an adequate energy supply to meet the increased metabolic demands of critical illness.31,124
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Glucocorticoids increase peripheral blood glucose concentrations, increase tissue protein
catabolism, and mobilize fatty acids from adipose depots.
Another major role of glucocorticoids is to down-regulate the inflammatory response and
prevent rampant production of pro-inflammatory mediators during sepsis.31,125 Accordingly,
exaggerated HPA activation is implicated in the immunosuppressive phase of sepsis.27,29,30 To
exert physiologic effects, glucocorticoids must diffuse across plasma membranes and bind to the
carboxyterminal end of a 777-amino acid cytosolic receptor.126 The glucocorticoid-receptor
complex translocates to the nucleus, where it either binds to specific regulatory sequences of
glucocorticoid-responsive genes or interferes with binding of other transcription factions to
promoter sites, thereby modulating gene transcription.126,127 In cells such as monocytes and
lymphocytes, glucocorticoids increase the expression of IκBα, preventing NFκB activation and
down-regulating the production of inflammatory mediators.128,129 Direct inhibitory interaction
between the glucocorticoid-receptor complex and NFκB has also been demonstrated in
endothelial cells.130 Glucocorticoids exert post-transcriptional effects by altering the stability of
messenger RNA (mRNA) and the rate of protein synthesis and release from the cell.126 Most
immune cells exhibit altered function when exposed to glucocorticoids.126 Macrophage and
neutrophil cytokine production and bactericidal activity decrease, neutrophil adhesion and
extravasation are reduced, and lymphocyte proliferation and activity, particularly in the Tlymphocyte subsets, is inhibited. Glucocorticoids also suppress the enzymes phospholipase
A2,131 COX-2,132 and iNOS,133 and dampen the inflammatory response.134
Arginine vasopressin (AVP), which is also called antidiuretic hormone, is produced by
neurons of the supraoptic and paraventricular nuclei of the hypothalamus and is a major regulator
of systemic blood pressure and osmolarity.135,136 Circulating AVP increases during shock and
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helps maintain perfusion to vital organs by inducing profound vasoconstriction in certain
vascular beds.137 Higher AVP concentrations are detected in septic and critically ill equine
neonates.120

Increased release of AVP and oxytocin from the hypothalamus has been

demonstrated in adult horses following administration of a single intravenous LPS bolus.138 The
mechanisms underlying this increase in AVP are likely to involve histamine, prostaglandins, and
cytokines such as IL-1β and IL-6.138
Many complex interactions exist among hormones and inflammatory mediators. For
example, AVP functions as an ACTH secretagogue in addition to its role in maintaining blood
pressure139,140

Also, direct neuronal connections exist between hypothalamic neurons that

produce corticotrophin-releasing hormone and those that produce norepinephrine, so each of
these hormones can induce the secretion of the other.134 As a result, increased catecholamine
concentrations during stress or illness promote glucocorticoid release. Inflammatory mediators
and PAMPs communicate with the central nervous system and exert effects on the HPA via the
circumventricular organs where the blood-brain barrier is incomplete, or through upregulation of
inflammatory mediator production in brain endothelial cells and perivascular microglia.125
Interleukin-1β, IL-6, and TNF-α are the most important cytokines involved in upregulating the
HPA during sepsis.134

In addition, IL-6 can stimulate ACTH and cortisol release through

receptors located directly on pituitary corticotrophs and the adrenal cortex.118,141 Activation of
lemniscal tract nociceptive pathways by inflammatory cytokines and mediators relays pain
signals to the thalamus and somatosensory cortex, ultimately leading to HPA activation.127
Interleukin-6 and glucocorticoids also act synergistically to stimulate the production of acutephase proteins.134 Other cytokines and mediators such as prostanoids, platelet activating factor,
and neuropeptides may also regulate the HPA axis.134
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1.1.7 Metabolic alterations and development of insulin resistance

Metabolic alterations occur as a result of mediators that are released during the systemic
inflammatory response.

A number of the inflammatory mediators upregulated by NFκB

signaling, as well as the counterregulatory hormones cortisol, epinephrine, glucagon, and growth
hormone, induce IR.91,142,143 The overall goal of these counterregulatory mechanisms is to
ensure the provision of adequate energy in the form of carbohydrates, proteins, and lipids to meet
the body’s requirements while fighting infection.124 Inducing a state of peripheral and hepatic IR
tips the balance in favor of glucose liberation from tissue stores and glucose synthesis via
gluconeogenesis in the liver.144 Energy requirements during critical illness may not be as high as
once believed, however,145 and IR can be detrimental because it can lead to endothelial
dysfunction and organ failure.91,143
Glucocorticoids are important regulators of metabolism during inflammation and sepsis,
and alter metabolic functions directly and by potentiating the effects of other hormones such as
insulin, glucagon, catecholamines, and growth hormone.146,147 Glucocorticoids promote hepatic
glucose

output

by

increasing

the

rate

of

gluconeogenesis

and

glycogenolysis.148

Gluconeogenesis is enhanced by stimulation of the rate-limiting enzymes phosphoenolpyruvate
carboxykinase (PEPCK) and glucose-6-phosphatase (G6P).148 Glycogen phosphorylase activity
is also stimulated.149 Skeletal muscle catabolism occurs through the activation of intracellular
proteases.150 Liberated amino acids are then utilized by the liver for gluconeogenesis. Adipose
tissue amino acid uptake is also inhibited.148 Glucocorticoids stimulate lipolysis by increasing
cyclic adenosine monophosphate production and activating protein kinase A, as well as through
phosphorylation and down-regulation of perilipin, a lipid droplet-associated protein that
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modulates lipolysis.151 Cytokines such as TNF-α and IL-6, catecholamines, and growth hormone
also down-regulate the function of lipoprotein lipase (LPL) and upregulate hormone sensitive
lipase (HSL), thereby increasing lipolysis.152-154 This results in a net efflux of free fatty acids
from adipose depots.151,155

Increased lipolysis also leads to a buildup of lipid metabolism

intermediates such as DAG in tissues, and these intermediates can activate PKC and induce
IR.82,156,157

Increased lipid oxidation may also decrease glucose phosphorylation, glucose

oxidation, and glycogen synthesis through inhibition of enzymes including phosphofructokinase,
pyruvate dehydrogenase, and hexokinase that are involved in these pathways.156 Very-low
density lipoprotein synthesis by the liver increases, while high density lipoprotein production is
reduced.155 Decreased insulin-independent glucose uptake occurs in adipocytes, and has been
attributed to decreased GLUT1 expression in response to glucocorticoids.103 Reduced glucose
uptake and glycogen synthesis by skeletal muscle has also been demonstrated following
glucocorticoid exposure.158 Reduced insulin-mediated phosphorylation of PKB/Akt prevents
phosphorylation and deactivation of glycogen synthase kinase-3, resulting in decreased glycogen
synthase activity.

Glucocorticoids also inhibit glucose-stimulated pancreatic β-cell insulin

secretion.159

1.2 Carbohydrate Metabolism

1.2.1 Dietary Carbohydrate

Carbohydrates represent the major source of calories in the equine diet.160

Horses

evolved to utilize forage as the primary source of carbohydrate, however concentrated feeds may

17

contribute significantly to the diet of animals under intensive management conditions.160 Grass
and legume nonstructural carbohydrate (NSC) content is subject to both diurnal and seasonal
variation, with forage NSC content highest in the spring, intermediate during the fall, and lowest
during the midwinter and midsummer.161,162 Nonstructural carbohydrate content is highest in the
late afternoon, and also increases in response to environmental factors that affect plant
photosynthesis rates, including amount of sunlight, rainfall, soil fertility, and stressors such as
drought or overgrazing.161,162

Pasture grass NSC content can exceed 400 g/kg of dry

matter.161,162 Depending on the individual animal and pasture conditions, a 500 kg horse may
consume approximately 0.75 to 10 kg of water soluble carbohydrate (WSC) per day, which
corresponds to 0.56 to 7.3 kg of ingested fructan.161 Administration of 2.5 kg of oligofructose
(OF), a type of fructan, to a 500 kg horse as a single bolus is sufficient to cause mild
laminitis,163,164 while administration of 6.25 kg results in severe disease.165 The specific fructan
structure also varies among plant species; those with lower molecular weights may be more
rapidly fermentable in the equine GI tract, and may therefore be more likely to cause laminitis.162
Photosynthetic plants convert atmospheric carbon dioxide into simple sugars and store
sugars that are produced in excess of the plant’s metabolic needs as the complex storage
carbohydrates starch and fructan.

Temperate (C3) grasses accumulate fructans in

nonreproductive tissues such as the stem, and accumulate starch in the seeds.161 Starch also
accumulates in both the seeds and nonreproductive tissues of legumes and warm season (C4)
grasses.161 Starch production and storage in leaf chloroplasts is a saturable process, whereas
fructan production can continue unrestrained.161 Therefore legumes and C4 grasses tend to
accumulate less NSC than C3 grasses.161

Stems and seeds of C3 grasses are highest in

18

carbohydrate, while the highest carbohydrate concentrations are found in the leaves and seeds of
C4 grasses and legumes.161
The term NSC refers to the sum of simple sugar, starch, and fructan content (equation 1),
while WSC refers to the sum of simple sugars and fructans only (equation 2).160-162 Ethanol
soluble carbohydrate includes only simple sugars, although some short-chain OFs may partition
into the ethanol-soluble fraction.160,162 “Nonstructural carbohydrate” has also been used to refer
to the sum of all simple sugars, starches, fructans, gums, mucilages, and pectins (equation 3), and
a similar method of calculating nonfiber carbohydrate (NFC) is sometimes used (equation
4).161,162

Eq. 1: NSC = simple sugar % + fructan % + starch %
Eq. 2: WSC = simple sugar % + fructan %
Eq. 3: NSC = 100 – (water % + crude protein % + fat % + ash % + neutral detergent fiber %)
Eq. 4: NFC = 100 – [crude protein % + (neutral detergent fiber % - neutral detergent insoluble
crude protein %) + fat % + ash %]

The ethanol soluble carbohydrate and starch content of the feed provide information about the
glycemic response, as well as the potential for rapid fermentation if fed in large quantities that
exceed small intestinal hydrolysis capacity.160 Mammals lack the digestive enzymes necessary
to hydrolyze fructans,166 although some acid hydrolysis or fermentation occurs in the equine
stomach.161 Most fructans, however, pass undigested through the stomach and small intestine
and are rapidly fermented in the hindgut.161,165 Fructan content therefore also provides
information about fermentability. Because simple sugars, starches, and fructans all have the
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potential to cause excessive hindgut fermentation and subsequent alterations in hindgut pH, all
have potential relevance to the development of pasture-associated laminitis.

1.2.2 Insulin Action in the Post-Prandial State

Blood glucose is tightly regulated, even after the intake of a large meal.167,168 The major
organ systems involved in macronutrient (glucose, amino acid, and fat) regulation following a
meal are the liver, skeletal muscle, and adipose tissue.94 The major hormones involved in
nutrient regulation are insulin, glucagon, glucocorticoids, epinephrine, and growth hormone.94 In
general, insulin’s actions oppose those of the counterregulatory hormones, except for some
overlap with growth hormone actions on amino acid and protein metabolism.169 Insulin secretion
increases following a meal, and insulin plays the dominant role in regulating glucose metabolism
in the fed state. Secretion of the other counterregulatory hormones decreases, so their role in
post-prandial nutrient metabolism has mostly to do with release of inhibition on metabolic
pathways. As such, the role of insulin will be focused upon. Rising blood glucose concentration
is detected by pancreatic β-cells, and this stimulates β-cell insulin secretion. Secretion of
glucagon from pancreatic α-cells also declines as blood glucose concentration rises.
Following a meal, macronutrients are transported out of the gut via the portal circulation
(sugars, amino acids, and a few lipids) or the lymphatics (chylomicrons and intestinal very low
density lipoprotein (VLDL) that contain triglycerides, phospholipids, and cholesterol).94
Glucose and amino acids circulate first to the liver, while chylomicrons and intestinal VLDL
enter the circulation via the thoracic duct. Most lipids therefore circulate to the periphery, where
LPL on the capillary endothelium of adipose and muscle tissues hydrolyzes triglyceride and
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liberates free fatty acids.170 The majority of the lipid is stored in adipose tissue depots, although
some is stored within myocytes to provide energy during fasting.

Lipoproteins become

progressively less dense as they lose triglyceride, and eventually circulate back to the liver,
where they are taken up by hepatocytes to be either oxidized, stored, or repackaged as VLDL and
recirculated to the periphery. Amino acids and glucose reach the liver before the periphery.
Amino acids are either partially catabolized in the liver or exit the liver and enter the peripheral
circulation. There is no storage form for amino acids, so they are either used immediately for
protein synthesis and turnover, or carbon skeletons generated from their partial catabolism are
used by the liver to synthesize glucose via gluconeogenesis. The glucose produced may then be
either oxidized or stored as glycogen. In the initial 2-3 hours following a meal, most tissues that
utilize glucose will do so. Therefore, in tissues such as the liver, and even in muscle, which
preferentially oxidizes fatty acids except when glucose is highly abundant, glycolysis and
glycogen synthesis are activated in parallel.94,169 In this way, the majority of glucose in a meal is
either oxidized for energy immediately or stored as glycogen in liver and muscle to provide
energy during fasting. In contrast, the gluconeogenesis and glycogenolysis pathways that lead to
glucose output from the liver are suppressed, as well as glycogenolysis in muscle. In addition,
pathways that promote amino acid catabolism are suppressed in muscle and lipolysis is
suppressed in adipose tissue. Diets high in carbohydrate and low in lipid promote de novo
lipogenesis in the liver, facilitating the conversion of excess dietary carbohydrates to lipids,
which are then exported from the liver via VLDL to peripheral adipose storage depots.171
Metabolic pathways of synthesis and catabolism for a given macronutrient are generally
regulated in tandem.94 This is often accomplished through phosphorylation or changes in gene
expression of key pathway enzymes. The same hormone can promote activity in one pathway
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(for example, synthesis), while inhibiting the opposing pathway (for example, catabolism). This
is seen in insulin’s control of macronutrient metabolism. In the liver, for example, insulin
promotes glycogen synthesis by increasing glycogen synthase activity, while inhibiting
glycogenolysis by decreasing activity of glycogen phosphorylase and G6P.172,173 Insulin also
promotes the activity of hexokinases, including glucokinase, thereby increasing glycolysis while
glucose is abundant. Insulin promotes fatty acid synthesis in the liver via the transcription factor
sterol regulatory element binding protein 1c, which enhances expression of genes involved in the
fatty acid synthesis pathway.174 Insulin restrains gluconeogenesis in the liver by inhibiting key
enzymes such as the rate-limiting enzyme PEPCK.173,175 Insulin down-regulates gene expression
of PEPCK and decreases activity of G6P, which therefore inhibits the final step of
gluconeogenesis.173,175 Insulin promotes GLUT4-mediated glucose uptake into adipose and
skeletal muscle tissues.176 Glucose is then either oxidized or converted into glycogen in muscle.
In adipose tissue, glucose is either oxidized for energy or partially oxidized to obtain a 3-carbon
glycerol backbone on which to esterify fatty acids and form triglycerides.
In general, insulin promotes the storage of fat. Accordingly, insulin increases the activity
of LPL so that fats are taken into storage depots, while decreasing the activity HSL and
inhibiting lipolysis.170,177,178 These effects occur primarily in adipose tissue, but also in muscle
since myocytes can store intramyocellular triglyceride.
Insulin has milder effects on amino acid metabolism. Insulin, in conjunction with growth
hormone (acting through insulin-like growth factor-1), promotes protein synthesis while
inhibiting protein catabolism.94,169

Inhibition of protein catabolism is the main mechanism

through which insulin promotes growth. Insulin may also enhance the uptake of some amino
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acids by increasing the activity of amino acid transporters, although this is only a minor function
of the hormone.

1.2.3 Metabolic Derangements in Insulin-Resistant and Diabetic States

Type 2 diabetes mellitus (T2DM) is characterized by a lack of insulin sensitivity in the
tissues that maintain glucose and nutrient homeostasis in the body.179-181

The initiating

pathology is loss of responsiveness to insulin in adipose, muscle, and liver tissues. Initially,
pancreatic β-cells become more responsive to glucose, and therefore compensate for the
decreased peripheral insulin action by increasing insulin secretion in response to elevated blood
glucose concentrations.4,182,183 Eventually, β-cells may decompensate and fail to secrete insulin,
whereupon glycemic control is lost.

Decompensation and true T2DM are infrequently

encountered in the horse, however the condition has been reported.184-188 Once decompensation
occurs, the body can no longer utilize glucose effectively and enters a state resembling
starvation. In this state, the majority of energy is provided by fat and amino acid catabolism.
Only obligate glycolytic tissues that obtain glucose through insulin-independent uptake,
including the brain, structures in the eye, and erythrocytes, utilize glucose for fuel.94
Hyperglycemia contributes to much of the pathology seen in diabetes.

Glucotoxicity

caused by elevations in ROS and consequent mitochondrial dysfunction, as well as glycation
reactions, lead to vascular disease, retinopathy, renal disease, and neurologic disease.189,190
Hyperglycemia that exceeds the renal threshold results in osmotic diuresis and causes
dehydration and electrolyte abnormalities.191,192 Since glucose is unable to reach its target
tissues, the body attempts to raise blood glucose concentrations by increasing gluconeogenesis,
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glycogenolysis, lipolysis, and protein catabolism.94 Atherosclerotic cardiovascular disease in
humans and other species can result from increased cholesterol synthesis and mobilization from
the liver, which is a consequence of increased lipolysis and loss of insulin inhibition of lipid
metabolism.193 In advanced disease, many tissues, including parts of the brain, switch to using
ketones for energy.194

Ketones are acids, so increased production results in metabolic

acidosis.195
A functional insulin signaling cascade is required for insulin to elicit its biological
actions, which include suppression of hepatic gluconeogenesis and glycogenolysis, suppression
of lipolysis and increased triglyceride storage, and inhibition of protein catabolism. 94 Insulin
performs these functions through regulation of key enzymes in these processes.

Enzymes

regulated by insulin include HSL and LPL in lipid metabolism, PEPCK and G6P in
gluconeogenesis, G6P and glycogen phosphorylase in glycogenolysis, hexokinase, and enzymes
of protein catabolism.94 Regulation occurs through both phosphorylation of enzymes as well as
upregulation or down-regulation of gene expression.

1.2.4 Intracellular Insulin Signaling Pathways

Intracellular signaling pathways diverge distal to the insulin receptor (Figure 1.2).85,196
Pathways lead to activation of PI3-kinase signaling, MAPK signaling, or activation of the
guanosine triphosphate-binding protein TC10. The PI3-kinase pathway is most important to the
metabolic actions of insulin, including phosphorylation of metabolic enzymes, phosphorylation
of endothelial nitric oxide synthase (eNOS), regulation of metabolic gene expression, and
GLUT4 translocation to the cell surface.85,197-199 Concurrent activation of TC10 is required for
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Figure 1.2 Insulin signaling pathways diverge distal to the insulin receptor and lead to various
biological responses.

Activation of the PI3-kinase pathways is required to stimulate the

metabolic actions of insulin, while MAPK signaling is critical for mitogenic functions. Crosstalk also occurs among signaling pathways. From Kanzaki M, Pessin JE. Signal integration and
the specificity of insulin action. Cell Biochem Biophys 2001;35:191-209.
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GLUT4 translocation (Figure 1.3).200-204 Insulin’s effects on cell growth and differentiation,
apoptosis, and gene expression are controlled through MAPK pathways involving ERK.85
The insulin receptor is a dimer composed of 2 α- and 2 β-subunits. The α-subunits are on
the extracellular face of the cell membrane, while β-subunits span the membrane and have
cytosolic portions that possess tyrosine kinase activity.85

Insulin binds to the α-subunits,

inducing a conformational change in the β-subunits and subsequent autophosphorylation of the
β-subunits on 3 tyrosine residues.94 The β-subunits then acquire tyrosine kinase activity and
phosphorylate downstream adaptor proteins including IRSs that lead to PI3-kinase activation,
casitas b-lineage lymphoma (Cbl) protein and Cbl-associated protein (CAP) that lead to
activation of the TC10 pathway, and the adaptor protein Shc and growth factor receptor binding
protein (Grb) that lead to MAPK activation.85
The PI3-kinase pathway is the most important with respect to glucose metabolism
because it is required for GLUT4 translocation to the cell membrane as well as regulation of
metabolic enzymes.

Insulin receptor substrate-1, located primarily in muscle and adipose

tissues, and IRS-2, located in the liver, are the most important IRS proteins.94 Phosphorylation
of IRSs on a specific tyrosine residue exposes a binding region for proteins that contain a highly
conserved, approximately 100 amino acid sequence known as the Src homology 2 (SH2)
domain. The lipid kinase PI3-kinase contains an SH2 domain in the p85 regulatory subunit. The
SH2 domain binds to tyrosine-phosphorylated IRSs, causing allosteric activation of the catalytic
p110 subunit. Phosphoinositide 3-kinase then phosphorylates a plasma membrane phospholipid
called phosphatidylinositol 4,5-bisphosphate (PIP2), generating phosphatidylinositol 3,4,5triphosphate (PIP3).94 Phosphatidylinositol 3,4,5-triphosphate serves as a binding domain for
the serine/threonine kinase 3-phosphoinositide-dependent protein kinase-1 (PDK-1) as well as its
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Figure 1.3 Insulin signaling pathways leading to cellular glucose uptake. Concurrent activation
of the PI3-kinase and TC10 pathways is required to stimulate GLUT4 vesicle translocation to the
cell surface. From Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends
Cell Biol 2002;12:65-71.
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substrates PKB/Akt and the atypical protein kinase C (aPKC) isoforms PKCδ and PKCλ.
Protein kinase B and aPKC are phosphorylated on serine and threonine residues by PDK-1 in
conjunction with the serine/threonine kinase mammalian target of rapamycin.205-207 Protein
kinase B, itself a serine/threonine kinase, functions through downstream targets to phosphorylate
and regulate several metabolic enzymes and eNOS, and is partially responsible for GLUT4
translocation from its intracellular storage vesicles to the cell surface following ingestion of
glucose.85,198,199,208
The PI3-kinase pathway alone is not sufficient for GLUT4 translocation because a second
signal is required from TC10.200-204
receptor.

The TC10 pathway also originates from the insulin

The receptor phosphorylates the adaptor protein Cbl, which is associated with

CAP.85,209,210 Since CAP associates with fillotin in the lipid bilayer caveolae, this pathway is
spatially segregated to lipid raft domains.201,211 Many stimuli can activate PKB/Akt signaling, so
the TC10 pathway ensures that only insulin mobilizes GLUT4 to the cell surface. Intermediates
downstream of PKB/Akt and TC10 that facilitate GLUT4 translocation have not been clearly
identified.208 Possible targets include PKB/Akt substrates such as Akt substrate of 160 kDa
(AS160) and phosphoinositide kinase for five position containing a Fyve finger.204,208,212
Impaired phosphorylation of AS160 has been associated with diabetes213 and increased TNF-α
concentrations.214 Results are inconsistent, however, and unchanged or increased muscle AS160
protein content has been detected in other studies of diabetic and insulin-resistant humans213,215
and rodents.213,216 A recent study of AS160 in horses did not detect any differences in protein
content or phosphorylation state in the muscles of insulin-resistant and insulin sensitive horses
despite differences in cell surface GLUT4 protein expression, suggesting that AS160 is not
essential to the pathogenesis of IR in this species.217
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In the unstimulated state, GLUT4 is largely sequestered in intracellular vesicles, with
only about 2-10% cycling to the cell surface at any given time.204,212,218 The mechanism of
GLUT4 vesicle fusion is similar to that of neural synaptic vesicles and involves PKB/Akt
substrates known as soluble NSF attachment protein receptors (SNARES).204,212 On the GLUT4
vesicle, SNARES such as vesicle-associated membrane protein (VAMP)2 and VAMP3 interact
with syntaxin4 and synaptosomal-associated protein 23 on the cell membrane to facilitate vesicle
fusion and GLUT4 expression on the cell surface.204,212 A small protein call synip appears to be
associated with syntaxin4, and is also a PKB/Akt substrate.204,208,212,219

This molecule is

phosphorylated and dissociates from syntaxin4 upon insulin stimulation, allowing vesicle fusion
to occur. In addition, TC10 and PI3-kinase signaling may be involved in depolymerization of
actin cytoskeleton tethers that anchor the GLUT4 vesicle to its intracellular location in the basal
state.200,201,212

It can therefore be appreciated that abnormalities in postreceptor signaling

pathways will reduce insulin’s ability to mobilize GLUT4 to the cell surface, as well as reduce
its ability to phosphorylate and regulate metabolic genes. Although the exact mechanism of IR
in EMS remains to be fully elucidated, altered GLUT4 protein trafficking has recently been
demonstrated in adipose tissue and skeletal muscle from insulin-resistant horses. 217,220

1.2.5 Assessment of Insulin Sensitivity

Insulin sensitivity can be assessed in a number of ways. The simplest of these is to
measure resting glucose and insulin concentrations in the blood.221,222 While easy to perform,
these tests are at best a screening tool because resting glucose and insulin concentrations
represent the endpoint of complex metabolic pathways that are subject to extensive regulation,
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diurnal and seasonal variation, and are affected by conditions such as stress and illness.167,182
Resting hyperglycemia and elevated hemoglobin A1c values, commonly measured in humans,223
suggest loss of glycemic control due to peripheral IR or from decreased pancreatic β-cell insulin
secretion, but factors such as stress, pain, and diet can also cause hyperglycemia.167
Hyperglycemia is uncommon in insulin-resistant horses and indicates progression to
uncompensated IR or diabetes mellitus.4
Resting insulin concentration is frequently used as a screening tool in horses and
hyperinsulinemia is suggestive of IR.4 However, insulin concentrations vary throughout the
day, so resting insulin concentration can fall within the normal range at the time of sampling in a
horses with IR.224 As with blood glucose, insulin concentration is also affected by factors such
as stress, pain, and diet,167 so a result is more likely to represent a true positive the further it falls
outside the reference range. Additionally, the test is only valid in animals with compensated IR,
and false negative results may be obtained if pancreatic β-cell exhaustion and decompensation
have resulted in declining insulin secretion.221,222
Ratios of resting glucose (in mg/dL) and insulin (in µU/mL or mU/L) concentrations can
also be calculated.

Glucose-to-insulin ratios correlate positively with peripheral insulin

sensitivity and describe the effectiveness of insulin on lowering blood glucose, while insulin-toglucose ratios describe pancreatic release of insulin in response to increasing blood glucose
concentration.221,222 Glucose-to-insulin ratios less than 10 indicate IR, while ratios less than 4.5
indicate severe IR or decompensation. As with resting glucose and insulin concentrations, ratios
are affected by factors such as stress that can confound the results.
In both humans and horses, proxies calculated from resting insulin and glucose
concentrations have been developed, and may offer a better indication of insulin sensitivity and
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pancreatic β-cell responsiveness.225,226

The modified insulin-to-glucose ratio (MIRG) and

reciprocal of the square root of insulin (RISQI) are calculated as follows:

MIRG = [800 – 0.3 × (basal insulin concentration – 50)2] / (basal glucose concentration – 30)
RISQI = 1 / [√ (basal insulin concentration)]

The MIRG proxy was designed to estimate the acute insulin response to glucose (AIRg)
parameter from minimal model analysis of insulin-modified frequently samples intravenous
tolerance test (FSIGTT) data, while the RISQI proxy was designed to estimate the insulin
sensitivity index (SI). Acute insulin response to glucose and insulin sensitivity can be calculated
from proxy values using the following formulas:

AIRg = 70.1 × (MIRG) – 13.8
Insulin sensitivity = 7.93 × (RISQI) – 1.03

Dynamic testing can unmask abnormalities in glucose and insulin homeostasis that are
not evident when resting samples are assessed, and additional metabolic function parameters can
be obtained. Tests are performed by administering a challenge dose of insulin or glucose and
monitoring physiologic responses. A number of techniques are available to assess whole-body
insulin sensitivity, each with its own benefits and limitations.221,222,227,228

Commonly used

procedures include oral glucose tolerance tests, intravenous glucose tolerance test (IVGTTs),
intravenous insulin tolerance tests, the combined glucose-insulin tolerance test (CGIT),
hyperinsulinemic-euglycemic clamp (HEC) procedures, hyperglycemic clamps, and the FSIGTT
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with minimal model analysis. These tests are interpreted by comparing parameters such as area
under the curve values for glucose or insulin, peak and trough glucose and insulin responses, and
the return of insulin and glucose concentrations to baseline. As an example, a glucose challenge
that elicits an abnormally high insulin peak, delayed return of insulin concentrations to baseline,
or an increased area under the insulin curve value could indicate increased β-cell responsiveness
to glucose or decreased insulin clearance. During the same test, delayed return of glucose
concentrations to baseline and an increased area under the glucose curve value could indicate
peripheral IR, since glucose is not cleared as rapidly as expected.
While dynamic tests offer several advantages, limitations of each test must be recognized.
Oral glucose tolerance tests are affected by gastric emptying time, small intestinal absorption
rates, hepatic glucose uptake, and pancreatic β-cell responsiveness.222 The IVGTT assesses
insulin sensitivity by providing information on the functional turnover rate of glucose, however
exaggerated peak glucose concentration or delayed return to baseline may be due to either
impaired insulin secretion or decreased insulin sensitivity.221,222 Insulin tolerance tests assess the
glycemic response to exogenous insulin, and may be confounded by endogenous insulin
secretion.221,222 It is therefore important to consider potential confounders when performing any
of these procedures.
The CGIT is useful for evaluating insulin sensitivity because it provides more
information than either the IVGTT or intravenous insulin tolerance test alone, and is easily
performed.227 During this test, an intravenous bolus of glucose is administered concurrently with
an intravenous bolus of insulin and blood glucose and insulin concentrations are monitored.
Failure of glucose concentrations to return to baseline by 45 minutes following intravenous
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glucose and insulin administration or an insulin concentration exceeding 100 µU/mL at 45
minutes are indicative of IR in the horse.4
The HEC is widely regarded as the gold standard test of insulin sensitivity in
humans,229,230 and has been adapted for use in the horse.231 This test utilizes an intravenous
insulin infusion to maintain supraphysiologic plasma insulin concentrations, thereby suppressing
hepatic glucose output.

A concurrent intravenous glucose infusion is titrated to maintain

euglycemia. The rate of the glucose infusion therefore equals the rate of whole-body glucose
disposal. Glucose disposal rate is a measure of peripheral insulin sensitivity, and is represented
by a parameter called the M/I ratio.
The FSIGTT and minimal model analysis can also be used to assess insulin sensitivity.
The test involves administration of an intravenous glucose bolus followed 20 minutes later by an
intravenous insulin bolus.232 The minimal model is a compartmental representation of glucose
and insulin regulatory systems that partitions glucose disposal into glucose-dependent and
insulin-dependent components.182,221,233 The SI parameter describes the change in the rate of
glucose clearance by tissues in response to a known dose of exogenous insulin.

Glucose

effectiveness is a parameter that describes the ability of glucose to stimulate its own disposal
through mass effect.234,235 Glucose effectiveness is determined by subtracting the rate of insulindependent glucose clearance from total glucose clearance to obtain the insulin-independent
component. The AIRg quantifies endogenous insulin secretion by pancreatic β-cells in response
to glucose. Disposition index is calculated by multiplying AIRg × SI. Comparison of pancreatic
insulin secretion with tissue insulin sensitivity provides information about whether β-cell
responses to exogenous glucose administration are appropriate, and detects exaggerated β-cell
responses that occur during compensated IR.
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In horses, the HEC was found to be more repeatable than the FSIGTT,236 however there
are also shortcomings.228

The test is less physiologic than the FSIGTT, more technically

challenging to perform, and fewer parameters of glucose and insulin dynamics can be assessed
than when minimal model analysis is performed on FSIGTT data.

In addition, difficulty

attaining steady state blood glucose concentrations may occur, and it can be challenging to
adequately restrain animals during the procedure without causing stress and confounding the
results. For these reasons, use of the FSIGTT is sometimes preferable.

1.3 Obesity

1.3.1 Equine Metabolic Syndrome

In a recent consensus statement,4 the American College of Veterinary Internal Medicine
has defined EMS as a syndrome with 3 key components:
1) Obesity or regional adiposity, particularly of the subcutaneous adipose tissues
surrounding the nuchal ligament, tail head, behind the shoulders, or in the prepuce or
mammary gland region
2) Insulin resistance
3) A predisposition towards the development of laminitis, where laminitis develops in the
absence of identifiable causes such as colic, colitis, grain overload, or retained placenta
Additional components of the syndrome include hyperleptinemia, dyslipidemia, arterial
hypertension, altered reproductive cyclicity in mares, and increased systemic inflammatory
markers associated with obesity.4
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Environmental conditions that favor increased NSC storage in plants also appear to be
associated with the development of pasture-associated laminitis.226,237,238 Pasture NSC content
correlates positively with circulating insulin concentrations in healthy horses, and IR and
compensatory hyperinsulinemia are exacerbated in laminitis-prone ponies that graze on pastures
high in NSC.162,226 Only a small subset of animals develop laminitis when allowed to graze
under such conditions, suggesting that some horses may be inherently more susceptible to the
disease than others. Ponies are more prone to developing EMS and laminitis than horses. 239-242
Among horses, Morgan, Spanish Mustang, Arabian, American Saddlebred, Haflinger,
Norwegian Fjord, Paso Fino, and warmblood horses are predisposed to developing EMS,
whereas Thoroughbreds and Standardbreds are less susceptible.4,243

Interactions between

environmental factors and genetic predisposition lower the threshold for developing T2DM in
humans,244,245 and a similar situation may occur with horses and laminitis.246 Although genes
that predispose an individual to IR may have conferred an evolutionary advantage on both horses
and humans during times of famine, it is likely that this genotype has become obsolete and is
now detrimental under modern conditions where food is abundant.226,247
As with the metabolic syndrome in humans,248 a set of risk factors has been identified to
predict the development of laminitis in apparently healthy ponies.226 Initial criteria were defined
using an inbred herd of Welsh and Dartmoor ponies. Fifty-four of 160 animals had previously
experienced laminitis, and pedigree analysis suggested a dominant pattern of inheritance partially
suppressed in males. Use of two proxies, RISQI and MIRG, to evaluate insulin sensitivity and
the insulin response to glucose, respectively, indicated that ponies predisposed to laminitis had
decreased insulin sensitivity and an exaggerated compensatory pancreatic response to glucose.
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Proxy measurements were validated using minimal model analysis in a subset of the ponies. A
prelaminitic metabolic syndrome (PLMS) was defined as meeting 3 of the following 4 criteria:
1) Insulin resistance (RISQI < 0.32 [mU/L])
2) Compensatory β-cell response to glucose (MIRG > 5.6 mUinsulin2/[10•L•mgglucose])
3) Hypertriglyceridemia (triglyceride concentration > 57.0 mg/dL)
4) Obesity (body condition score > 6.0 on a scale of 1 to 9,249 and regional adiposity of the
neck and tailhead)
The presence of PLMS predicted the development of laminitis with an overall power of 78%,
sensitivity of 74%, and specificity of 79%, and development of laminitis coincided with an
increase in pasture starch content. The odds of developing laminitis were 10 times higher in
ponies with PLMS than in healthy ponies.
Using the same group of ponies, individual variables were subsequently identified that
accurately predicted the development of laminitis when at-risk animals were exposed to nutrientdense pastures.250 Predictive variables and cut-off values included plasma insulin concentration
greater than 32 mU/L, plasma leptin concentration greater than 7.3 ng/mL, neck circumference to
height ratio greater than 0.71, body condition score of 7/9 or above, and cresty neck score of 4/5
or above. Diagnostic accuracy of the individual variables was found to be comparable to the
combinations originally used to define PLMS. A standardized scoring system called the cresty
neck score was developed as part of this work to assess regional adiposity of the nuchal crest, 251
since this adipose depot is thought to be the most metabolically active in the horse and may
therefore secrete adipokines that contribute to the development of IR and laminitis.226,252,253
Increased overall adiposity as well as local adiposity of the neck were found to be associated
with elevations in blood variables such as insulin.251 In another study, obesity and IR were also
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associated with increased resting glucose, insulin, and leptin concentrations, and increased neck
circumference was positively correlated with area under the insulin curve measured during the
CGIT.254

Increased plasma concentrations of nonesterified fatty acid, very low-density

lipoprotein, and high-density lipoprotein-cholesterol were detected, indicating that obese,
insulin-resistant horses suffer from dyslipidemia. Increased inflammatory cytokine production
has been detected in obese horses104 and in ponies that are prone to developing laminitis,255 and
may represent the underlying link between obesity, IR, and the development of laminitis in these
animals.
Underlying predispositions may not lead to the development of laminitis or to expression
of the EMS phenotype until an animal is exposed to certain environmental factors. For example,
PLMS criteria were not evident in a population of ponies while grazing on winter pasture,
however, blood insulin, triglyceride, and uric acid concentrations increased, insulin sensitivity
decreased, and mean blood pressure increased in laminitis-prone animals after exposure to
summer pasture.256 In another study, feeding inulin, a type of fructan, to laminitis-prone ponies
resulted in an exaggerated insulin response when compared to normal animals.257

Insulin

concentrations were also significantly higher in laminitis-prone ponies following dexamethasone
administration.257

1.3.2 Abnormal Adipose Tissue in Obesity

Besides its function in energy storage, adipose tissue is an important endocrine
organ.105,106,258,259 The adipose tissue of an obese individual is abnormal.260 Adipocytes tend to
be larger than normal, and a number of pathologies stem from the fact that these adipocytes have
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reached their maximal storage capacity.260 Adipocytes become stressed for a variety of reasons.
Hypoxia may be a major factor in adipocyte stress during obesity.260,261 Typically, oxygen
diffuses about 100 µm from capillary beds, and the diameter of large adipocytes may exceed this.
In addition, the endothelium of vessels within the adipose tissue may become unresponsive to
NO-induced vasodilation, and this may further contribute to hypoxia.260,262 Hypoxia affects cells
in a number of ways, including reducing mitochondrial function and stimulating hypoxiainduced genes that promote inflammation.

Stressed adipocytes therefore secrete pro-

inflammatory mediators including cytokines and acute-phase proteins that promote inflammation
and coagulation.

Stressed adipocytes, and those that have become necrotic as a result of

hypoxia, also release cytokines such as macrophage chemoattractant proteins that recruit
macrophages to adipose tissues.260,263-265 Resident tissue macrophages within adipose tissue tend
to be of an anti-inflammatory phenotype, while those recruited by stressed adipocytes exhibit a
more pro-inflammatory profile.260

Resident macrophages may also convert to a pro-

inflammatory profile under these conditions.266,267

Inflammatory mediators secreted from

adipose tissue act locally to promote inflammation, and also evoke inflammation at distant
locations. This becomes important with respect to laminitis in horses because the vascular
endothelium is a target of many of these mediators.198,199
Increased fat mass may also predispose individuals to more severe inflammatory
reactions when exposed to stimuli such as LPS, because adipocytes express PRRs such as TLR2
and TLR4.110 Some studies have suggested that adipose tissues from obese and diabetic humans
and rodents express more TLR2 and TLR4 than tissues of lean individuals, but this has not been
a consistent finding.110,268 Higher mRNA expression of both receptors has been detected, but
TLR4 protein abundance is not consistently increased. However, TLR4 reactivity may be
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enhanced in obesity and diabetes, and responsiveness of adipocytes to the TLR4 ligand LPS has
been demonstrated in the horse.269
Adipocytes that are laden with triglycerides also lose their ability to buffer lipid fluxes
within the body.260,270 In the adipocyte, this can cause inflammation due to a buildup of lipid
metabolism intermediates such as DAG, long-chain fatty acyl coenzyme A, and ceramide, which
further stresses the adipocyte.82,89,114

Lipid buffering capacity is lost, so lipids can also

accumulate in other tissues, including the liver, muscle, and pancreas, and this may result in
pathology in these organs.90,270-272 Reduced sensitivity of the capillary endothelium to NOdependent vasodilation may also impede post-prandial capillary recruitment in adipose tissue,
thereby reducing lipid delivery to storage depots and contributing to fat accumulation in other
tissues.260

1.3.3 Hepatic Manifestations of Obesity

Hepatic lipidosis is a frequent manifestation of obesity in humans,273-275 and has been
detected in some horses that suffer from EMS.276 Enhanced peripheral lipolysis secondary to IR
represents the major cause of lipid accumulation in the steatotic liver, with a smaller contribution
by de novo lipid synthesis within hepatocytes.277 Lipid negatively affects hepatic macrophage
(Kupffer cell) function. Intermediates of fatty acid metabolism are agonists for Kupffer cell
PRRs and therefore trigger an inflammatory cascade.90,278

Lipid-laden hepatocytes also

compress liver sinusoids and this promotes Kupffer cell activation. Compression decreases
blood flow velocity and prolongs exposure of Kupffer cells to leukocytes and antigens present in
the sinusoids.279 Activated Kupffer cells secrete pro-inflammatory mediators which damage
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surrounding hepatocytes and cause them, in turn, to secrete more pro-inflammatory mediators.280282

Lipid accumulation within hepatocytes may also cause dysfunction of mitochondria and the

endoplasmic reticulum, further stressing cells and exacerbating inflammatory mediator
production.282-285

Hepatocytes with mitochondrial dysfunction may also have difficulty

oxidizing lipids, resulting in a build-up of toxic lipid metabolism intermediates that promote
inflammation.55,278,282 It has also been shown that chronic hyperinsulinemia depresses Kupffer
cell phagocytosis in rats,286

so the liver may be less effective at clearing toxins such as LPS

from the portal blood and may allow these antigens to pass into the systemic circulation where
they incite an inflammatory reaction.
The liver,107-109 along with adipose tissue,104-106 contributes to the low-grade
inflammatory state that characterizes obesity.106-109 A key cytokine produced by the liver (and
adipose) during obesity is IL-6.109,283 A major function of IL-6 is to stimulate hepatic production
of acute-phase proteins. One of these acute-phase proteins is LBP, and LBP is elevated in obese
humans.287 Increased circulating LBP suggests a role for LPS-induced inflammation in obesity.
Obesity-related

liver

dysfunction

might

also

contribute

to

sepsis-associated

hyperglycemia, which has been documented in the horse and is associated with a poorer clinical
outcome in affected animals.288-291 Glucotoxicity and increased free radical production can incite
tissue damage, heighten inflammation, and negatively impact immune function.91 The major
source of glucose during sepsis is from increased hepatic gluconeogenesis.91,144,292 In an obese
liver that is already insulin-resistant, sepsis-associated hepatic IR may be more pronounced, and
a predisposition towards hyperglycemia may exist.
Gastrointestinal flora differs between obese and lean individuals of many species,
including rodents and humans,293,294

and this may have implications for the obese horse.
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Differences in GI flora may be particularly important if hepatic steatosis causes the liver to be
less effective in clearing bacterial toxins that arrive from the gut via the portal circulation. One
study examining fecal pH following inulin administration failed to detect a difference between
normal and laminitis-prone ponies, suggesting that differences in gut microflora may not feature
prominently in this species.295

1.3.4 Insulin Resistance and the Vasculature

In obese and insulin-resistant humans, the underlying defect that links obesity with
cardiovascular disease is endothelial dysfunction.296,297 In this paradigm, the PI3-kinase insulin
signaling pathway is inhibited during IR, while the MAPK pathway remains functional. 198,199
Although there is significant cross-talk between these pathways, some functions appear to be
initiated almost exclusively by one or the other signaling cascade. With regard to endothelial
dysfunction, an important point is that the PI3-kinase pathway is responsible for the production
of endothelial-derived NO, while the MAPK pathway is responsible for the production of ET1.198,199

These endothelial-derived vasoactive compounds are primarily responsible for

regulating vascular tone in capillary beds.198,199 Under normal conditions, the opposing actions
of NO (vasodilation) and ET-1 (vasoconstriction) are in balance because both arms of the insulin
signaling cascade are active. When PI3-kinase signaling is inhibited, however, NO production is
reduced, and only the vasoconstrictive force of ET-1 remains. Vasoconstriction may be further
exacerbated when compensatory hyperinsulinemia occurs secondarily to IR,162,199,298 however,
the relative importance of MAPK pathway overstimulation by hyperinsulinemia remains
controversial.299-301

In addition, constitutively produced NO is consumed when ROS are
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scavenged, making less NO available to promote vasodilation. In individuals with endothelial
dysfunction, this can also lead to paradoxical vasoconstriction in response to stimuli such as
inflammation that normally cause vasodilation.39,302 Vascular dysfunction associated with IR is
relevant to horses because vasoconstriction has long been proposed as an underlying cause of
laminitis.303
Endothelial dysfunction in obese individuals might also result from effects of
inflammatory cytokines produced by adipose104-106 and liver tissues,

107-109

and antigens such as

endotoxin that have escaped clearance by Kupffer cells.286,304 Similar to endothelial dysfunction
during sepsis, these stimuli cause the endothelium to produce pro-inflammatory cytokines and
express adhesion molecules,262,305,306 with the following ramifications.
endothelium promotes coagulation.305

First, the activated

Second, an individual with underlying endothelial

dysfunction that experiences inflammation is more susceptible to endothelial damage from
leukocyte adherence and free radical production.307

Third, the activated endothelium

experiences stress, which can lead to mitochondrial dysfunction.198,199,308

Obesity-related

endothelial dysfunction may therefore lower the “threshold” for activation during sepsis and
predispose the animal to laminar damage caused by neutrophil migration into laminar
tissues.162,298,309
In addition to activation by cytokines or endotoxin, adipokines such as leptin and
adiponectin have direct effects on the vascular endothelium, as well as indirect vascular effects
exerted through modulation of insulin sensitivity and inflammation.310-312 Adiponectin has antiinflammatory actions and can therefore counteract the effects of cytokines such as TNF-α on the
endothelium.313-317 Leptin is generally pro-inflammatory, and exacerbates endothelial activation
and the generation of free radicals that damage the endothelium.318,319 In obese individuals,
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secretion of adiponectin by adipose tissue decreases,259 while leptin secretion increases.315
Adipose-derived cytokines are also affected by systemic inflammation. Adiponectin decreases
and leptin increases following experimental administration of endotoxin as well as during
clinical sepsis.320-323

It has been suggested that obese individuals with adiponectin deficiency

may have a higher risk of mortality during sepsis because they lose the immunomodulatory
effects of adiponectin and its protective actions on the endothelium.313

1.3.5 Obesity, Sepsis, and the Immunomodulatory Properties of Adipokines

In many species, metabolic and nutritional status has been shown to affect immune
function. Both obesity and starvation can negatively impact immune function.88,154,324 Obese
patients in human critical care units experience increased mortality rates, 325,326 and it has been
suggested that inflammation further exacerbates IR in obese individuals, which results in more
extensive organ damage.

Insulin resistance also causes loss of glycemic control.

Sepsis-

associated hyperglycemia has been documented in horses,288-291 and experimental administration
of LPS to horses induces IR.327 Hyperglycemia increases activation of NFκB signaling and
production of pro-inflammatory mediators.91,328,329

In addition, hyperglycemia can cause

glucotoxic endotheliopathy and promote organ damage.328,330 A well-known series of studies by
van den Berghe and colleagues331-333 demonstrated that tight glycemic control (maintenance of
circulating glucose concentrations between 80-110 mg/dL) significantly reduced morbidity and
mortality in critically ill humans.
Comorbid conditions commonly seen with obesity, such as hepatic steatosis, can also
increase inflammatory responses and organ damage.286,304

Kupffer cells and hepatocytes are
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adversely affected by hepatic lipid accumulation, and this could impair the clearance of
pathogens and toxins from blood.

In the case of a septic, hypotensive individual already

predisposed to GI ischemia and bacterial translocation, inflammatory stimuli such as LPS may
reach the systemic circulation more easily.
Inflammatory responses in the obese individual may be exaggerated simply due to
increased fat mass. Adipocytes express PRRs including TLR2 and TLR4110 and both adipocytes
and preadipocytes secrete inflammatory cytokines in response to stimulation by LPS.110,269,334
Adipose tissues may therefore contribute more to the inflammatory milieu in the obese
individual.
Leptin is an adipocyte-derived hormone that is almost exclusively produced by white
adipose tissue.335 Leptin concentrations increase in direct proportion to increasing adipose depot
size.336,337 This hormone acts as an adiposity signal to keep other systems in the body apprised
of the adipose depot size.315,338

Interaction of leptin with its long-form receptor in the

hypothalamus is involved in satiety signaling.338 Leptin signals the size of adipose depots to the
hypothalamus, affecting the way in which short-term satiety signals are processed.338
Hypothalamic leptin signaling also regulates functions such as reproduction that rely on an
adequately sized adipose depot.339,340 The immune system utilizes approximately 15% of the
body’s energy,154 so it has been proposed that this system has evolved to recognize leptin and
tailor its responses accordingly.
Leptin and its receptors share structural similarities with other pro-inflammatory
cytokines, and its actions on the immune system are pro-inflammatory.105,315,341

Leptin

concentrations increase during sepsis323 and following exposure to LPS.322 Leptin secretion can
also be induced by cytokines such as TNF-α and IL-6.218

In humans, elevated leptin
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concentrations and the associated pro-inflammatory actions have been proposed to be one reason
why obese individuals have a poorer prognosis during sepsis. However, results of one study
examining leptin concentrations in diabetic and non-diabetic critically ill patients provided only
equivocal results.342 Leptin stimulates innate immunity and promotes the activation of NFκB
signaling, and therefore the production of cytokines such as TNF-α.258,343 It also influences
lymphocyte proliferation and differentiation.105 Lymphocyte differentiation is polarized towards
a T-helper 1 (cytotoxic) rather than T-helper 2 (humoral) response.

Leptin also activates

endothelial cells directly, causing expression of adhesion molecules and generation of ROS that
can lead to cellular stress and mitochondrial dysfunction.318 Endothelial activation is necessary
for leukocyte emigration and also plays a major role in the pathogenesis of organ failure during
sepsis.35,344,345 Increased leptin may therefore lead to detrimental outcomes, especially in the
obese individual.
Obesity is associated with lower adiponectin concentrations.315 Adiponectin is secreted
by adipocytes,315 and decreases in response to inflammation and sepsis.320,321

Adiponectin

improves insulin sensitivity in tissues such as skeletal muscle, and counteracts IR caused by
cytokines such as TNF-α.346 In obese patients that have preexisting adiponectin deficiency, a
further reduction in adiponectin secretion might exacerbate IR following an inflammatory event,
and could magnify the negative effects of IR on the vasculature and immune system.313,347
Adiponectin also exerts direct anti-inflammatory actions on cells of the immune system, so lower
concentrations might result in an exaggerated inflammatory response that leads to organ
failure.315,317,348
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Resistin is a hormone produced by adipocytes and macrophages,
IR.259,315

and it promotes

Resistin has similar immune effects as leptin, and also increases in response to

inflammation.349-351
In conclusion, inflammation may predispose obese individuals to endothelial dysfunction
and subsequent organ damage during sepsis, and could exacerbate IR as a result of altered
adipokine secretion.
Some drugs used to treat IR have proven efficacious in mitigating the detrimental effects
of inflammation and sepsis.

For example, administration of exogenous thyroid hormone

increases insulin sensitivity in horses,352,353 and has been shown to ameliorate IR following LPS
administration.354

The peroxisome proliferator-activated receptor-γ agonists known as

thiazolidinediones, which include rosiglitazone, improve insulin sensitivity and may have
beneficial effects during endotoxemia and sepsis.355-357 Also, blockade of the renin-angiotensinaldosterone system with agents such as the angiotensin-II receptor antagonist losartan improves
insulin sensitivity because angiotensin-II inhibits activation of the PI3-kinase pathway.358,359 The
finding that these drugs reduce inflammation and sepsis-related mortality underscores the
potential importance of IR in the pathogenesis of these disorders.

1.4 Laminitis

1.4.1 Overview of Laminitis Pathophysiology

There are several ways in which to group the inciting causes of laminitis, and a great deal
of overlap exists among individual causes.360 At the organism level, laminitis can be broadly
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thought of as occurring secondary to endocrine and metabolic derangements, inflammation,
derangements in digital blood flow, or mechanical overload.237 Within the laminar tissue, the
three main mechanisms that have been proposed are vascular disorders leading to hypoxia and
ischemia/reperfusion injury, metabolic and enzymatic derangements, and mechanical trauma.303
In reality, these mechanisms overlap, since diseases have multiple effects on the hoof. At its
most fundamental level, laminitis results in structural failure of the tissues that connect the loadbearing hoof capsule to the underlying bony column.361 Any weakening or disruption of these
tissues causes mechanical forces to pull the bony column, specifically the distal phalanx, into an
abnormal position and results in pain.362-366 Nociceptive, inflammatory, and neuropathic pain
states feature prominently in this disease.365 Regardless of the underlying cause, once laminar
failure occurs, the clinical signs look very much alike.
Mechanical, or “support limb,” laminitis appears to be the most dissimilar
mechanistically.303,367 This form of laminitis occurs during prolonged unilateral weight-bearing
or excessive concussion on a hard surface, and the cause appears to be traumatic injury to
laminar tissues and compromise of the vasculature.367 Tissue trauma may incite inflammation,
which is also a feature of other forms of laminitis.368 Vascular damage and resultant tissue
hypoxia can be due either to mechanical trauma, or in the case of prolonged unilateral weightbearing, from decreased venous return.367

Inflammatory or mechanical damage to the

vasculature results in edema, which can be particularly dangerous in a closed compartment such
as the hoof.369,370 In a manifestation of compartmental syndrome, extravascular pressure may
exceed the capillary wall strength, causing collapse of capillaries and further reduction in tissue
perfusion. Structural failure of the lamina may then occur as load-bearing continues. The
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importance of edema to tissue injury and the development of neuropathic pain in laminitis is an
unresolved question.303,365,371
The next broad category to consider includes diseases involving systemic inflammation.
Examples include GI diseases such as colic and colitis, metritis, pleuritis, and exposure to black
walnut heartwood extract.360,368 Also in this category is carbohydrate-overload laminitis, and this
may illustrate the link between inflammation and laminitis that occurs with metabolic and
endocrine disease.165,372 In these processes, inflammatory stimuli gain access to the circulation
and incite a systemic inflammatory response. In the case of infection, PAMPs are recognized by
the host immune system.368 For example, when GI disease develops, the integrity of the mucosal
barrier is compromised and this allows translocation of whole bacteria, bacterial toxins, cells
wall components, and vasoactive amines into the portal circulation.238 Inflammation appears to
cause laminar damage in much the same way as it induces failure of other organs during
sepsis.373 Host recognition of PAMPs activates signaling cascades that result in the production
of pro-inflammatory cytokines, acute phase proteins, vasoactive eicosanoids, and NO.
Inflammation also results in a pro-thrombotic state,374 as well as activation of the complement
cascade.8

As a result, the vascular endothelium is activated, abnormal vasodilation and

vasoconstriction occur (depending on the stage of the disease), systemic hypotension may
develop, and leukocytes emigrate from the vasculature into tissues. Effects on the laminae
include tissue hypoxia and ischemia/reperfusion injury, as well as direct tissue damage caused by
neutrophil-derived ROS and proteolytic enzymes.368,373 Release of vasoactive amines from the
hindgut might also potentiate abnormal vascular contractility.375 It should be noted that the
mucosal barrier can be compromised in any septic patient with poor perfusion,376 as well as in
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cases of primary GI disease. An important point to consider is that, since inflammation results in
IR, this may be the link to metabolic and endocrine disease.
The final broad category is metabolic and endocrine disease.

The two diseases of

importance to laminitis are EMS and PPID.377 Potential overlap exists between the two diseases,
as well as between metabolic dysregulation and inflammation in general. In the case of PPID,
laminitis may be related either to glucocorticoid excess or to IR.5,378,379 Insulin resistance may be
the most important risk factor for laminitis in affected horses, and it is possible that IR is a preexisting condition in some horses with PPID.380,381 Glucocorticoids may also exert effects
directly on laminar tissues and weaken their structure.5,378,379 The mechanism proposed is that of
protein catabolism, and is similar to cutaneous manifestations of Cushing’s disease in other
species.382,383
In the case of EMS, both inflammation and IR may be involved in the pathogenesis of
laminitis because of obesity-related changes in the vascular endothelium.4,276 Obesity is a proinflammatory condition, and endothelial activation might increase susceptibility to inflammatory
insults. Pasture-associated laminitis is thought to involve inflammation.162,298 In this situation, a
horse ingests large amounts of dietary carbohydrates, which leads to carbohydrate overload and
subsequent GI mucosal compromise.161,162,298 The laminar tissue of animals with EMS may be
more susceptible to damage from inflammatory events that occur secondary to minor GI
disturbances.162,298
In addition, hyperinsulinemia itself might induce laminitis.384,385 Maintaining insulin at
supraphysiologic concentrations in excess of 1000 µU/mL for approximately two days induces
laminitis in normal horses and ponies.384,385 Hyperinsulinemia could induce laminitis through
changes in digital perfusion, increased ET-1 concentrations within the laminar capillary beds, or
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localized glucotoxicity to laminar tissues.296,299 Glucotoxicity would occur through increased
passive uptake of glucose via GLUT1, since laminar keratinocytes do not appear to express the
insulin-responsive GLUT4 transporter.386

Mitogenic stimulation by insulin and abnormal

laminar tissue proliferation has also been suggested.387,388 It should be noted however, that the
direct role of insulin in the development of laminitis is poorly understood.

Although

administration of supraphysiologic doses of insulin to normal horses in the absence of systemic
inflammation results in clinical laminitis, the histopathologic lesions seen in this model are not
the same as those seen in inflammatory models such as carbohydrate overload or black walnut
heartwood extract administration.388
Regardless of the inciting cause, all pathways, with the possible exception of the
hyperinsulinemia model, converge on a common pathway that incites laminar damage.303,389-391
Although the events leading to laminar separation must still be fully characterized, laminar
separation results from destruction of the laminar basement membrane (BM).361

Loss of

attachments between the lamina densa of the BM and hemidesmosomes of basal keratinocytes in
the secondary epidermal laminae causes separation at the dermo-epidermal junction, and this
process is mediated by matrix metalloproteinases (MMPs).392-395 These enzymes are involved in
normal tissue extracellular matrix remodeling and also are induced by inflammation.396 Both
endogenous MMPs, such as MMP-2,397 and those released by neutrophils, such as MMP-9, are
important in the development of laminitis.398 Although MMPs can be inappropriately activated
by many stimuli, including pro-inflammatory cytokines,396 ROS,396 and bacterial enzymes,399 the
cause of activation in laminitis is still uncertain.

It has recently been proposed that a

metalloproteinase enzyme called a disintegrin and metalloproteinase with thrombospondin type 1
motifs-4 may be responsible for destruction of the BM early in the disease process prior to
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immigration of neutrophils into tissues or stimulation of other MMPs.390,400 According to this
theory, neutrophil infiltration would be a response to existing laminar inflammation, perhaps
differentiating laminitis pathophysiology from other manifestations of septic organ failure.
Calprotectin staining of laminae during the developmental phase of laminitis has demonstrated
that neutrophil emigration precedes inflammation of the basal keratinocytes, therefore systemic
inflammatory processes likely contribute to the pathogenesis of the disease.372 With regard to
the insulin-resistant horse, studies in other species have shown that both insulin and glucose can
directly activate MMPs, so this may again explain why affected animals are at greater risk for
developing laminitis.401,402

1.4.2 Role of Inflammation and Endotoxemia

Laminitis appears to be associated with endotoxemia, although the exact role that
endotoxin plays in laminitis remains elusive. The odds of developing laminitis are 5 times
higher in hospitalized horses that exhibit clinical signs consistent with endotoxemia or systemic
inflammation.3 Endotoxin administration to horses impairs endothelium-dependent vasodilation
in digital vessels.303,403-406 Endotoxin also reduces digital perfusion coincident with increases in
blood concentrations of platelet-derived thromboxane A2 and 5-hydroxytryptamine,407
suggesting that endotoxin primarily affects platelets rather than the digital vasculature itself.407409

Despite these findings, administration of LPS to horses has uniformly failed to induce

laminitis.327,410-415
One criticism of LPS administration as a means of inducing laminitis is that it only
stimulates a short-lived inflammatory response when compared with the complex
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pathophysiology of clinical sepsis.416 Inflammation is of longer duration in the carbohydrate
overload models that are used to study laminitis.165,417,418 In these models, horses are given
carbohydrates such as starch or OF via nasogastric tube. Excess carbohydrate reaches the
hindgut where it is rapidly fermented by lactic acid producing bacteria.419 The subsequent
decline in colon pH kills resident colon bacteria and denudes the colon epithelium,420 thereby
allowing bacterial products such as LPS or lipoteichoic acid, as well as vasoactive protein
metabolites,421 to enter the portal circulation.422 Some of these contaminants are cleared by
hepatic Kupffer cells, however, the liver is unable to clear all of them, and some reach the
systemic circulation. Endotoxin has been detected in the peripheral blood of horses following
carbohydrate overload.409,423 In addition, carbohydrate overload results in systemic inflammation
and an associated decrease in insulin sensitivity.164,165,409
The pathological changes seen in the laminitic hoof resemble those seen in sepsisassociated organ failure.373,424-428

Elevated concentrations of pro-inflammatory mediators

including IL-1β, the potent neutrophil chemokine IL-8, free radicals, COX-2, and COX-2
products such as prostaglandins have been detected in hoof tissues following laminitis
induction.429-435 A significant influx of neutrophils into the laminar tissue also occurs following
carbohydrate overload.368,436 Inflammatory cytokine gene expression also increases in hepatic
and lung tissues following laminitis induction.427 Hoof tissues share many similarities with
organs damaged in sepsis, so laminitis is a manifestation of multi-organ failure.
A recent study demonstrated that administration of LPS via an 8-hour long intravenous
infusion prior to administration of OF resulted in a greater incidence and severity of laminitis
than administration of OF alone.164 There are two likely possibilities to explain these findings.
The first is that the initial inflammatory stimulus (LPS) primed cells of the immune system to
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respond more strongly to a second inflammatory stimulus (either LPS or other bacterial-derived
toxins) from the hindgut following OF challenge. This theory is supported by the “two-hit
hypothesis” of organ damage during sepsis.21,437-439

The second explanation is that insulin

sensitivity decreased with LPS pretreatment since IR has been demonstrated for at least 24 hours
following a single LPS bolus.327 Insulin resistance would therefore have still been present when
the gut-derived toxic insult affected the laminar tissues. Endothelial activation caused by IR
might have led to more severe laminar endothelial damage when a second inflammatory stimulus
was superimposed.

1.4.3 The “Two-Hit” Hypothesis of Organ Dysfunction

Humans with sepsis experience an initial pro-inflammatory period which subsides, and
some subsequently develop acute lung injury, a manifestation of organ failure, in response to a
seemingly innocuous second stimulus.440,441

Animal studies have also demonstrated that

sequential exposure to combinations of inflammatory stimuli such as LPS, fecal peritonitis,
burns, or hypovolemia and hypoxia results in more severe hemodynamic changes, aggravated
inflammation, and increased mortality.440 The two-hit hypothesis of sepsis-associated organ
failure holds that an initial systemic inflammatory response primes the immune system and
causes an exaggerated response to the second stimulus.21,437-439
Animals exposed to multiple inflammatory stimuli have increased neutrophilic
infiltration into tissues and this corresponds to increased concentrations of inflammatory
cytokines.442,443 Fecal peritonitis alone does not induce hemodynamic changes indicative of
severe sepsis or acute lung injury in pigs despite the development of systemic bacteremia, but
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combining fecal peritonitis with gut ischemia/reperfusion injury induces marked hemodynamic
alterations, acute lung injury, and greater elevations in serum and lung inflammatory cytokine
production.444 Rats that experience hemorrhagic shock followed by LPS exposure demonstrate
earlier and more pronounced expression of cytokine-induced neutrophil chemoattractant (the rat
ortholog of IL-8) in alveolar macrophages, enhanced TNF-α expression,445 and a greater degree
of alveolar neutrophil sequestration than animals that receive either treatment alone.443 Use of a
mouse model of burn injury followed by LPS administration has shown a marked increase in
death associated with neutrophil and mononuclear cell infiltration of the lungs and liver in
animals exposed to both insults.442 Plasma concentrations of IL-6, IL-10, and TNF-α were
greatly increased, but IL-1β remained unchanged. Cytokine expression within the lungs and
livers of these animals was similar to plasma, with the notable exceptions that IL-1β was
elevated in all organs examined, and TNF-α expression was unaffected in the liver. Although
cell-surface TLR4 and MD-2 expression did not change, results suggested an increase in TLR4
reactivity to the second LPS stimulus. Finally, a study in humans demonstrated enhanced in
vitro superoxide anion release from stimulated neutrophils harvested from trauma patients
compared to healthy donors.446
Similar mechanisms may contribute to the pathophysiology of laminar injury. Diseases
such as colic and sepsis are usually present for several days prior to the development of
laminitis.447 Frequently, animals appear to experience recurrent “toxic showers,” or episodes
during which inflammation appears to be exacerbated. These events presumably occur as waves
of inflammatory stimuli enter the circulation from sources such as an infection site or the gut,
and could represent multiple insults to the laminar tissues. Additionally, since IR and loss of
glycemic control are associated with inflammation, local glucose concentrations in the hoof may
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increase during each inflammatory episode, leading to glucotoxic effects.

This has been

suggested to occur even if peripheral blood glucose concentrations remain within reference
range.299

1.4.4 Endotoxin Tolerance and its Relevance to Laminitis

Endotoxin tolerance refers to a decrease in the ability of LPS to elicit certain clinical and
biochemical responses following repeated exposures.76,448

Early-phase endotoxin tolerance

occurs within hours to days, while late-phase tolerance takes days to weeks to develop.449 Earlyphase endotoxin tolerance is an adaptation that limits the deleterious effects of excessive
inflammation on the host.70,450 However, this process has also been implicated in the later
immunosuppressive phase of sepsis and may contribute to the increased risk of secondary
infections seen in septic patients.451-454 This refractory condition has been documented in vitro
and also in vivo in numerous studies of septic humans and rodents,455-459 as well as the
horse.460,461 Lipopolysaccharide stimulation of whole blood from septic human patients results
in decreased release of TNF-α, IL-1β, and IL-6 from peripheral blood mononuclear cells when
compared to non-septic patients, and decreased responsiveness can persist for 10 days or
more.455 Isolated monocytes from patients with both Gram-negative and Gram-positive sepsis
produce less TNF-α and IL-1β in response to stimulation by multiple ligands including LPS and
staphylococcal enterotoxin B, indicating that cross-tolerance develops between Gram-negative
and Gram-positive bacterial components.462
Late-phase endotoxin tolerance is antibody-mediated, and may be directed either towards
the highly variable O-antigen or towards the conserved core antigens if tolerance is induced
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using mutant bacterial strains that lack O-antigen.449 Although antibodies directed against the Oantigen are protective, clinical applicability is questionable given the variability of this region
among bacterial species.9,463

Although all portions of the LPS molecule are theoretically

antigenic, antibodies produced against other portions of the molecule confer less protection than
those directed against the O-antigen.449,464,465 Failure of monoclonal antibodies generated against
lipid A to cross-react with LPS suggests that the lipid A portion is not exposed to the host
immune system in the native configuration of the molecule.9 Various monoclonal antibodies
directed against the conserved inner core region have shown mixed results in protecting animals
from endotoxemia.9
Although prolonged or repeated exposure of macrophages, neutrophils, and endothelial
cells to LPS may induce a refractory state,466-468 endotoxin tolerance does not result in global
down-regulation of the inflammatory response.76,468 Rather, intracellular signaling cascades are
altered to favor the down-regulation of pro-inflammatory mediator secretion and upregulation of
anti-inflammatory mediator secretion through complex alterations within the TLR4 signaling
pathway.76,448,469 Interaction of TLR4 with MyD88 decreases,470 and decreased association of
MyD88 with IRAK-4 has also been demonstrated.471 Upregulation of IRAK-M, which is a
negative regulator of TLR4 signaling,472 has been demonstrated in endotoxin-tolerant Kupffer
cells collected from mice.473 Increased turnover of IκB appears to be instrumental in preventing
NFκB activation in the endotoxin-tolerant state.474

Endotoxin tolerance also results in an

increase in the transcriptionally inactive p50/p50 homodimer of NFκB, which competes with the
active p50/p65 heterodimer for binding sites on gene promoter regions.475,476 The MyD88independent pathway has been implicated in the development of endotoxin tolerance.70,74-76
Myeloid differentiation factor 88-independent signaling upregulates negative feedback inhibitors
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of the inflammatory cascade, while it also stimulates late-phase pro-inflammatory gene
expression. This leads to low-grade prolonged exposure of cells to cytokines, which promotes
tolerance.

Endotoxin tolerance enhances certain cellular functions including macrophage

phagocytic activity.76 Tolerant neutrophils also continue to secrete IL-8,477 a chemokine with
importance to laminitis pathophysiology.430

1.4.5 Role of Insulin Resistance

Although IR has been identified as a risk factor for the development of laminitis,226 the
underlying mechanisms must still be elucidated. Initial efforts to explain the association focused
on insulin-mediated glucose metabolism in laminar keratinocytes. Insulin resistance decreases
GLUT4-mediated glucose uptake in insulin-sensitive tissues.478-480 Laminar tissue consumes
large amounts of glucose,481 and glucose deprivation caused separation between basal
keratinocytes and the BM in laminar explants.392,482

In addition, one study demonstrated

decreased GLUT4 immunostaining in the laminar tissues of horses with laminitis, leading to the
assumption that glucose uptake in laminar tissue is insulin-dependent.483 Although this theory
offered a plausible explanation for why IR predisposes horses to laminitis, it was later called into
question when further studies revealed that glucose uptake in the hoof is not affected by insulin,
and GLUT4 mRNA and protein are not expressed in laminar keratinocytes. 386,484

Rather,

laminar tissue appears to rely on the constitutive GLUT1 transporter. However, the insulin
receptor is expressed by the digital endothelium and vascular smooth muscle, so it is more likely
that IR is related to laminitis through vascular effects in the same way that obesity-related
endothelial dysfunction predisposes to cardiovascular disease.198,199
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Low-grade endothelial activation associated with IR may render the laminar vasculature
more susceptible to injury when a second insult such as systemic inflammation is
superimposed.307 Horses may experience transient inflammation when grazing on pasture if
carbohydrate overload occurs, and this may be sufficient to trigger a laminitis episode in
predisposed animals.

Overproduction of ET-1 is a feature of IR-associated endothelial

dysfunction in other species,198,199 and ET-1 has also been demonstrated to increase during
laminitis in the horse.485,486 If NO production is impaired in insulin-resistant horses, endothelial
cells may be unable to counteract the vasoconstrictive actions of ET-1, leading to laminar
hypoperfusion and stress. The role of NO in laminitis pathology is unclear, however, because
impaired NO production has not been demonstrated in laminitis models. Topical NO donors
have been reported to cause clinical improvement in ponies with lamintis487and in horses
following the administration of black walnut heartwood extract,488 but results are
inconsistent.489,490
The hyperinsulinemic model of laminitis achieves blood insulin concentrations greatly in
excess

of

those

commonly found

in

insulin-resistant

animals

with

compensatory

hyperinsulinemia,384,385 so its relevance to clinical disease is not clear. However, prolonged
exposure to moderately elevated insulin concentrations in horses with IR may also be detrimental
to laminar tissues.

1.5 Conclusions

Inflammation and IR are important risk factors for laminitis, and often develop
concurrently in animals with systemic illness. These conditions might have synergistic effects
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on tissues and vessels in the hoof, increasing their susceptibility to damage.

Chronic

inflammation and IR that accompany obesity are also likely to lower the threshold for laminitis
to develop if a triggering event occurs.
In order to identify therapeutic targets, the role of systemic inflammation in laminitis
must first be clarified. Although systemic inflammation is associated with laminitis, the specific
mediators involved are not well characterized. In systemically ill horses, inflammation is often
attributed to endotoxemia despite the fact that plasma endotoxin concentrations are not
commonly measured in clinical cases. A theoretical role exists for endotoxin in the pathogenesis
of laminitis because endotoxin is known to affect the digital vascular and activate platelets.
Endotoxin has also been detected during experimental laminitis induction, and laminitis is a
complication of diseases in which endotoxemia has been demonstrated. However, experimental
endotoxin administration does not induce laminitis, and this could be related to differences
between experimental models and naturally occurring disease.
The studies presented in this dissertation were performed to address the overall
hypothesis that systemic inflammation causes laminitis and new experimental models can be
developed to better represent clinical disease.

First, a study examining blood cytokine

expression during the induction of carbohydrate overload laminitis was undertaken to establish
the association between systemic inflammation and laminitis, and to more fully characterize
inflammatory mediators involved in the process. To further clarify the role of endotoxin in the
pathogenesis of laminitis, a second study was performed to determine whether an endotoxin
model that induced laminitis could be developed. The remaining studies explored whether
predisposing conditions such as EMS or existing endotoxemia increased susceptibility to
laminitis during systemic inflammation. Inflammatory cytokine responses and alterations in
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glucose and insulin homeostasis were assessed in horses with EMS following intravenous
endotoxin administration. The incidence and severity of carbohydrate overload laminitis were
also evaluated in horses with preexisting endotoxemia to assess whether repeated inflammatory
events caused more laminar damage than a single insult.
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CHAPTER 2
Inflammatory cytokine blood messenger RNA expression during the development of
oligofructose-induced laminitis in horses

2.1 Introduction

Inflammation is hypothesized to play a key role in the pathogenesis of equine laminitis,
with leukocyte infiltration436,491,492 expression of inflammatory cytokines and chemokines,400,429431,493,494

cyclooxygenase-2,432,495 and leukocyte adhesion molecules430,491 increasing in the hoof

tissues as laminitis develops.

These changes resemble the pathological events of sepsis-

associated organ failure,373,424 so it is hypothesized that systemic inflammation precedes the
onset of lameness in experimental models and incites laminar damage. Pyrexia and tachycardia
precede the development of laminitis in carbohydrate overload models165,409 and results of a
retrospective study showed that horses with clinical signs consistent with systemic inflammation
had 5-fold higher odds of developing laminitis.3 Peripheral leukocyte activation,425 increased
hepatic and pulmonary cytokine expression,427 and increased plasma tumor necrosis factor-α
(TNF-α) protein concentrations409 have all been detected during the developmental phase of
carbohydrate and black walnut extract laminitis models, indicating that these events cause or
accompany the development of laminitis.

Inflammation also causes peripheral insulin

resistance,164 which is an independent risk factor for laminitis.182
In carbohydrate overload models, starch418 or oligofructose (OF)165 is administered to
horses via nasogastric intubation. Fructans are non-structural storage carbohydrates that differ
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among plant species with regard to chain length, linkage of fructose residues, and degree of
branching and polymerization.496 Oligofructose is an inulin-derived short-chain polymer of β(21)-linked fructose residues that is commercially extracted from the root of the chicory plant
(Cichorium intybus) and used as a sweetener.497,498 Horses, like most mammals, lack the small
intestinal digestive enzymes necessary to hydrolyze dietary fructans, although some acid
hydrolysis may occur in the stomach.499 Oligofructose passes into the hindgut, where it is
rapidly fermented to lactic acid by Gram-positive streptococcal species.500-502

Cecal pH

decreases precipitously from approximately 7 to 4 in experimental models,165,503 causing damage
to the epithelium420 and increased permeability of the mucosal barrier.165,422,504 Death of Gramnegative

bacteria

ensues

and

endotoxin

concentrations

increase

in

cecal

fluid.505

Lipopolysaccharide has been detected in the blood of horses that receive carbohydrate409,423 and
it is assumed that translocation of endotoxin and other bacterial products into circulation incites
systemic inflammation.
Inflammatory gene expression in blood can be measured in whole blood samples or the
leukocyte fraction. The commercially available PAXgene® whole blood RNA collection systema
has successfully been used to quantify inflammatory responses in horses. 269,506 Advantages of
this system include the ease of sample collection, time efficient processing, and minimal RNA
degradation and alterations in the gene expression profile during collection and storage.507
The current study was undertaken to assess the systemic inflammatory response during
the development of OF-induced laminitis using the PAXgene® whole blood RNA collection
system in horses.

We hypothesized that systemic inflammation could be quantified by

measuring whole blood inflammatory cytokine gene expression and horses would develop
systemic inflammation during the OF laminitis induction model. We further hypothesized that
a

Qiagen/PreAnalytiX, Valencia, CA
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the time to onset and severity of laminitis would correlate with the magnitude of inflammatory
gene expression.

2.2 Materials and methods

Animals – Fourteen healthy adult geldings (10) and mares (4) received OF in a study conducted
at East Tennessee Clinical Research, Inc.b Horses ranged in age from 2 to 5 years old and
weighed between 358 and 556 kg (mean, 455 kg; median, 458 kg). Breeds included Quarter
Horse (5), Standardbred (3), Tennessee Walking Horse (2), mixed breed (2), Thoroughbred (1),
and Standardbred cross (1). The study protocol was approved by the East Tennessee Clinical
Research, Inc. Institutional Animal Care and Use Committee.

Study Design – Blood samples were obtained from horses undergoing laminitis induction as part
of a study in which animals were randomly assigned to receive either the placebo control
treatment (4 horses) or one of 3 drugs; the identities of which were not disclosed. Horses
received 1 g/kg OFc added to the basal ration for 3 days to adapt the hindgut flora to this
carbohydrate. Laminitis was induced in all animals on the fourth day by administering 10 g/kg
OF dissolved in 4 L of warm water via nasogastric tube as previously described. 165 Whole blood
was collected at 0, 8, 12, 16, 20, and 24 hours for evaluation of inflammatory cytokine gene
expression. Lameness evaluations were performed every 4 hours, and laminitis was graded
accordingly to the Obel grading scale.508 Horses were euthanized at the onset of Obel grade 3

b
c

80 Copper Ridge Farm Road, Rockwood, TN 37854
Orafti® P95, formerly marketed as Beneo® 95, BENEO-Orafti S.A., Pemuco, Chile
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laminitis or at 48 hours if Obel grade 3 laminitis did not occur. All other physical examination
data were withheld from the investigators.

Whole blood inflammatory cytokine gene expression – Blood samples for quantitation of
Interleukin (IL)-1β, IL-6, IL-8, IL-10, TNF-α, and β-glucuronidase gene expression were
collected into PAXgene® blood RNA tubesd and allowed to incubate at room temperature for 4
hours. Samples were then transferred to a –20ºC freezer for 24 hours, and were subsequently
stored at – 80 °C until analysed.
Total RNA was extracted from thawed whole blood samples using the corresponding
PAXgene® blood RNA extraction kitd accordingly to the manufacturer’s protocol. Concentration
and purity of RNA in each sample was measured via spectrophotometry. e Reverse transcription
was performed using 1 μg of RNA diluted in 41.5 μL nuclease-free water and added to 38.5 μL
of master mix that contained 0.5 μL avian myeloblastosis virus reverse transcriptase f (AMV RT;
22 U/μL), 1 μL oligo dT primerf (0.5 μg/μL), 1 μL RNAsinf (40 U/μL), 4 μL dNTP mixf (10
mM), 16 μL magnesium chloridef (25 mM), and 16 μL AMV RT 5X bufferf per reaction.
Reactions were incubated in a thermal cyclerg at 42ºC for 15 minutes followed by 95ºC for 5
minutes.
Real-time polymerase chain reaction (PCR) was performed using validated equine
specific intron-spanning primers and probes.104,269 Primers and probes were designed to be
intron spanning based on comparisons of the equine mRNA sequences to homologous splice
sites reported for other species. Predicted junctional sequences were then blasted against the

d

Qiagen/PreAnalytiX, Valencia, CA
NanoDrop ND-1000, Thermo Fisher Scientific, Wilmington, DE
f
Promega Corp., Madison, WI
g
TaKaRa PCR Thermal Cycler Dice,™ TaKaRa Bio Inc., Otsu, Shiga, Japan
e
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equine genome to confirm target gene specificity. Assays using known positive and negative
control samples, genomic DNA, and non-reverse transcribed RNA were employed to ensure that
each primer/probe combination performed appropriately and did not amplify genomic DNA.
For each PCR reaction, cDNA was diluted 1:1 with 80 μL of nuclease-free water. The
PCR reaction mixture contained 4.5 μL of diluted cDNA, 5 μL of master mix,h and 0.5 μL of
20X primer/probe assay mix.i Samples were loaded onto platesj using an automated systemk and
analyzed in duplicate using a real-time PCR thermal cycler.l Thermal cycling parameters were
95ºC for 10 minutes followed by 40 cycles of 95ºC for 15 seconds and 60ºC for 60 seconds.
Amplification efficiencies of individual PCR reactions were verified to be between 80 and 120%
using computer software.m The comparative CT (ΔΔCT) method was used to determine fold
changes in inflammatory cytokine gene expression.509 For each sample, cytokine threshold cycle
(Ct) values were first normalized to the housekeeping gene β-glucuronidase.

Baseline

measurements were not available for 4 of 14 horses, therefore a pooled calibrator was generated
for each cytokine by averaging all baseline ΔCt values for that gene. The pooled calibrator was
used to calculate fold changes in gene expression.

Statistical Analysis – Mixed model analysis of variance (ANOVA) for repeated measures was
performed using computer softwaren to determine the effect of time on whole blood
inflammatory cytokine gene expression. Data were blocked on horse. The autoregressive

h

TaqMan® Gene Expression Master Mix, Applied Biosystems, Foster City, CA
TaqMan® Custom Gene Expression Assays, Applied Biosystems, Foster City, CA; primer sequences provided
courtesy of Dr. David Horohov
j
MicroAmp® Optical 384-Well Reaction Plate with Barcode, Applied Biosystems, Foster City, CA
k
epMotion 5070, Eppendorf, Hamburg, Germany
l
7900HT Fast Real-Time PCR System, Applied Biosystems, Foster City, CA
m
LinRegPCR, http:// LinRegPCR.HFRC.nl
n
PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC
i
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correlation parameter was excluded from the model for analysis of IL-6, IL-10, and TNF-α gene
expression. Data for IL-1β, IL-6, IL-8, and IL-10 required logarithmic transformation to fit
ANOVA normal distribution assumptions and are reported as geometric means with 95% CI.
Data for TNF-α were normally distributed and are reported as least squares means ± SEM. Mean
separation was performed using Fisher’s protected least significant difference. The trapezoidal
method was employed to calculate AUC for inflammatory cytokine expression using computer
software.o Peak inflammatory cytokine expression and AUC were correlated with time to onset
of Obel grade 1 and 3 laminitis and maximum recorded Obel score at the level of the individual
animal using Pearson correlation coefficients. To eliminate any potential treatment effects, all
data analyses were repeated using only the 4 control group horses and results were compared to
the 10 treated animals. Significance was set at P < 0.05 for all comparisons.

2.3 Results

Development of laminitis – All horses developed clinically detectable laminitis during the 24hour blood sampling period. The onset of Obel grade 1 laminitis occurred between 12 and 24
hours (Table 2.1). Two horses progressed to Obel grade 3 laminitis at 20 hours and were
euthanized before the final blood sample was collected. Four animals were euthanized at 48
hours without having reached Obel grade 3. The 4 horses in the control group developed
laminitis at 12 hours (1) and 16 hours (3). Two control animals progressed to Obel grade 3 at 24
hours (1) and 28 hours (1). Other physical examination parameters were not made available for
the purposes of this study.

o

SAS, version 9.2, SAS Institute, Inc., Cary, NC
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Table 2.1 Time to onset of Obel grade 1 and Obel grade 3 laminitis in horses following
administration of a 10 g/kg dose of OF. All 14 horses developed Obel grade 1 disease, and 10
horses progressed to Obel grade 3. Numbers indicate how many animals developed either Obel
grade 1 or 3 laminitis at the specified time points.

Time to onset of laminitis
20h
24h
28h
32h

12h

16h

Obel grade 1
14 horses

2

8

3

1

-

Obel grade 3
10 horses

-

-

2

1

3

36h

40h

-

-

-

1

-

3
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Inflammatory cytokine gene expression – Interleukin-1β (P < 0.001; Figure 2.1A), IL-6 (P =
0.005; Figure 2.1B), IL-8 (P < 0.001; Figure 2.1C), and IL-10 (P < 0.001; Figure 2.1D)
expression increased following OF administration. Interleukin-6 and IL-10 expression peaked at
16 hours, followed by IL-1β and IL-8 at 20 hours. A lower IL-8 peak was also detected at 8
hours.

Tumor necrosis factor-α expression did not change over time (Figure 2.1E).

No

significant correlations were identified between peak gene expression values or AUC and time to
onset or severity of laminitis. When only control group animals were considered, IL-1β (P =
0.002), IL-8 (P = 0.017), and IL-10 (P = 0.013) expression increased significantly, and gene
expression curves retained the same shapes as in the full analysis. Interleukin-6 did not increase
significantly over time in the control group, resulting in a significant treatment effect (P = 0.040)
when control and treatment groups were compared. Although time effects were not significant
for TNF-α, a treatment × time effect was detected (P = 0.048) because expression differed
between control (2.2 ± 0.5 fold increase relative to baseline) and treatment (1.2 ± 0.2 fold
increase) groups at 24 hours.

2.4 Discussion

Inflammatory responses were successfully quantified using the PAXgene® whole blood
RNA collection system and systemic inflammation was detected during the OF carbohydrate
overload model, so our hypothesis was supported. The magnitude of systemic inflammation was
not associated with either time to onset or severity of laminitis.
The pro-inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α measured in this study are
major regulators of the innate immune response,18,19 while IL-10 is an anti-inflammatory
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Figure 2.1 Change in whole blood gene expression of IL-1β, IL-6, IL-8, IL-10, and TNF-α in
horses following administration of a 10 g/kg dose of OF. Geometric means and 95% CI for IL1β, IL-6, IL-8, and IL-10, and mean ± SEM for TNF-α are displayed on a logarithmic scale.
Letters refer to significant time effects on all graphs.

*Treatment × time effects indicate

significant differences between control and treatment groups. For IL-6 and TNF-α, values for
the treated groups, collectively, and the control group are displayed separately. Pooled data from
all 14 horses are presented for all other variables. A) Time (P < 0.001) effects were detected for
IL-1β. B) Time (P = 0.005) and treatment (P = 0.040) effects were detected for IL-6. C) Time
(P < 0.001) effects were detected for IL-8. D) Time (P < 0.001) effects were detected for IL-10.
E) Time (P = 0.369) effects were not significant for TNF-α, however treatment × time (P =
0.048) effects were detected.
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Figure 2.1, continued.
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Figure 2.1, continued.
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Figure 2.1, continued.
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Figure 2.1, continued.
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Figure 2.1, continued.
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mediator that plays an important role in sepsis.32

Changes in cytokine expression were

consistent with the systemic inflammatory response reported in other studies using the OF
model.165,409 Expression of IL-1β, IL-8, and IL-10 increased above baseline beginning at 8
hours, and IL-6 began to increase at 16 hours. Although endotoxin concentrations were not
measured in our study, this time frame coincides with previously reported increases in plasma
endotoxin concentrations between 8 and 12 hours following OF administration.409 In the same
report, increased plasma TNF-α protein concentrations were detected between 12 and 24
hours.409
Endotoxin and other bacterial products activate circulating leukocytes through pattern
recognition receptors such as Toll-like receptor 4.13

Activated leukocytes then secrete

inflammatory mediators that orchestrate the innate and adaptive immune responses.7,11 The time
course of gene expression in sepsis is variable among studies,510 and species-specific data are
scarce in the horse. Tumor necrosis factor-α and IL-1β generally increase first and stimulate the
release of more distal mediators such as IL-6, IL-8, and IL-10.511 Plasma cytokine levels are
often detectable within minutes to hours and may persist for several days.18,19 Because gene
expression was first analysed at 8 hours in our study, temporal relationships among cytokines
should be interpreted with caution. Overall, cytokine expression in our study coincided with
previously reported increases in plasma endotoxin and TNF-α protein concentrations, as well as
fever, tachycardia, and the onset of diarrhea.165,409 Unfortunately, physical examination data
were withheld in this study, so further comparisons are not possible.
Increased peripheral leukocyte IL-1β, IL-6, and IL-8 expression is consistent with
changes described in the laminitic hoof,429-431,493 and these cytokines predict organ failure and
correlate negatively with outcome in septic humans.28,512-514 In the study reported here, IL-10
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expression increased in the blood, which contrasts with previous reports of normal or decreased
expression of this cytokine in laminar tissues.429,493 Interleukin-10 is an important negative
regulator of inflammation that prevents excessive tissue damage while also contributing to the
development of immunosuppression.24,29,32

In humans, high

IL-10 concentrations are

negative prognostic indicator for sepsis,30,515 yet inadequate IL-10 responses can also

a
be

detrimental.516 Compartmentalization of the inflammatory response often occurs during sepsis,
and inflammatory responses can differ markedly between organs and blood.517

Peripheral

leukocytes may therefore produce IL-10 while laminar tissues do not.
Higher plasma TNF-α concentrations have previously been detected following OF
administration to horses,409 but gene expression did not change at comparable time points in our
samples. One explanation for this discrepancy is that peripheral leukocytes are not the primary
source of TNF-α protein, and the liver and lungs produce the majority of circulating
protein.427,518,519 Tumor necrosis factor-α also consistently fails to increase in the laminitic hoof,
so it may not be important in the pathogenesis of this disease.429,493 It is also conceivable that
compartmentalization of the inflammatory response occurs517,520 such that the liver and lungs
produce TNF-α while hoof tissues do not. Another explanation for our finding is that TNF-α
peaked early and expression had decreased below detectable levels by the time that the blood
sample was collected at 8 hours. This inflammatory cytokine peaks early in the inflammatory
cascade and has a half-life of approximately 20 minutes in humans.18
The commercially available PAXgene® whole blood RNA extraction system was used in
this study and inflammatory gene expression was successfully quantified. Use of whole blood
provides an advantage when multiple samples are obtained because samples can be stored and
processed later. Leukocyte isolation was considered as an alternative because it eliminates
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contaminating RNA derived from the erythrocyte and reticulocyte fraction521-523 and increases
the sensitivity of certain gene expression assays.522 However loss of leukocyte subsets may
occur during fractionation and sample handling associated with additional processing steps may
induce alterations in the gene expression profile.524,525 Gene expression profiles change rapidly
following blood collection,526,527 so fractionation procedures must be performed immediately.
This approach would not have been feasible in the current study due to logistical considerations.
Laminitis was first detected between 12 and 24 hours, which is earlier than the 20 to 36
hour range previously reported.165,409,417 The significance of this finding is unclear, but may
reflect differences in the processing or purity of OF obtained from various commercial suppliers.
Response of individual animals to carbohydrate overload is also variable, and laminitis has
previously been reported to develop in approximately 80 to 100% of horses receiving 10 g/kg
OF.165,409,417 All horses in the currently study developed laminitis and 10 animals were severely
affected (Obel grade 3).
No association was found between peak cytokine expression or AUC and laminitis onset
or severity. This may be explained by the compartmentalization of inflammatory responses
within different tissues,517 such that whole blood inflammatory cytokine expression fails to
parallel expression within laminar tissues.

Alternatively, our results suggest that laminitis

develops closer to the onset of systemic inflammation, before gene expression peaks. This
theory is supported by our finding that 10 horses developed laminitis before mean cytokine
expression peaked at 16 to 20 hours.
Our results indicate that systemic inflammation accompanies the development of
laminitis, but we do not provide evidence of a direct cause and effect relationship. It remains
conceivable that other factors trigger laminitis and systemic inflammation is just a co-morbid
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condition. The equine gastrointestinal tract contains a diverse population of Gram-negative and
Gram-positive bacteria,528 as well as vasoactive protein metabolites,375 that gain access to
systemic circulation following carbohydrate overload.295,421 Vasoactive amines directly affect
the vasculature of the equine digit due to their structural similarities with the endogenous
vasoconstrictors, serotonin and norepinephrine.375

These vasoactive amines, or other gut-

derived factors, may be the trigger for laminitis, with systemic inflammation contributing to the
process or merely occurring concurrently.
The main weakness of our study was that samples were obtained from a study examining
the efficacy of three different drugs and these products were not described. Treatment groups
cannot be accounted for in our statistical analyses and it is conceivable that one or more of these
drugs impacted results. However, with the exception of IL-6 and TNF-α, horses receiving drugs
did not differ significantly from the control group. Shortcomings of this study are balanced by
the advantages of testing hypotheses without duplicating laminitis studies. This is particularly
important when the animal welfare concerns of laminitis research are considered.
We conclude that systemic inflammation can be detected during the experimental
induction of laminitis by measuring whole blood inflammatory gene expression and the
magnitude of this inflammatory response does not correlate with time to onset or severity of
laminitis.
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CHAPTER 3
Effects of continuous or intermittent lipopolysaccharide administration for 48 hours on the
systemic inflammatory response in horses

This chapter is a revised version of an article by the same name that has been accepted for
publication in the American Journal of Veterinary Research by Elizabeth M. Tadros and
Nicholas Frank.

Reference: Tadros EM, Frank N. Effects of continuous or intermittent lipopolysaccharide
administration for 48 hours on the systemic inflammatory response in horses. Am J Vet Res. In
press.

3.1 Introduction

Systemic inflammation increases the risk of laminitis in horses.529 Endotoxin has been
detected in the blood of horses with gastrointestinal disease,530 and exposure to
lipopolysaccharide (LPS) likely contributes to the development of inflammation in these cases.
Although LPS elicits a marked inflammatory response,13 the true role of LPS in the
pathophysiology of laminitis remains unclear. Recent focus has shifted towards understanding
laminitis as an inflammatory process with similarities to sepsis-associated organ failure.373,424
Increased laminar expression of pro-inflammatory genes has been demonstrated400,430,493,494,531
and laminar inflammation coincides with systemic inflammatory events.425,428,532 Intravenous

79

LPS administration increases gene expression of interleukin (IL)-1α, IL-1β, IL-6, IL-8, and
tumor necrosis factor-α (TNF-α) in equine peripheral blood leukocytes533 and also raises
circulating IL-6 and TNF-α protein concentrations in treated horses.410,534

Endotoxemia is

therefore expected to contribute to the development of laminitis in horses. It must be recognized
however, that endotoxin is just one component of a complex syndrome of sepsis, so it may be
necessary for several factors to converge before laminitis develops in the horse with systemic
illness.
Despite the theoretical basis for endotoxemia inducing laminitis, this condition has not
been induced by intravenous infusion of LPS in experimental models.410,414,415,460,534 One group
reported hoof discomfort following a 24-hour LPS infusion, yet gross pathological lesions were
not identified at necropsy.460

This discrepancy may be explained by differences between

experimental models and clinical endotoxemia.416

Lipopolysaccharide has usually been

administered as a single low-dose intravenous bolus infusion in experimental models, although
longer duration infusions,410,460 repeated boluses,414,415 and higher dosing regimens414,460 have
been used. Lipopolysaccharide infusions have not extended beyond 24 hours in previous studies.
In contrast, clinical endotoxemia is often present for several days before laminitis develops.
Anecdotal experience also suggests that horses with gastrointestinal diseases such as bacterial
colitis can experience intermittent worsening of vital parameters and clinical condition. These
episodes may correspond to fluctuating amounts of LPS or other trigger factors translocating
from the gastrointestinal tract. Repeated exposure to inflammatory stimuli has been implicated
in the pathogenesis of organ failure during sepsis,442,444 so intermittent exposure to LPS could
increase the magnitude of systemic inflammation and prove more detrimental to laminar tissue.
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Inflammation increases secretion of inflammatory cytokines and hormones that inhibit
insulin signaling and induce insulin resistance.91

Altered glucose and insulin homeostasis

therefore serves as a marker of systemic inflammation. A single dose of endotoxin perturbs
insulin sensitivity and glucose homeostasis in horses for 24 hours,327 and decreased insulin
sensitivity persists for 48 hours following an 8-hour LPS infusion.164 Measures of glucose and
insulin dynamics may therefore reflect the magnitude and persistence of systemic inflammation.
This study was undertaken to evaluate two experimental models for endotoxemia in
horses and determine whether laminitis results from LPS administration over 48 hours. We
hypothesized that the method of LPS administration (intermittent versus continuous) affects the
magnitude and duration of the systemic inflammatory response, and that prolonged (48 hours)
endotoxemia induces laminitis.

3.2 Materials and methods

Animals - Twelve healthy adult mares (10) and geldings (2) from the University of Tennessee
teaching and research herd were included in the study. Animals ranged in age from 4 to 17 years
old and body weight ranged from 364 to 559 kg (mean, 502 kg; median, 513 kg). Breeds of
horse included Thoroughbred (5), Quarter horse (4), Paint horse (1), Appaloosa (1), and Arabian
(1). Horses with a known history of laminitis or evidence of laminitis on physical examination
were excluded. Horses were housed in stalls within the University of Tennessee Veterinary
Medical Center throughout the testing period. Grass hay and water were provided ad libitum.
The study protocol was approved by the University of Tennessee Institutional Animal Care and
Use Committee.
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Study design – Horses were evaluated in groups of 3 and each animal was evaluated once.
Animals were transported to the Veterinary Medical Center and allowed to acclimate to their
environment for 24 hours before procedures were initiated.

Physical examinations were

performed and body weight measurements obtained at the time of admission. A 14-gauge
intravenous (IV) cathetera was placed in each jugular vein and baseline (–24 hour) intravenous
glucose tolerance tests (IVGTTs) were performed between 0930 and 1100 the morning after
arrival.

One IV catheter was used for infusions and the other for blood collection.

Administration of LPS or saline was initiated the following day between 0900 and 0930 (time =
0 hours). Horses were randomly assigned to receive a constant rate infusion (CRI) of LPS
(LPS-CRI; n = 4) or saline (SAL; n = 4), or 8 bolus infusions of LPS over 48 hours (LPS-BOL;
n = 4). A crossover study design could not be employed because horses have been shown to
develop antibodies to core LPS.535 Blood samples were collected immediately prior to LPS or
saline administration for complete blood count (CBC) analysis, biochemical profile, and
assessment of whole blood inflammatory cytokine gene expression. Additional CBCs were
performed at 3 and 24 hours. Physical examinations were performed every 4 hours, at which
time horses were also assessed for the development of laminitis using the Obel scoring
method.536 Blood samples were collected every 8 hours, and IVGTTs were performed at 8, 24,
32, and 48 hours. Intravenous catheters were removed at the end of the study period.

Lipopolysaccharide and saline administration – The LPS-CRI group received commercially
available Escherichia coli O55:B5 LPS solution.b

Lipopolysaccharide used to prepare the

solution was phenol-extracted, then purified using gel filtration and ion exchange

a
b

Abbocath-T 14 G X 140 mm, Abbott Laboratories, North Chicago, IL
Sigma Aldrich, Inc., St Louis, MO
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chromatography to yield a product containing < 1% protein and < 1% RNA. The LPS solution
was diluted to a final concentration of 0.021 μg/mL infused via the IV catheter at a rate of 80
mL/hr for 48 hours. Each LPS bolus contained 10 μg LPS diluted in 60 mL sterile saline and
was administered IV every 6 hours as a slow bolus over 30 minutes. Horses in the control group
received a CRI of sterile saline at a rate of 80 mL/hr for 48 hours.

IVGTT procedure – Baseline plasma and serum samples were collected via the IV catheter into
sodium fluoride / potassium oxalate and serum tubes. An IV bolus of 50% dextrose solutionc
was then administered at a dosage of 100 mg/kg bwt. Serum and plasma samples were collected
at 15, 30, 45, 60, 75, 90, 105, 120, and 150 minutes for measurement of blood glucose and
insulin concentrations. Sodium fluoride / potassium oxalate tubes were immediately cooled on
ice and serum tubes were allowed to clot at room temperature for 1 hour.

Tubes were

centrifuged at 1,000 × g for 10 minutes and plasma or serum was harvested and stored at –20 ºC
until analyzed.

Measurement of blood variables – Blood samples for CBC, fibrinogen, and biochemical profile
analysis were collected into appropriate anticoagulant or serum tubes and analyzed by the
University of Tennessee Clinical Pathology laboratory.

Whole blood inflammatory cytokine gene expression – Blood samples for quantitation of IL-1β,
IL-6, IL-8, IL-10, TNF-α, and β-glucuronidase (B-Gus) gene expression were collected into
whole blood RNA collection tubesd and allowed to incubate at room temperature for 8 hours,

c
d

Vedco, Inc., St. Joseph, MO
PAXgene® blood RNA tubes, Qiagen/PreAnalytiX, Valencia, CA
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then stored at – 20 °C until analyzed. Total RNA extraction and real-time polymerase chain
reaction were performed as previously described (refer to chapter 2). The comparative CT
(ΔΔCT) method was used to determine fold changes in inflammatory cytokine gene
expression.509 Cytokine expression was normalized to the housekeeping gene B-Gus and each
horse’s baseline value was used as the calibrator. Baseline gene expression was therefore equal
to a 1-fold change for all cytokines.

Plasma glucose and serum insulin concentrations – Plasma glucose concentrations were
measured in duplicate using a colorimetric assaye on an automated discrete analyzer.f Serum
insulin concentrations were measured in duplicate using a radioimmunoassayg that has been
validated for use with equine plasma in our laboratory and by others.537 Intra-assay coefficient
of variation < 5% was required for acceptance of glucose assay results and <10% was required
for acceptance of insulin assay results. Area under the curve for glucose (AUCg) and area under
the curve for insulin (AUCi) were calculated using the trapezoidal method and computer
software.h

Statistical Analysis – Mixed model analysis of variance (ANOVA) for repeated measures was
performed using computer softwarei to determine effects of treatment and time on rectal
temperature, heart rate, and respiratory rate.

The autoregressive correlation parameter was

excluded from the model for analysis of AUCg, AUCi, total white blood cell count, neutrophil
count, lymphocyte count, and fold changes in whole blood inflammatory cytokine gene
e

Glucose, Roche Diagnostic Systems, Inc., Somerville, NJ
Cobas Mira, Roche Diagnostic Systems, Inc., Somerville, NJ
g
Coat-A-Count Insulin, Diagnostic Products Corp., Los Angeles, CA
h
SAS, version 9.2, SAS Institute, Inc., Cary, NC
i
PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC
f
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expression. Mean separation was performed using Fisher’s protected least significant difference
and significance was set at P < 0.05. Gene expression data required logarithmic transformation
to fit ANOVA normal distribution assumptions and data are reported as geometric means with
95% CI. One-sample t-tests with Bonferroni correction for multiple comparisons were used to
compare mean cytokine expression at each time point to the pre-infusion baseline. Significance
was set at P<0.0028 when the Bonferroni correction was applied. Single degree of freedom
contrasts were employed to compare mean cytokine expression averaged over all time points on
the first day of sampling to the second day within each treatment group. Contrasts were also
used to compare gene expression at corresponding time points on the first and second day (e.g. 8
hours to 32 hours) within each treatment group. Body weight was initially included in the model
as a covariate term, but was excluded from the statistical model due to lack of significance.
Exclusion of body weight was further supported by Spearman’s rank correlation coefficients and
Pearson correlation coefficients, which revealed only weak associations between weight and
other dependent variables. Associations between cytokine expression, rectal temperature, heart
rate, and respiratory rate were assessed using Spearman’s rank correlation coefficients.
Correlation analysis was performed at the level of the individual animal. Significance was set at
P<0.05 for all correlations. Data from both LPS groups were pooled and compared to the SAL
group for analysis of AUCg and AUCi. Values for AUCg and AUCi also required logarithmic
transformation and are reported as geometric means with 95% CI. All other data are reported as
least squares means ± SEM.
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3.3 Results

Clinical signs – Treatment groups did not differ significantly with respect to body weight or age.
All LPS-treated horses exhibited depression, anorexia, and mild colic signs including pawing,
yawning, stretching, muscle fasciculations, and lateral recumbency in response to LPS. Three of
4 horses in the LPS-BOL group exhibited little or no clinical response to LPS after 24 hours,
although the attitude of one animal remained depressed until 32 hours. The fourth horse showed
mild colic signs after LPS administration for 7 of 8 infusions, but did not respond to the final
infusion. Depression, anorexia, and signs of colic abated in all horses in the LPS-CRI group by
12 hours, with the exception of one horse that had a dull attitude until 32 hours. Laminitis was
not detected in any of the horses.
All LPS-treated horses developed fever (rectal temperature > 38.5 ºC) and transient fever
was detected at 40 hours in one SAL group horse that developed cellulitis at the IV catheter site.
Time (P < 0.001) and treatment × time (P < 0.001) effects were significant (Figure 3.1). Mean
rectal temperature was significantly above baseline from 4 to 16 hours in the LPS-CRI group and
peaked at 8 hours (38.9 ± 0.2 ºC). In the LPS-BOL group, mean rectal temperature was above
baseline at 4, 8, and 20 hours, and also peaked at 8 hours (39.0 ± 0.1 ºC). No increase in rectal
temperature was observed in the LPS-CRI group after 16 hours or in the LPS-BOL group after
20 hours. Peak rectal temperature did not differ significantly in magnitude between the two LPS
treatment groups. Six of 8 horses that received LPS developed tachycardia (heart rate ≥ 48
bpm), however neither treatment nor time effects were significant. No significant differences
were detected in respiratory rate following LPS administration.
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Figure 3.1 Change in mean ± SEM rectal temperature of horses receiving an LPS CRI of 80μg
total over 48 hours, 8 boluses of 10μg LPS q6h for 48 hours, or a saline CRI at 80 mL/h for 48
hours. *LPS-BOL: Significant difference from baseline. †LPS-CRI: Significant difference from
baseline. ‡SAL: Significant difference from baseline. Significant time (P < 0.001) and treatment
× time (P < 0.001) effects were detected.
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Hematology – Leukocyte counts were not affected by the method of LPS administration (data not
shown). Leukopenia (reference range = 4.6 – 12 × 103 WBC/μL)j was detected in 1 of 4 horses
from the LPS-CRI group and 2 of 4 horses in the LPS-BOL group.

Inflammatory cytokine gene expression – Significant time effects were detected for the
expression of IL-1β (P < 0.001; Figure 3.2A), IL-6 (P < 0.006; Figure 3.2B), IL-8 (P < 0.005;
Figure 3.2C), and IL-10 (P < 0.009; Figure 3.2D). Treatment × time effects were detected for
IL-1β (P < 0.001), IL-8 (P < 0.047), and TNF-α (P < 0.044; Figure 3.2E) expression. A
significant treatment effect was also detected for IL-8 (P < 0.029), but no differences were
detected between LPS groups. Expression of IL-1β, IL-6, and IL-8 significantly increased in
both LPS groups at one or more time points relative to pre-infusion baseline when one-sample ttests were performed, whereas IL-10 and TNF-α expression did not increase over time in either
group. Except for TNF-α in the LPS-CRI group, peak expression of cytokines was detected at 8
hours in the LPS groups.
Comparison of corresponding time points on the first and second days of sampling
revealed significant differences for IL-1β and IL-10 in both LPS groups and IL-6, IL-8, and
TNF-α in the LPS-BOL group (Table 3.1). Differences in IL-10 and TNF-α expression were
detected between days 1 and 2, although there were no differences from baseline. When gene
expression was averaged across all time points for each day, expression of IL-1β in both LPS
groups, and IL-8 and IL-10 in the LPS-BOL group was significantly higher on day 1 than day 2.
Expression of IL-1β and TNF-α expression varied significantly in the SAL group, but did not
increase significantly relative to baseline.

j

Reference ranges used by the University of Tennessee Clinical Pathology laboratory
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Figure 3.2 Change in whole blood gene expression of IL-1β, IL-6, IL-8, IL-10, and TNF-α in
horses receiving an LPS CRI of 80μg total over 48 hours, 8 boluses of 10μg LPS q6h for 48
hours, or a saline CRI at 80 mL/h for 48 hours. Data are expressed as geometric means and 95%
CI, and are displayed on a logarithmic scale. Significance was set at P < 0.0028 for one-sample
t-test comparisons between cytokine expression at each time point, compared to baseline.
Significance for ANOVA main effects and interactions was defined by P < 0.05. *LPS-BOL:
Significant difference from baseline. †LPS-CRI: Significant difference from baseline. A) Time
(P < 0.001) and treatment × time (P < 0.001) effects were detected for IL-1β. B) Time (P =
0.006) effects were detected for IL-6. C) Treatment (P = 0.029), time (P = 0.005), and treatment
× time (P = 0.047) effects were detected for IL-8. D) Time (P = 0.009) effects were detected for
IL-10. E) Treatment × time (P = 0.044) effects were detected for TNF-α.
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Figure 3.2, continued.
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Figure 3.2, continued.
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Figure 3.2, continued.
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Figure 3.2, continued.
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Figure 3.2, continued.
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Table 3.1. Geometric means and 95% CI expression of inflammatory cytokines in horses
receiving an LPS CRI of 80μg total over 48 hours, 8 boluses of 10μg LPS q6h for 48 hours, or a
saline CRI at 80 mL/h for 48 hours. Corresponding time points on days 1 and 2 are compared, as
well as overall mean values across the two 24-h periods, and P values for treatment × time
effects obtained by analyzing all data using ANOVA are also displayed. Significance is defined
by P < 0.05.

Cytokine

Group

Relative expression

24-h
Mean
Day
1 vs. 2

Treatment
× time

Day 1
Time = 8h

Day 2
Time = 32h

P

P

Interleukin-1β

LPS-BOL
LPS-CRI
SAL

26 (13 to 50)a
18 (5.5 to 62)a
1.1 (0.62 to 2.0)b

1.9 (1.3 to 2.7)b
2.9 (2.0 to 4.3)b
3.2 (1.1 to 8.8)a

0.001
0.001
0.068

0.001

Interleukin-6

LPS-BOL
LPS-CRI
SAL

5.3 (2.8 to 10)a
4.2 (1.2 to 15)a
1.8 (1.1 to 2.9)a

0.83 (0.34 to 2.0)b
1.6 (1.1 to 2.3)a
2.6 (1.6 to 4.4)a

0.220
0.091
0.193

0.054

Interleukin-8

LPS-BOL
LPS-CRI
SAL

69 (21 to 232)a
14 (7.0 to 30)a
1.1 (0.28 to 4.7)a

10 (1.9 to 56)b
6.6 (3.2 to 14)a
1.2 (0.41 to 3.5)a

0.002
0.155
0.404

0.047

Interleukin-10

LPS-BOL
LPS-CRI
SAL

6.3 (0.95 to 42)a
4.9 (1.1 to 21)a
1.1 (0.61 to 2.1)a

0.37 (0.10 to 1.3)b
1.2 (0.43 to 3.1)b
1.4 (0.88 to 2.3)a

0.003
0.278
0.752

0.208

TNF-α

LPS-BOL
LPS-CRI
SAL

2.5 (0.83 to 7.5)a
0.67 (0.34 to 1.3)a
2.1 (1.2 to 3.6)a

0.78 (0.50 to 1.2)b
1.0 (0.30 to 3.6)a
0.66 (0.29 to 1.5)b

0.276
0.990
0.074

0.044

a,b

For each variable, different letters indicate significant (P < 0.05) differences between day 1
and day 2
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Correlations among gene expression and vital parameters – Interleukin-1β expression was
positively correlated with rectal temperature (Spearman’s rho = 0.49; P < 0.001), IL-8
expression (Spearman’s rho = 0.57; P < 0.001), and IL-10 expression (Spearman’s rho = 0.53; P
< 0.001). Other correlations with Spearman’s rho coefficients less than ± 0.37 were identified,
but are not reported.

When only peak cytokine expression values and maximum rectal

temperature, heart rate, and respiratory rate were included in analyses, peak IL-1β expression
was positively correlated with peak rectal temperature (Spearman’s rho = 0.69; P < 0.013).

Glucose and insulin dynamics – A significant time effect (P = 0.028) was detected for AUCg
(Figure 3.3A). Horses that received LPS did not differ from those that received saline. Neither
treatment nor time effects were significant for AUCi (Figure 3.3B).

3.4 Discussion
Exposure to LPS induced systemic inflammation, but our hypothesis was not supported
because the method of LPS administration did not affect the magnitude or duration of the
inflammatory response or induce laminitis. Clinical responses to LPS abated over time in all
animals indicating the development of endotoxin tolerance. Inflammatory cytokine expression
profiles were comparable between groups, with positive correlations detected between IL-1β
gene expression and rectal temperature, as well as among IL-1β, IL-8, and IL-10 values.
Rectal temperature significantly increased following LPS infusion, which is consistent
with previous reports.164,327 Temperature only increased in response to LPS on the first day,
indicating that animals became refractory to the effects of LPS over time. No increase in rectal
temperature was observed in the LPS-CRI and LPS-BOL groups after 16 hours or 20 hours,
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Figure 3.3 Area under the glucose and insulin concentration curves in horses receiving an LPS
CRI of 80μg total over 48 hours, 8 boluses of 10μg LPS q6h for 48 hours, or a saline CRI at 80
mL/h for 48 hours. A) Area under the glucose concentration curve values for horses receiving
LPS or saline. Data were pooled for horses receiving LPS as a continuous rate infusion to deliver
80μg total over 48 hours and 8 boluses of 10μg LPS q6h for 48 hours. The control group
received saline as a CRI at 80 mL/h for 48 hours. Data are expressed as geometric means and
95% CI on a linear scale. Letters denote significant changes in AUCg over time (P = 0.028),
although the treatment × time effect was not significant.

B)

Area under the insulin

concentration curve values for the same horses expressed as geometric means and 95% CI. Time
and treatment effects were not significant.
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Figure 3.3, continued.
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respectively. When a cut-off value of 38.5°C was used to define a clinically significant fever,
this response was only detected in the LPS-BOL group at 4 and 8 hours, and in the LPS-CRI
group from 4 to 12 hours. Fever was not detected in the SAL group, and the increases in rectal
temperature observed at 16 and 40 hours likely represent diurnal variation.538 A transient fever
was detected at 40 hours in one SAL group horse and this affected mean temperature for this
group.
Subjective observations also supported the development of endotoxin tolerance in horses
of both LPS groups. Attitudes of most animals returned to normal by 12 and 24 hours in the
LPS-CRI and LPS-BOL groups, respectively. One horse in the LPS-BOL group continued to
exhibit mild colic signs and depression following LPS administration for 7 of 8 infusions, but
reactions became milder over time and eventually ceased in this animal. Endotoxin tolerance has
been observed in horses,460,461 and refers to a decrease in the ability of LPS to elicit certain
clinical and biochemical responses following repeated exposures.
Inflammatory mediators examined in this study included the pro-inflammatory cytokines
IL-1β, IL-6, IL-8, and TNF-α, as well as the anti-inflammatory cytokine IL-10, which has
received much attention for its role in sepsis.32 Interleukin-1β, IL-6, IL-8, and TNF-α are major
regulators of innate immunity,18,19 and altered expression of these cytokines as well as cytokines
of the adaptive immune response occurs in the lamina, lungs, and livers of laminitic horses.531,532
In the current study, peripheral leukocyte responses to LPS infusion were assessed by extracting
RNA from whole blood samples. This method was chosen because whole blood RNA collection
systems have been shown to minimize RNA degradation and alterations in the gene expression
profile during sample collection and storage.507 One finding of this study is that LPS increased
IL-1β, IL-6, and IL-8 expression. Surprisingly, IL-10 and TNF-α expression did not increase
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significantly compared to pre-infusion baseline values in either LPS group. This may reflect, in
part, the conservative nature of the Bonferroni correction used in the statistical analysis.539
Alternatively, TNF-α expression may have peaked and declined prior to collection of the first
blood sample. This cytokine can peak early in the inflammatory response and decline rapidly
after 1 to 2 hours, even with continuous infusion of LPS and persistent fever.410
Two potential weaknesses of our study design were identified. First, all horses received
the same total dose of LPS instead of doses calculated by body weight. This approach was
deliberately selected to expose all horses to the same challenge because endotoxin load
associated with clinical disease does not vary according to body weight. A dose of 10μg per
bolus infusion was chosen because it approximates a commonly used LPS dose of 20 ng/kg bwt
for an average 500 kg horse.327 The total dose received by each horse in the LPS-BOL group
was therefore 80 µg, and the same total dose was administered to horses in the LPS-CRI group.
The impact of this selecting this approach was determined by including body weight as a
covariate in all analyses. No significant effects were detected. Second, blood samples were
collected 2, 4, or 6 hours following LPS administration in the LPS-BOL group. Decreasing
cytokine expression across each day might therefore reflect widening intervals between LPS
administration and blood sample collection.

However, comparisons between the first and

second day remain meaningful because collection schedules were the same for both days. For
example, expression was significantly higher for all cytokines at 8 hours on day 1 in the LPSBOL group compared to the corresponding time point relative to LPS administration on day 2
(time = 32 hours). Direct comparisons between the two LPS groups were also made at 24 and 48
hours when horses had received the same cumulative dose of endotoxin. Cytokine expression
was also averaged across all time points for each day and compared within groups. Markedly
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decreased or absent inflammatory cytokine responses on day 2 compared to day 1 in both LPS
groups support the conclusion that horses developed endotoxin tolerance.
Early-phase endotoxin tolerance occurs within hours to days and results, in part, from
down-regulation of Toll-like receptor 4 signaling cascades.76,448 Tolerance reprograms the cell
so that secretion of pro-inflammatory cytokines decreases while anti-inflammatory mediator
secretion and certain antimicrobial functions remain largely unchanged. This is a protective
mechanism by which cells minimize damage from rampant inflammation.

It should be

recognized that this study focused on blood inflammatory cytokine expression, so tissues were
not evaluated. Systemic inflammation could still contribute to the development of laminitis, if
tissues fail to develop tolerance. Fulminant inflammation can persist in organs even as tolerance
develops in circulating leukocytes,469,517 and sequential exposure of leukocytes to inflammatory
stimuli aggravates inflammation and worsens organ damage.440

Macrophage exposure to

xanthine oxidase - derived free radicals540 or LPS541 during the initial inflammatory event may
enhance the strength of signaling through Toll-like receptor 4 upon subsequent stimulation.442
Additionally, some tolerized cells may retain the ability to produce pro-inflammatory mediators.
For example, tolerized neutrophils can continue to produce IL-8 in response to LPS
stimulation.477 Interleukin-8 is a potent neutrophil chemoattractant, so this finding has relevance
to neutrophil emigration during laminitis.428 Further studies are needed to determine whether
laminar tissues respond to multiple inflammatory events by entering a refractory state, or if
multiple insults enhance inflammation and increase tissue damage.
Laminitis did not develop in any of the horses that received LPS and this finding is
consistent with results of previous studies.327,411-413 Direct evidence linking endotoxemia with
laminitis remains elusive. Differences between experimental models and clinical disease include
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the greater magnitude and duration of clinical endotoxemia and presence of other toxins
originating from the gastrointestinal tract. The equine gastrointestinal tract contains a diverse
population of Gram-negative bacteria, as well as multiple Gram-positive species,528 so the LPS
derived from a single bacterial strain used in most experimental studies is only one component of
this complex mixture.

Factors other than endotoxins and exotoxins might also play a role.

Vasoactive protein metabolites are present in the equine hindgut,375 and increase in response to
excess dietary carbohydrate intake.295 It is therefore likely that combinations of toxins are
responsible

for

triggering

laminitis,

and

LPS

is

only

one

contributing

factor.

Lipopolysaccharide-induced platelet activation409 and altered vascular reactivity403,406 might
increase the susceptibility of laminar tissue to damage from other factors. Tissue samples were
not assessed in this study, so it remains conceivable that LPS induces mild inflammatory changes
within the hoof that increase susceptibility to damage from other factors if true clinical sepsis
were to develop. Lipopolysaccharide did not induce leukocyte emigration or activate matrix
metalloproteases in laminar tissue collected 12 hours after infusion in a recent study, but vascular
function and endothelial activation were not assessed directly.426 Laminar biopsies should be
collected in future studies to examine markers of endothelial cell dysfunction in hoof tissues
following LPS infusion.542
Lipopolysaccharide administration did not induce significant alterations in glucose and
insulin dynamics, and this differs from results of our previous studies164,327 This discrepancy
may be explained by the repeated administration of LPS over 48 hours instead of a single bolus
infusion327 or the small group sizes. Although not significantly lower than baseline, AUCg was
lowest at 8 hours compared with subsequent time points in all treatment groups, indicating that
glycemic control decreased over time. Lower insulin sensitivity has been detected in healthy
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horses after prolonged stall confinement and this finding is attributed to stress.354 Horses in the
current study were confined to stalls and subjected to testing procedures that could have induced
stress and affected glucose homeostasis.
We conclude that endotoxin tolerance develops in horses continuously or intermittently
exposed to LPS via intravenous administration. Inflammatory cytokine expression was only
examined in peripheral leukocytes, so further studies are required to determine whether the same
process occurs in tissues. Results do not support a direct causal role for endotoxin in the
pathogenesis of laminitis, but LPS induces systemic inflammation and may therefore act in
synergy with other factors to cause disease. Future studies should therefore focus on whether
endotoxemia predisposes laminar tissue to damage from other triggering factors, potentially
through its effects on the vascular endothelium.
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CHAPTER 4
Effects of Equine Metabolic Syndrome on inflammatory responses to intravenous
lipopolysaccharide infusion

4.1 Introduction

Equine metabolic syndrome (EMS) is characterized by 3 key abnormalities: generalized
or regional adiposity, insulin resistance (IR), and laminitis.4 While most affected animals exhibit
all three problems, a lean phenotype also exists. Although EMS shares some characteristics with
the metabolic syndrome in humans,248 laminitis rather than cardiovascular disease is of primary
importance in the horse.

It has been established in humans that obesity causes increased

secretion of inflammatory cytokines and adipokines from adipose tissue and this leads to
IR105,106,543 and vascular endothelial dysfunction.199,305,307 Obese horses, like obese humans,
appear to be in a low-grade systemic inflammatory state.544 Increased interleukin (IL)-1 and
tumor necrosis factor-α (TNF-α) expression has been detected in the blood of obese horses,104
and serum TNF-α protein concentrations are higher obese, laminitis-prone ponies.255 The extent
to which equine adipose tissue contributes to systemic inflammation during obesity has only
recently been examined. Studies to date have demonstrated that cytokine expression is highest in
nuchal fat,253 but omental fat is also a site of inflammatory mediator production in horses.545
Anecdotal reports suggest that horses with EMS are more prone to developing laminitis
when affected by systemic illness such as bacterial enterocolitis. In human medicine, obesity is
associated with a poorer outcome in septic patients.325,326 Because endothelial cells are already
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compromised in obese individuals, they appear to be less capable of withstanding damage
associated with pathological conditions such as sepsis or ischemia-reperfusion injury.307 Obesity
may render certain vascular beds more vulnerable than others to damage, exacerbating
microvascular dysfunction and increased susceptibility to organ damage at these sites.307,546,547
The inflammatory and vascular events that occur during laminitis bear many similarities to
sepsis-associated organ failure.303,373 It is therefore conceivable that the laminar vasculature may
be particularly sensitive to damage from inflammation in obese horses.298

Evidence also

suggests that inflammatory responses may be exaggerated in obese individuals, further
increasing their risk of organ failure.325,548
Hepatic lipidosis is manifestation of the metabolic syndrome in humans,273,274 and the
steatotic liver contributes to systemic inflammation and IR.107,109,114 Hepatic involvement may
also occur in EMS because postmortem hepatic lipid accumulation and increased plasma γglutamyl transferase and aspartate aminotransferase activities have been detected in some
affected horses.4,549 The liver is a major site of toxin clearance from the body, so compromised
liver function might contribute to increased inflammation in obese animals.279 A recent study
showed that hepatic toll-like receptor (TLR) signaling is upregulated in horses with
endocrinopathic laminitis and this further supports a role for hepatic dysfunction in the
pathogenesis of this disease.550
The current study was performed to determine whether horses with EMS respond
differently than normal animals to systemic inflammation. We hypothesized that EMS would
affect the systemic inflammatory response and expression of inflammatory cytokines in
peripheral blood leukocytes and hepatic tissues induced by endotoxin.
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4.2 Materials and methods

Animals – Six healthy adult mares and 6 horses previously diagnosed with EMS (3 mares and 3
geldings) from the University of Tennessee teaching and research herd were included in the
study. Control animals had no history of laminitis and fasting serum insulin concentrations
below 20 µU/mL. Horses with EMS had a history of chronic obesity or abnormal regional
adiposity, and previously documented resting hyperinsulinemia or IR confirmed by combined
glucose-insulin or insulin-modified frequently-sampled intravenous glucose tolerance testing.
Abnormal hoof morphology and radiographic evidence of chronic laminitis were present in 5 of
6 animals, and divergent hoof growth rings were noted upon physical examination in 1 horse.
Normal horses ranged in age from 10 to 18 years (mean 12.8 years; median 12 years) and
weighed 427 to509 kg (mean 473.5 kg; median 480.5 kg). Breeds included Quarter horse (3),
Quarter horse cross (1), Appaloosa (1), and Standardbred cross (1). Horses with EMS were 8 to
22 years old (mean 15.7 years; median 16 years) and weighed 394 to 525 kg (mean 441.8 kg;
median 425 kg). Breeds included Paso Fino (2), Morgan (1), Arabian (1), Tennessee Walking
Horse (1), and Azteca (1). Body condition score was assessed by two observes on a scale of 1 to
9 as described by Henneke, et al.249 and mean scores were calculated. Mean body condition
scores ranged from 5 to 7.25 (mean 6; median 5.9) for normal horses and from 4 to 9 (mean 6.3;
median 6.4) for horses with EMS.
Animals were paired (1 normal and 1 EMS) and housed together in 15 m × 55 m dirt
paddocks with run-in sheds at the University of Tennessee Cherokee Farm research facility for a
minimum of 2 weeks prior to the start of the study. Grass hay and water were provided ad
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libitum. The study protocol was approved by the University of Tennessee Institutional Animal
Care and Use Committee.

Study Design – Testing was performed between February and April 2010.

A completely

randomized design with split plot and crossover in the sub plot was employed and horses were
evaluated in pairs over 2 consecutive weeks. Three pairs were randomly assigned to receive an
intravenous (IV) infusion of lipopolysaccharide (LPS) the first week and an IV infusion of
sterile saline the second week. Treatment order was reversed for the remaining 3 pairs of horses.
Animals were transported to the Veterinary Teaching Hospital and housed in 3.7 m × 3.7 m box
stalls at the start of each testing week. Body weight measurements and physical examinations
were performed at the time of arrival.

Horses were allowed to acclimate to the hospital

environment for a minimum of 24 hours prior to testing.
A 14-g polypropylene IV cathetera was aseptically placed in one jugular vein and blood
was submitted for complete blood count (CBC) analysis and biochemical profile at 0830 on day
1 (time = -27 hours).

Baseline physical examination parameters and blood samples were

obtained at 1100 on day 2 (time = -30 minutes), followed immediately by IV infusion of LPS or
saline as a slow bolus over 30 minutes. Conclusion of the IV infusion was designated as time =
0 minutes. Whole blood was collected for inflammatory cytokine gene expression analysis at 30,
60, 90, 120, 180, and 240 minutes. An additional CBC was submitted at 180 minutes.
Liver biopsies were performed under standing sedation between 240 and 360 min.
Physical examinations were performed hourly for 9 hours following LPS or saline
administration, and at 15 and 21 hours.

Insulin-modified frequently-sampled intravenous

glucose tolerance tests were performed at -27 hours, 30 minutes, and 21 hours as part of a
a

Abbocath-T 14 G X 140 mm, Abbott Laboratories, North Chicago, IL
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concurrent study to assess glucose and insulin dynamics (refer to chapter 5). Animals had access
to grass hay and water at all times. Intravenous catheters were removed at the end of the study
period and horses were returned to the research farm. Procedures were repeated the following
week and the opposite treatment (LPS or saline) was administered to each animal.

Lipopolysaccharide and saline administration – Commercially available Escherichia coli O55:B5
LPSb (20 ng/kg) was diluted in 60 mL sterile saline and administered IV over 30 minutes.

Horses receiving the control treatment were administered 60 mL of sterile saline IV over 30
minutes.

Measurement of blood variables – Blood samples for CBC, fibrinogen, and biochemical profile
analysis were collected into appropriate anticoagulant or serum tubes and analyzed by the
University of Tennessee Clinical Pathology laboratory.

Whole blood inflammatory cytokine gene expression – Blood samples for quantitation of IL-1β,
IL-6, IL-8, IL-10, TNF-α, and β-glucuronidase (B-Gus) gene expression were collected into
whole blood RNA collection tubesc and allowed to incubate at room temperature for 8 hours,
then stored at – 20 °C until analyzed. Total RNA extraction and real-time polymerase chain
reaction were performed as previously described (refer to chapter 2). The comparative CT
(ΔΔCT) method was used to determine fold changes in inflammatory cytokine gene
expression.509 Cytokine expression was normalized to the housekeeping gene B-Gus and each

b
c

Sigma Aldrich, Inc., St Louis, MO
PAXgene® blood RNA tubes, Qiagen/PreAnalytiX, Valencia, CA
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horse’s baseline value was used as the calibrator. Baseline gene expression was therefore equal
to a 1-fold change for all cytokines.

Liver Biopsies – Horses were restrained in stocks and sedated. A 15 cm × 15 cm area overlying
the right 12th – 14th intercostal spaces was clipped and prepped using povidone-iodine surgical
scrub. The biopsy site was infiltrated with 12 mL of 2% mepivacaine hydrochloride and an
ultrasound-guided needle biopsy was performed using a 14-guage spring-action needle biopsy
device.d Two 1.5-cm biopsy cores were collected from each animal. One core was immediately
fixed in 10% neutral buffered formalin and the other was snap frozen on dry ice and stored at -80
°C until gene expression analysis. The skin was sutured and animals were monitored for
complications following the procedure.

Liver Histopathology – Routing hematoxylin and eosin and periodic acid-Schiff staining was
performed on formalin-fixed biopsy samples. Tissue sections (5 µm thickness) were evaluated
using light microscopy by a single board-certified veterinary pathologist who remained blinded
to treatment group allocations. Inflammation, lipid content, and glycogen content were graded
subjectively on a scale of 0 (absent) to 3 (marked).

Inflammatory cytokine gene expression in liver – Total RNA was extracted from frozen tissue
samples using a commercially available guanidine-thiocyanate-based extraction kite accordingly
to the manufacturer’s instructions.

d
e

Concentration and purity of RNA in each sample was

Temno Evolution® biopsy needle, CareFusion Corp., Waukegan, IL
RNeasy® Mini Kit, Qiagen, Valencia, CA
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measured via spectrophotometry.f Reverse transcription was performed using a kitg and 1 μg of
RNA was loaded into each reaction. Complementary DNA was then diluted 1:10 with 180 µL of
nuclease-free water.
Real time PCR was performed for IL-1β, IL-6, IL-8, IL-10, TNF-α, and β2 microglobulin
(B2M) as described for whole blood. β2 microglobulin was selected as the housekeeping gene
because B2M expression in liver tissue was more stable than expression of B-Gus in preliminary
tests. Cytokine expression in each sample was normalized to B2M and the calibrator used for
comparative CT (ΔΔCT) calculation was each horse’s ΔCt value after saline infusion.
Lipopolysaccharide-induced gene expression is therefore expressed relative to the saline
treatment.

Statistical Analysis – Mixed model analysis of variance (ANOVA) was performed using
computer softwareh to determine effects of group (EMS vs. normal), treatment (LPS vs. saline),
time, and main effect interactions.

Area under the curve (AUC) values for whole blood

inflammatory cytokine gene expression were calculated using the trapezoidal method and
computer software.i Blood and hepatic gene expression data, AUC for blood gene expression,
heart rate, and respiratory rate required logarithmic transformation to fit ANOVA normal
distribution assumptions. Transformed data are reported as geometric means with 95% CI. All
other data are reported as least squares means ± SEM. The autoregressive correlation parameter
was included in the final model for analysis of rectal temperature and heart rate only. Mean

f

NanoDrop ND-1000, Thermo Fisher Scientific, Wilmington, DE
High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor, Applied Biosystems, Foster City, CA
h
PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC
i
SAS, version 9.2, SAS Institute, Inc., Cary, NC
g
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separation was performed using Fisher’s protected least significant difference and significance
was set at P < 0.05.
Mean cytokine expression at each time point was also compared to the pre-infusion
baseline using one-sample t-tests with Bonferroni correction for multiple comparisons.
Significance was set at P < 0.0021 because the Bonferroni correction was applied. Hepatic gene
expression following LPS administration was compared to saline infusion using the same
method.
Baseline blood (time = -30 minutes) and hepatic (following saline administration) gene
expression was compared between groups by recalculating ΔΔCT using a pooled calibrator value
for each cytokine generated by averaging all baseline ΔCt values for that gene. Mean cytokine
expression was then compared between groups using independent sample t-tests.
Associations among blood and hepatic cytokine expression and vital parameters were
assessed using Spearman’s rank correlation coefficients. Correlation analysis was performed at
the level of the individual animal. Significance was set at P < 0.05 for all correlations.

4.3 Results

Group comparisons – No differences were detected between EMS and control groups with
respect to mean age, weight, or body condition score. Two animals in the EMS group exhibited
generalized obesity with prominent nuchal crest adipose accumulation (body condition score >
7/9), 2/6 were of normal body condition but showed regional adiposity of the neck and tail head,
and 2/6 displayed a lean phenotype. In contrast, only one horse in the control group was obese
and none of the horses exhibited regional adiposity.
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Clinical signs – Ten of 12 animals demonstrated transient depression, anorexia, pawing,
yawning, head shaking, stretching, or muscle fasciculations following LPS infusion. Two horses
(1 normal and 1 EMS from the same pair) showed no clinical response to LPS. Physical
examination parameters did not change and leukopenia was not detected, so all data from these
animals collected after LPS infusion were excluded from further analyses.
With the exception of the two non-responders, all horses developed fever (rectal
temperature > 38.5 ºC) following LPS infusion. Lipopolysaccharide administration significantly
increased mean rectal temperature (treatment × time; P < 0.001), but no differences were
detected between groups (Figure 4.1A). Mean heart rate increased significantly following LPS
infusion (treatment × time; P < 0.001; Figure 4.1B). A group effect was detected for this
variable (P = 0.048), with higher heart rates detected in EMS horses. Mean respiratory rate
significantly increased following LPS administration (treatment × time; P < 0.001), with higher
rates detected in the EMS group (P = 0.017; Figure 4.1C). Group × treatment × time effects
were not significant for any of the physical examination variables recorded.

Hematology and plasma biochemical profile analysis – Anemia (red blood cell count < 6.3 ×106
cells/µL)j was detected on 1 or more CBCs in 5/6 (83%) EMS horses and 2/6 (33%) normal
horses. Concurrently decreased hematocrit values (< 28%)j and hemoglobin concentrations (<
10.2 g/dL)j were detected in 5/7 (71%) animals. Mean hematocrit was significantly lower (P <
0.01) in horses with EMS (32.3 ± 1.0 %) than in normal horses (36.6 ± 0.7 %).

Mean

hemoglobin concentration was also lower (P < 0.009) in the EMS group (10.9 ± 0.3 g/dL) than
the normal group (12.32 ± 0.2 g/dL).

j

Reference ranges used by the University of Tennessee Clinical Pathology laboratory
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Figure 4.1 Changes in physical examination parameters of normal and EMS horses following
IV bolus administration of LPS at 20 ng/kg or saline infusion. Data for rectal temperature are
expressed as means ± SEM, while data for heart rate and respiratory rate are expressed as
geometric means and 95% CI on a linear scale. *Asterisks refer to treatment × time effects and
denote significant differences from baseline following LPS infusion. A) Treatment × time (P <
0.001) effects were detected for rectal temperature. B) Treatment × time (P < 0.001) and group
(P = 0.048) effects were detected for heart rate. C) Treatment × time (P < 0.001) and group (P
= 0.017) effects were detected for respiratory rate.
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Figure 4.1, continued.
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Figure 4.1, continued.
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Leukopenia (total white blood cell count < 4.6 × 103 cells/μL)k was detected 180 minutes
after LPS infusion in 9/10 (90%) horses that were considered LPS responders. Neutropenia (<
2.6 × 103 cells/μL)k and lymphopenia (< 1.5 × 103 cells/μL)k were detected in 7/9 (78%) and 8/9
(89%) of these animals, respectively.

Whole blood cytokine gene expression – Treatment × time effects were significant for IL-1β (P <
0.001; Figure 4.2A) and TNF-α (P < 0.001; Figure 4.2B), and significant treatment effects were
detected for IL-6 (P < 0.001; Figure 4.2C), IL-8 (P < 0.001; Figure 4.2D), and IL-10 (P <
0.001; Figure 4.2E).
Group × treatment × time effects did not reach statistical significance for any of the
inflammatory cytokines examined, but group × time effects were significant for IL-1β (P =
0.027) and group effects were significant for TNF-α (P = 0.040).
Results of one-sample t-tests demonstrated that cytokine expression remained
significantly elevated above baseline for longer in horses with EMS following LPS
administration (P < 0.0021). Expression of IL-6 and IL-8 increased relative to baseline in EMS
but not normal horses at 1 and 3 time points, respectively. Interleukin-10 expression did not
differ statistically from baseline at any time point in the normal group, but was increased at 30,
180, and 240 minutes in the EMS group. Tumor necrosis factor-α expression increased relative
to baseline at all time points in horses with EMS, but was only increased at 60 minutes in normal
animals. Baseline (-30 minute) gene expression did not differ between normal horses and
animals with EMS.
Lipopolysaccharide administration significantly increased AUC for IL-1β, IL-6, IL-8, IL10, and TNF-α expression (treatment, P < 0.001), but differences between EMS and normal
k

Reference ranges used by the University of Tennessee Clinical Pathology laboratory
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Figure 4.2 Change in whole blood gene expression of IL-1β, TNF-α, IL-6, IL-8, and IL-10 in
normal and EMS horses following IV bolus administration of LPS at 20 ng/kg or saline infusion.
Data are expressed as geometric means and 95% CI, and are displayed on a logarithmic scale.
Significance was set at P < 0.0021 for one-sample t-test comparisons between cytokine
expression at each time point, compared to baseline. Significance for ANOVA main effects and
interactions was defined by P < 0.05. *Significant difference from baseline following LPS
infusion in EMS group only.

†

Significant difference from baseline following LPS infusion in

both normal and EMS groups. A) Treatment × time (P < 0.001) and group × time (P = 0.027)
effects were detected for IL-1β. B) Treatment × time (P < 0.001) and group (P = 0.040) effects
were detected for TNF-α.

C) Treatment (P < 0.001) effects were detected for IL-6.

D)

Treatment (P < 0.001) effects were detected for IL-8. E) Treatment (P < 0.001) effects were
detected for IL-10.
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Figure 4.2, continued.
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Figure 4.2, continued.
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Figure 4.2, continued.
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Figure 4.2, continued.
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Figure 4.2, continued.
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horses were not detected by ANOVA (Table 4.1).

Area under the curve for IL-10 was

significantly increased in horses with EMS compared to normal animals (group, P = 0.046).

Liver cytokine gene expression – Expression of IL-6 increased following LPS infusion in normal
horses, and IL-8 expression increased in both normal and EMS animals (P < 0.0025; Figure
4.3). Expression did not differ in magnitude between the EMS and normal groups. Baseline
gene expression was assessed after saline infusion, and did not differ significantly between
horses with EMS and normal animals.

Liver histopathology – Twenty-three biopsy specimens of diagnostic quality were obtained. One
unusable sample from an EMS horse receiving LPS was excluded from analysis. Differences
were not apparent between normal and EMS horses or between animals that received LPS or
saline. Moderate (grade 2) to abundant (grade 3) intracellular glycogen was detected in all
samples. Mild intracellular lipid accumulation (grade 1) was observed in 1 normal horse and 1
horse with EMS following saline infusion. Lipid was not identified in the second biopsy sample
from either horse. Mild to moderate mixed portal inflammation (grade 1 - 2) was identified in
both biopsy specimens from 1 EMS horse, and in the post-LPS samples from 2 normal and 2
EMS horses. Two animals with portal inflammation also had ductal hyperplasia and edema (1
normal and 1 EMS) and moderate portal fibrosis was identified in 1 horse with EMS. Mild
sinusoidal accumulation of non-degenerate neutrophils (grade 1) was identified in 2 normal and
2 EMS horses following LPS administration, including the 2 animals that were considered nonresponders to LPS infusion.
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Table 4.1 Geometric means and 95% CI of AUC values for whole blood inflammatory cytokine
expression in normal and EMS horses following IV bolus administration of LPS at 20 ng/kg or
saline infusion. Significance was set at P < 0.05.

P value

Cytokine

Group

Treatment

AUC ([fold change
× min] × 102)

Interleukin-1β

EMS

LPS
Saline

175.7 (107.6 to 286.8)
2.37 (1.66 to 3.39)

Normal

LPS
Saline

133.7 (70.8 to 252.4)
2.07 (1.56 to 2.73)

EMS

LPS
Saline

80.8 (44.1 to 148.0)
3.37 (2.10 to 5.40)

Normal

LPS
Saline

49.6 (21.6 to 113.7)
4.07 (3.04 to 5.43)

EMS

LPS
Saline

97.6 (74.3 to 128.1)
3.04 (1.14 to 8.14)

Normal

LPS
Saline

67.4 (17.4 to 261.4)
2.19 (1.23 to 3.93)

EMS

LPS
Saline

44.7 (24.7 to 81.0)
4.40 (2.67 to 7.25)

Normal

LPS
Saline

10.4 (3.40 to 31.8)
2.87 (1.40 to 5.88)

EMS

LPS
Saline

31.3 (13.7 to 71.7)
4.57 (2.47 to 8.43)

Normal

LPS
Saline

12.6 (6.45 to 24.7)
2.86 (1.74 to 4.71)

Interleukin-6

Interleukin-8

Interleukin-10

TNF-α

Group*

Treatment†

Group ×
treatment

0.417

0.001

0.739

0.644

0.001

0.183

0.510

0.001

0.953

0.046

0.001

0.151

0.077

0.001

0.493

*Where significant, AUC increased in the EMS group relative to the normal group.
†
Where significant, AUC increased in horses that received LPS compared to those that received
saline.
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Figure 4.3 Hepatic gene expression of IL-1β, IL-6, IL-8, IL-10, and TNF-α in normal and EMS
horses after receiving a 20 ng/kg IV bolus of LPS. Data are expressed as geometric means and
95% CI, and are displayed on a logarithmic scale. *Significantly higher expression following
LPS administration compared to saline infusion. Significance was set at P < 0.025.
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Correlations – Analysis was performed using data from all time points when both physical
examination parameters and whole blood inflammatory gene expression were measured.
Cytokine gene expression was positively correlated with rectal temperature, heart rate, and
respiratory rate (Table 4.2). Positive correlations were also identified among inflammatory
cytokines (data not shown).

4.4 Discussion

Systemic inflammation developed in both normal and EMS horses following an
endotoxin challenge, and whole blood inflammatory cytokine gene expression increased in both
groups. Although the magnitude of the increase in expression did not differ between groups,
increased cytokine expression persisted for longer in horses with EMS. Endotoxin infusion also
increased hepatic cytokine gene expression, but differences were not detected between normal
and EMS horses. Results therefore support our hypothesis that EMS affects inflammatory
responses to endotoxin, but further studies are required to confirm these findings.
Lipopolysaccharide infusion increased rectal temperature, heart rate, and respiratory rate
in a manner consistent with previous studies,164,354 but responses did not differ significantly
between normal and EMS horses. These alterations in physical examination parameters are
expected, considering the known effects of inflammatory mediators such as IL-1β on body
temperature regulation and metabolic rate.551 Interestingly, horses with EMS demonstrated
higher overall heart rates and respiratory rates than normal animals following both LPS and
saline administration. Cardiopulmonary abnormalities relating to fat mass are well described in
obese humans,552 and these findings suggest that similar abnormalities occur in obese horses.
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Table 4.2 Spearman’s rank correlation coefficients for associations among whole blood gene
expression values and physical examination parameters in normal and EMS horses after
receiving a 20 ng/kg IV bolus of LPS. Significance was set at P < 0.05 and P values are
displayed in parentheses.

Rectal temperature

Heart rate

Respiratory rate

Interleukin-1β

0.606
(0.001)

0.395
(0.005)

-

Interleukin-6

0.469
(0.001)

0.611
(0.001)

-

Interleukin-8

0.503
(0.001)

0.396
(0.005)

-

Interleukin-10

0.537
(0.001)

-

0.440
(0.002)

TNF-α

0.291
(0.045)

0.500
(0.001)

-
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Inflammatory cytokine expression increased in both blood and hepatic tissues following
LPS infusion. Lipopolysaccharide is recognized by the cell-surface pattern recognition receptor
TLR4,13 and many cells, especially those with immunologic functions, express this receptor and
respond to LPS stimulation.11,553 Activation of TLR4 signalling culminates in the secretion of
inflammatory mediators that orchestrate the innate and adaptive immune responses.7,11 The proinflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α measured in this study are major regulators
of innate immunity,18,19 and are known to increase in response to LPS administration in
horses.269,410,506,534 Interleukin-1β, IL-6, and IL-8 are used as prognostic indicators in septic
humans, with increased cytokine expression predicting organ failure and mortality.28,512-514
Laminar tissue expression of these mediators increases during the onset of laminitis,429-431,493 and
increased expression of IL-1β, IL-6, IL-8, and TNF-α occurs in the liver and lungs of laminitic
horses.427

Interleukin-10 is an anti-inflammatory mediator that is responsible for limiting

inflammation and reducing tissue damage during sepsis.24,32,516

When produced in excess,

however, IL-10 contributes to the development of immunosuppression,24,29,32 and high IL-10
concentrations are a negative prognostic indicator in septic humans.30,515
Lipopolysaccharide administration increased the expression of all cytokines in whole
blood samples, with TNF-α peaking at 60 and 90 minutes in normal and EMS horses,
respectively, and IL-1β, IL-6, IL-8, and IL-10 peaking between 120 and 240 minutes in all
horses. Our findings are consistent with those of a recent report in which administration of a 30
ng/kg IV bolus of LPS increased inflammatory cytokine gene expression in the blood of healthy
horses.506 Although we report longer times to peak cytokine expression, LPS was administered
at a lower dose in the current study, which could account for this discrepancy. In both studies,
TNF-α expression returned to baseline by 180 minutes in normal horses, although our results
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indicate that elevated TNF-α expression persisted in horses with EMS. Interleukin-8 expression
returned to baseline in the previous study, but remained elevated in normal and EMS horses in
this study.
Although the magnitude of cytokine responses did not differ significantly between
normal and EMS horses, inflammatory gene expression remained elevated longer in horses with
EMS. Most notably, TNF-α expression only increased relative to baseline at 1 time point in
normal horses, whereas expression was consistently increased in horses with EMS. Disparity
between groups was also seen in IL-8 and IL-10 expression. These differences between normal
and EMS horses are not directly explained by obesity because only 2 of 6 affected animals were
obese, while another 2 horses exhibited regional adiposity. It must therefore be concluded that
IR or the historical problem of obesity affected the systemic inflammatory response. It is also
possible that adipose tissues are abnormal even in lean EMS horses and may contribute to
differences in the inflammatory response.
Baseline blood cytokine expression did not differ between normal and EMS horses in this
study, but significant group × time and group effects were detected for IL-1β and TNF-α,
respectively, indicating that cytokine expression was higher overall in horses with EMS during
the 240 minute periods following LPS and saline infusion. Area under the curve for IL-10 was
also higher in EMS horses. These results further support obesity as a pro-inflammatory state in
the horse as it is in other species, and are consistent with previous findings in obese horses.104,255
Although increased IL-10 is not consistently associated with obesity, increased IL-10 production
by adipose tissues and higher blood concentrations have been described in humans and
rodents.554,555
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The extent to which obesity impacts circulating leukocyte responses to inflammatory
stimuli is not clear. Cross-talk between adipose tissue macrophages and circulating leukocytes is
likely to occur because peripheral blood mononuclear cells from obese humans are in a proinflammatory state and demonstrate increased basal cytokine expression when compared to
normal-weight individuals.556 Equine peripheral blood mononuclear cells also show different
cytokine responses to in vitro stimulation if harvested from obese versus thin animals.557
Other potential modulators of cross-talk between adipose depots and circulating
leukocytes include the adipokines adiponectin and leptin.
substantial amount of energy, so

Immune functions consume a

adipokines make sure that the immune system remains

appraised of available energy stores in the body.154 Adiponectin, which decreases during both
obesity336 and inflammation,321 exerts direct anti-inflammatory effects on cells of the immune
system.317,558

Leptin secretion increases in direct proportion to fat mass,336,337 and also in

response to inflammation.322,323 Leptin promotes pro-inflammatory responses such as cytotoxic
polarization of lymphocyte differentiation105 and increased inflammatory cytokine expression.343
Whether obesity affects in vivo leukocyte responses to endotoxin remains unknown, but results
of the current study suggest that cytokine production is prolonged in horses with EMS.
We did not demonstrate that EMS altered the magnitude of blood inflammatory cytokine
responses in horses, but it is possible that exaggerated inflammatory responses originate from
tissues rather than circulating leukocytes.

Adipocytes express TLR4 and are capable of

responding to LPS stimulation by secreting pro-inflammatory cytokines and chemokines such as
IL-6, TNF-α, and macrophage chemoattractant protein-1.110,334 Cultured equine adipocytes and
preadipocytes produce IL-1β, IL-6, and TNF-α in response to LPS stimulation, and adipose
tissue biopsies obtained from horses following IV LPS infusion demonstrate increased
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expression of these cytokines.269 Inflammatory reactions may therefore be exaggerated in EMS
by virtue of increased fat mass or abnormal adipose tissues.110

Adipose tissue cytokine

responses were not assessed in the current study, but warrant further consideration.
Lipopolysaccharide administration increased the expression of IL-6 and IL-8 in hepatic
tissues, but differences were not apparent between normal and EMS horses. It is possible that
aspects of the study design limited out ability to detect differences between groups. Because
hepatic cytokine responses to an endotoxin challenge have not previously been examined in
horses, timing of sample collection was based on gene expression studies in rodents559-561 and
approximated times previously reported for increased serum and plasma cytokine expression in
horses after IV LPS administration.410,534 Differences might have been detected between normal
and EMS horses had the timing of sample collection differed or if multiple samples were
collected. Obesity promotes hepatic inflammation in other species because intermediates of lipid
metabolism are toxic to hepatocytes and activate Kupffer cells.278,279,562 Lipid accumulation
within hepatocytes also distorts

sinusoids and decreases blood flow velocity, leading to

prolonged exposure of Kupffer cells to antigens or leukocytes.279

More comprehensive

examination of hepatic dysfunction in horses with EMS is therefore indicated in future studies.
Alterations in liver function may be relevant to the pathophysiology of laminitis in EMS
horses. It has been hypothesized that EMS horses are more susceptible to laminitis because
repeated inflammatory insults occur to the laminar vascular endothelium, and these processes
may be exaggerated in affected animals.298,307 Inflammatory insults may arise from minor
intestinal carbohydrate overload events occurring in horses grazing on pasture.298 Because a
major function of the liver is to remove toxins that escape the gastrointestinal tract before they
enter systemic circulation, horses with liver dysfunction associated with EMS may experience
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more frequent and severe inflammatory events that might increase their risk of developing
laminitis.
An important finding of this study is that LPS administration neither induced laminitis in
normal horses nor exacerbated the condition in horses with EMS. Although horses with clinical
signs suggestive of endotoxemia are at an increased risk of developing laminitis3 and endotoxin
has been detected in the blood during carbohydrate overload laminitis induction,409,423
administration of LPS alone has consistently failed to induce the disease.327,354,410,534
Endotoxemia may act synergistically with other factors such as hindgut-derived Gram-positive
exotoxins or vasoactive amines375,528 to induce laminitis, but multiple factor models have not
been explored to date in horses.
One aspect of the current study that may have limited our ability to detect differences
between normal and EMS horses was that horses with EMS were part of an intensively managed
research herd and several animals had lost weight prior to enrollment in this study. It is therefore
possible that administration of LPS to obese animals in an exacerbated state of inflammation and
IR would have produced greater disparity in the cytokine responses between groups. Weight
loss and normalization of metabolic functions in the EMS group could explain why differences
were not detected in baseline blood or hepatic gene expression values, and why liver
histopathology did not differ between normal and EMS horses.
Despite losing weight, horses with EMS still responded differently to endotoxin
challenge than normal animals. This could reflect underlying physiological defects that are not
strictly related to adiposity. Evidence from human studies indicates that not all metabolic
parameters normalize with weight loss.563-565 In the current study, some EMS horses with a lean
phenotype still retained abnormal characteristics such as regional adiposity.

Additionally,
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certain phenotypic abnormalities in horses with EMS may only be unmasked in response to a
challenge.

For example, laminitis-prone obese ponies manifest seasonal hypertension and

reduced insulin sensitivity in response high dietary carbohydrate intake.256 Endotoxin challenge
may therefore have unmasked inherent defects in the inflammatory responses of horses with
EMS.
An interesting finding in this study was that anemia was detected at least once in 5 of the
6 horses with EMS, and affected horses had significantly lower hematocrit values and
hemoglobin concentrations than normal animals. Horses with EMS may develop anemia of
chronic disease from obesity-related inflammation.566 Iron deficiencies have been described in
obese humans,567,568 and are ascribed to both true iron deficiency and inflammation-related
functional deficiencies.569 Iron status was not assessed in the current study, but measurements of
serum iron and ferritin and total iron binding capacity should be considered in the future.
We conclude that EMS affects systemic inflammatory responses to endotoxin by
prolonging inflammatory cytokine gene expression in the blood. However, physical examination
findings and the magnitude of the inflammatory response did not differ between groups.
Intravenously administered LPS also induces pro-inflammatory cytokine expression in hepatic
tissue of both normal and EMS horses. Notably, endotoxin challenge does not induce laminitis
or exacerbate the condition in horses with EMS. Further studies are required to determine the
role of inflammation in EMS. Future studies should also include direct assessment of adipose
tissue inflammatory responses.
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CHAPTER 5
Intravenous lipopolysaccharide infusion alters glucose and insulin dynamics in horses with
Equine Metabolic Syndrome

5.1 Introduction

Obesity and insulin resistance (IR) are established risk factors for laminitis in horses and
ponies,182,226,250 and the term Equine Metabolic Syndrome (EMS) has been adopted to describe
animals that exhibit generalized or regional adiposity, IR, and laminitis. In human medicine,
metabolic syndrome defines a set of risk factors, including obesity and IR that predict the
development of cardiovascular disease.248 In contrast, laminitis is of primary importance in
horses with EMS. Insulin resistance is linked to cardiovascular disease through its effects on the
vascular endothelium in humans and this mechanism is also being examined in horses.296
Increased expression of microvascular endothelial insulin receptors occurs in the equine hoof
following high dietary carbohydrate consumption, indicating that insulin affects endothelial
function in this species.570
Hyperglycemia is not a component of EMS,4 but abnormal glucose homeostasis might
still play a role in the development of laminitis.

A recent report identified increased

fructosamine concentrations in laminitic horses, although the study population was not limited to
animals with EMS.571 Hyperglycemia increases the production of reactive oxygen species and
the formation of advances glycation end products, which damage tissues and are important in the
pathogenesis of cardiovascular disease in diabetic humans.190,572

Interstitial glucose
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concentrations in obese, insulin-resistant horses are variable throughout the day and sometimes
exceed reference range.243 This may be important because it has been demonstrated in humans
that mild fasting hyperglycemia increases cardiovascular risk, and postprandial hyperglycemia
well below the cutoff for diabetes causes endothelial dysfunction if occurring over a prolonged
period of time.573-575 These findings can be related to laminitis because horses with EMS often
suffer from mild laminitis that goes unnoticed by owners and develops over time after grazing
on carbohydrate-rich pasture.4
Both IR and hyperglycemia develop acutely during systemic inflammation because
inflammatory cytokines and stress hormones such as glucocorticoids, catecholamines, and
glucagon inhibit post-receptor insulin signaling pathways and promote hepatic glucose
output.91,576 Horses with EMS often develop laminitis after grazing on carbohydrate-rich pasture
and it has been suggested that inflammation contributes to the development of disease.4 Pasture
grazing increases the risk of intestinal carbohydrate overload and translocation of gut-derived
toxins such as lipopolysaccharide (LPS), exotoxins, and vasoactive amines into systemic
circulation.298 Horses could therefore experience mild episodes of systemic inflammation while
on pasture, and this might have an additional impact on glucose and insulin dynamics.
Lipopolysaccharide infusion decreases insulin sensitivity in normal horses,164,269,327,354 but this
situation has not been examined in horses with EMS. It must therefore be determined whether
pre-existing derangements in glucose and insulin homeostasis are acutely exacerbated by
inflammation in these animals, which could increase their risk of developing laminitis.
Clinical experience suggests that horses with EMS are at greater risk of developing
laminitis when systemic illnesses such as bacterial enterocolitis develop. Obesity is associated
with increased morbidity and mortality in critically ill humans,325,326 and obese patients are at
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increased risk of developing hyperglycemia.142,144

Laminitis shares many similarities with

sepsis-associated organ failure, including microvascular dysfunction,303,373 and endothelial
function is further compromised in obese individuals during sepsis.307 It is therefore our overall
hypothesis that EMS increases the risk of laminitis developing in association with systemic
inflammation. The current study was undertaken to determine whether glucose and insulin
dynamics differ between EMS and normal horses in response to inflammation. We hypothesized
that EMS impacts alterations in glucose and insulin homeostasis induced by LPS infusion.

5.2 Materials and methods

Animals – Six healthy adult mares and 6 horses previously diagnosed with EMS (3 mares and 3
geldings) from the University of Tennessee teaching and research herd were included in the
study. Control animals had no history of laminitis and fasting serum insulin concentrations
below 20 µU/mL. Horses with EMS had a history of chronic obesity or abnormal regional
adiposity, IR, and laminitis. Body condition scores ranged from 5 to 7.25 (mean 6; median 5.9)
for normal horses and from 4 to 9 (mean 6.3; median 6.4) in horses with EMS on the scale of 1
to 9 described by Henneke, et al.249 The study protocol was approved by the University of
Tennessee Institutional Animal Care and Use Committee.

Study Design – Glucose and insulin dynamics were assessed concurrently with inflammatory
responses to LPS infusion, and the complete study design is described in chapter 4. Baseline
insulin-modified frequently-sampled intravenous glucose tolerance tests (FSIGTTs) were
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performed at 0830 on day 1 (time = -27 hours) and then repeated at 0.5 and 21 hours (0830 on
day 3).

FSIGTT procedure – Testing was performed as described by Hoffman, et al.232 and modified by
Tóth, et al.577 Plasma and serum samples were collected into sodium fluoride / potassium
oxalate and serum tubes via the intravenous (IV) cathetera at -10, -5, and 0 minutes relative to
dextrose infusion and values were averaged to obtain the baseline. An IV bolus of 50% dextrose
solutionb was then administered at a dosage of 150 mg/kg bwt. Plasma and serum samples were
collected at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 minutes for measurement of blood glucose
and insulin concentrations. A bolus of regular insulinc (30 mU/kg bwt) was administered IV at
20 minutes. Plasma and serum were subsequently collected at 22, 23, 24, 25, 27, 30, 35, 40, 50,
60, 70, 80, 90, 100, 120, 150, and 180 minutes. Sodium fluoride / potassium oxalate tubes were
immediately cooled on ice and serum tubes were allowed to clot at room temperature for 1 hour.
Tubes were centrifuged at 1,000 × g for 10 minutes and plasma or serum was harvested and
stored at –20 ºC until analyzed.

Plasma glucose and serum insulin concentrations – Plasma glucose concentrations were
measured in duplicate using a colorimetric assayd on an automated discrete analyzer.e Serum
insulin concentrations were measured in duplicate using a radioimmunoassayf that has been
validated for use with equine plasma in our laboratory and by others.537 Intra-assay coefficient

a

Abbocath-T 14 G X 140 mm, Abbott Laboratories, North Chicago, IL
Vedco, Inc., St. Joseph, MO
c
Humulin R, Eli Lilly and Co., Indianapolis, IN
d
Glucose, Roche Diagnostic Systems, Inc., Somerville, NJ
e
Cobas Mira, Roche Diagnostic Systems, Inc., Somerville, NJ
f
Coat-A-Count Insulin, Diagnostic Products Corp., Los Angeles, CA
b
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of variation < 5% was required for acceptance of glucose assay results and <10% was required
for acceptance of insulin assay results.

Interpretation of FSIGTT data using the minimal model – Minimal model578 parameters for
insulin sensitivity (SI), glucose effectiveness (Sg), acute insulin response to glucose (AIRg), and
disposition index (DI) were calculated as previously described232,579 using computer software.g,h
Disposition index was calculated by multiplying AIRg × SI.

Statistical Analysis – Mixed model analysis of variance (ANOVA) was performed using
computer softwarei to determine effects of group (EMS vs. normal), treatment (LPS vs. saline),
time, and main effect interactions. Area under the curve values for glucose and insulin were
calculated using the trapezoidal method and computer software.j Area under the curve for
insulin and baseline insulin values required logarithmic transformation to fit ANOVA normal
distribution assumptions.

Minimal model parameters required square root transformation.

Transformed data are reported as geometric means with 95% CI. All other data are reported as
least squares means ± SEM. The autoregressive correlation parameter was excluded from the
final model for all analyses. Mean separation was performed using Fisher’s protected least
significant difference and significance was set at P < 0.05.
Associations among peak blood cytokine expression values (refer to chapter 4) and
indices of glucose and insulin homeostasis were assessed using Spearman’s rank correlation

g

MinMod Millennium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA
Stata 9.2, Stata Corp., College Station, TX
i
PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC
j
SAS, version 9.2, SAS Institute, Inc., Cary, NC
h
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coefficients.

Correlation analysis was performed at the level of the individual animal.

Significance was set at P < 0.05 for all correlations.

5.3 Results

Group comparisons – Mean body condition score did not differ between the EMS and control
group, however 2 animals in the EMS group exhibited generalized obesity with prominent
nuchal crest adipose accumulation (body condition score > 7/9), 2/6 were of normal body
condition but showed regional adiposity of the neck and tail head, and 2/6 displayed a lean
phenotype. In contrast, only one horse in the control group was obese and none of the horses
exhibited regional adiposity.

Clinical signs – As reported in chapter 4, 10 of 12 animals demonstrated transient depression,
anorexia, pawing, yawning, head shaking, stretching, or muscle fasciculations following LPS
infusion. Two horses (1 normal and 1 EMS from the same pair) showed no clinical response to
LPS. Vital parameters did not change and leukopenia was not detected, so all data collected after
LPS infusion was excluded from further analyses.

Baseline glucose and insulin values – Baseline plasma glucose and serum insulin concentrations
from each FSIGTT are summarized in Table 5.1. Values represent resting glucose and insulin
concentrations. Lipopolysaccharide significantly increased baseline insulin (P < 0.001) and
glucose (P < 0.001) concentrations at 21 hours, but differences were not detected between EMS
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Table 5.1 Baseline plasma glucose and serum insulin concentrations from each FSIGTT in normal and EMS horses following IV
bolus administration of LPS at 20 ng/kg or saline infusion. Baseline insulin values are reported as geometric means and 95% CI and
baseline glucose values are reported as means ± SEM. Significance was set at P < 0.05.

FSIGTT

Baseline
insulin
(µU/mL)

Baseline
glucose
(mg/dL)

P value

Group

Treatment

-27 Hours

0.5 Hours

21 Hours

EMS

LPS
Saline

13.7 (9.8 to 19.2)
13.9 (8.0 to 23.9)

8.0 (6.9 to 9.3)
25.8 (12.1 to 55.1)

31.4 (19.4 to 51.0)
24.1 (11.9 to 49.2)

Normal

LPS
Saline

7.1 (4.1 to 12.3)
5.4 (3.8 to 7.7)

6.1 (2.9 to 12.9)
6.0 (3.2 to 11.4)

11.5 (5.9 to 22.6)
5.3 (3.7 to 7.5)

EMS

LPS
Saline

89.0 ± 2.9
92.7 ± 4.5

85.7 ± 2.8
92.5 ± 2.4

112.2 ± 7.0
94.9 ± 4.1

LPS
Saline

90.7 ± 3.0
90.2 ± 4.3

85.2 ± 4.0
90.5 ± 3.1

103.7 ± 3.1
90.1 ± 2.1

Normal

Group*

Treatment
× time†

0.007

0.001

0.371

0.001

*Insulin concentrations were higher overall in horses with EMS than in normal animals
†
For each variable, values increased significantly at 21 hours in the LPS groups, but differences between EMS and normal horses were
not detected. Changes were not significant in horses that received Saline infusions.
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and normal horses. Horses with EMS has higher baseline insulin concentrations overall (P <
0.007).
Resting hyperinsulinemia (> 20 µU/mL)a was detected in 2/6 horses with EMS and 1/6
normal horses prior to the testing period (at -27 hours) during one or both weeks of the study.
Lipopolysaccharide infusion induced hyperinsulinemia in 5/5 (100%) EMS horses and 1/6 (17%)
normal horses at 21 hours. This normal horse was not the same one in which hyperinsulinemia
was detected at -27 hours. Saline infusion induced hyperinsulinemia 4/6 (67%) and 3/6 (50%)
EMS horses at 0.5 and 21 hours, respectively. Resting hyperinsulinemia was not detected in
normal horses when they received saline.
Resting hyperglycemia (>110 mg/dL)b was not detected in any horse at -27 or 0.5 hours,
but LPS infusion induced hyperglycemia in 4/5 (80%) EMS horses and 1/6 (17%) normal horses
at 21 hours. One of 6 (17%) horses with EMS became hyperglycemic 21 hours after saline
infusion.

Area under the curve for glucose and insulin – Area under the curve values for glucose and
insulin are summarized in Table 5.2. Significant group × treatment × time interactions were
detected for area under the curve for glucose (AUCg) from 0 to 180 min (P = 0.039) and area
under the curve for insulin (AUCi) during the first 19 minutes, before IV dextrose administration
(P = 0.016). Treatment × time interactions were significant for AUCi from 0 to 180 min (P =
0.014; Figure 5.1) and AUCg for the first 19 minutes (P < 0.001; Figure 5.2). When group and
group x time effects were examined, AUCi (group; P = 0.005) and AUCg (group; P = 0.030,
group × time; P = 0.011) from 0 to 180 min were higher in horses with EMS.

a
b

Reference range for the Coat-A-Count insulin radioimmunoassay
Reference range used by the University of Tennessee Clinical Pathology laboratory
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Table 5.2 Area under the curve values for glucose and insulin in normal and EMS horses following IV bolus administration of LPS at
20 ng/kg or saline infusion. Values for AUCi (0 to 180 minutes) are reported as geometric means and 95% CI and all other data are
reported as means ± SEM. Significance was set at P < 0.05.

FSIGTT
Group

Treatment

-27 Hours

0.5 Hours

P value
21 Hours

Group
× treatment
× time

0 to 180 minutes
AUCi
[(µU/mL ×
min) × 103]

AUCg
[(mg/dL ×
min) × 103]

AUCi
[(µU/mL ×
min) × 103]

AUCg
[(mg/dL ×
min) × 103]

EMS

LPS
Saline

8.6 (7.1 to 10.3)
10.8 (8.4 to 14.0)

12.3 (6.9 to 22.1)
15.4 (9.4 to 25.2)

20.1 (12.9 to 31.3)
13.2 (7.4 to 23.6)

Normal

LPS
Saline

5.4 (4.5 to 6.4)
6.0 (4.7 to 7.5)

6.8 (5.6 to 8.2)
4.8 (3.7 to 6.3)

8.5 (6.4 to 11.2)
6.1 (4.4 to 8.4)

EMS

LPS
Saline

18.7 ± 0.2f
21.6 ± 1.0c,d,e

20.1 ± 0.5c,d,e,f
21.8 ± 0.8c

29.8 ± 1.01a
21.8 ± 0.9c,d

f

e,f

LPS
Saline

19.0 ± 0.9
20.0 ± 1.1c,d,e,f

19.2 ± 0.5
19.4 ± 0.6e,f
0 to 19 minutes

25.3 ± 1.5
19.5 ± 0.4d,e,f

EMS

LPS
Saline

2.3 ± 0.3a,b,c
2.1 ± 0.3b,c,d

1.4 ± 0.6d
3.2 ± 0.6a

2.5 ± 0.4a,b
3.0 ± 0.6a

d

0.039

b

Normal

c,d

0.185

0.016

b,c,d

Normal

LPS
Saline

1.3 ± 0.2
1.4 ± 0.2c,d

1.1 ± 0.1
1.3 ± 0.2c,d

1.7 ± 0.3
1.3 ± 0.1c,d

EMS

LPS
Saline

3.6 ± 0.1
3.8 ± 0.1

3.7 ± 0.2
3.9 ± 0.1

4.4 ± 0.1
3.9 ± 0.1

Normal

LPS
Saline

3.7 ± 0.1
3.7 ± 0.1

3.8 ± 0.1
3.8 ± 0.1

4.1 ± 0.1
3.8 ± 0.1

0.226

a-f

Within each variable, superscript letters indicate significant (P < 0.05) differences between means.
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Figure 5.1 Treatment × time interactions (P = 0.014) for AUCi from 0 to 180 minutes following
IV bolus administration of LPS at 20 ng/kg or saline infusion in normal and EMS horses. Data
are expressed as geometric means and 95% CI, and are displayed on a linear scale. Letters
denote significant differences among means.
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Figure 5.2 Treatment × time interactions (P < 0.001) for AUCg from 0 to 19 minutes following
IV bolus administration of LPS at 20 ng/kg or saline infusion in normal and EMS horses. Data
are expressed as means ± SEM, and are displayed on a linear scale. Letters denote significant
differences among means.
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Minimal Model Analysis – Minimal model results are summarized in Table 5.3.

Insulin

sensitivity decreased in response to LPS infusion (treatment × time, P < 0.001; Figure 5.3A) and
significant group × time interactions were also detected (P = 0.016; Figure 5.3B). Baseline
mean SI values did not differ between normal and EMS horses, but SI was lower overall in EMS
horses (group; P < 0.001) across the study. Glucose effectiveness decreased in the EMS group
over time (group × time; P = 0.002; Figure 5.4), while treatment × time effects were significant
for AIRg (P < 0.001; Figure 5.5). Disposition index decreased in response to LPS infusion
(treatment × time; P < 0.001; Figure 5.6A) and in EMS horses over time (group × time, P =
0.044; Figure 5.6B).

Correlations – Peak cytokine gene expression (refer to chapter 4) in the blood was negatively
correlated with minimal model parameters at 0.5 and 21 hours, and positively correlated with
AUCi at 21 hours (Table 5.4).

5.4 Discussion

Lipopolysaccharide lowered insulin sensitivity in normal and EMS horses, but did not
induce laminitis. Horses with EMS exhibited a transient decrease in pancreatic insulin secretion
and greater loss of glycemic control following LPS administration.

Our hypothesis that EMS

impacts alterations in glucose and insulin dynamics induced by LPS administration was therefore
supported.
Two methods were used to assess glucose and insulin dynamics from FSIGTT data. Area
under the curve values for glucose and insulin were calculated for each full FSIGTT procedure
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Table 5.3 Minimal model results for normal and EMS horses following IV bolus administration of LPS at 20 ng/kg or saline infusion.
Data are reported as geometric means and 95% CI. Significance was set at P < 0.05.

FSIGTT

SI
(L × min-1
× mU-1) × 10-4

Sg
(min ) × 10-2

Group

Treatment

-27 Hours

0.5 Hours

21 Hours

EMS

LPS
Saline

2.28 (1.24 to3.64)
1.03 (0.59 to 1.59)

0.93 (0.34 to 1.82)
0.86 (0.48 to 1.35)

0.22 (0.11 to 0.38)
0.70 (0.33 to 1.20)

Normal

LPS
Saline

3.25 (2.24 to 4.45)
1.81 (0.86 to 3.11)

3.40 (1.90 to 5.33)
3.99 (2.39 to 6.01)

0.98 (0.15 to 2.55)
2.43 (1.41 to 3.74)

EMS

LPS
Saline

2.64 (1.44 to 4.19)
2.58 (1.89 to 3.38)

3.25 (1.92 to 4.94)
2.15 (1.68 to 2.69)

0.64 (0.22 to 1.27)
1.42 (0.65 to 2.48)

Normal

LPS
Saline

2.66 (2.10 to 3.29)
2.01 (1.53 to 2.56)

3.10 (1.74 to 4.84)
2.61 (1.81 to 3.54)

2.74 (1.41 to 4.52)
2.36 (1.77 to 3.04)

EMS

LPS
Saline

660 (357 to 1055)
533 (309 to 820)

309 (10 to 1021)
883 (518 to 1345)

423 (206 to 719)
821 (458 to 1291)

Normal

LPS
Saline

255 (143 to 400)
212 (87 to 394)

108 (22 to 258)
260 (128 to 439)

333 (206 to 493)
278 (147 to 453)

EMS

LPS
Saline

1479 (603 to 2743)
622 (182 to 1327)

250 (0.34 to 1037)
819 (285 to 1628)

61 (25 to 116)
522 (286 to 829)

LPS
Saline

770 (423 to 1220)
372 (108 to 796)

379 (45 to 1039)
923 (521 to 1439)

339 (22 to 1035)
603 (341 to 942)

-1

AIRg
(mU × min
× L-1)

DI
× 102

P value

Normal

Group
× treatment
× time

0.919

0.200

0.114

0.487
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Figure 5.3 Insulin sensitivity in normal and EMS horses following IV bolus administration of
LPS at 20 ng/kg or saline infusion. Data are expressed as geometric means and 95% CI, and are
displayed on a linear scale. A) Treatment × time (P < 0.001) and B) group × time (P = 0.016)
interactions were significant. Letters denote significant differences among means.
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Figure 5.3, continued.
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Figure 5.4 Group × time interactions (P = 0.002) for Sg in normal and EMS horses following
IV bolus administration of LPS at 20 ng/kg or saline infusion. Data are expressed as geometric
means and 95% CI, and are displayed on a linear scale. Letters denote significant differences
among means.
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Figure 5.5

Treatment × time interactions (P < 0.001) for AIRg following IV bolus

administration of LPS at 20 ng/kg or saline infusion in normal and EMS horses. Data are
expressed as geometric means and 95% CI, and are displayed on a linear scale. Letters denote
significant differences among means.

150

Figure 5.6 Disposition index in normal and EMS horses following IV bolus administration of
LPS at 20 ng/kg or saline infusion. Data are expressed as geometric means and 95% CI, and are
displayed on a linear scale. A) Treatment × time (P < 0.001) and B) group × time (P = 0.044)
interactions were significant. Letters denote significant differences among means.
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Figure 5.6, continued.
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Table 5.4 Spearman’s rank correlation coefficients for associations among peak blood cytokine
gene expression values and minimal model parameters in normal and EMS horses after receiving
a 20 ng/kg IV bolus of LPS. Significance was set at P < 0.05 and P values are displayed in
parentheses.

SI
0.5 hours

SI
21 hours

Sg
21 hours

AUCi
21 hours

Peak IL-1β

-0.762
(0.028)

-

-

-

Peak IL-8

-0.810
(0.015)

-

-0.762
(0.028)

0.714
(0.047)

Peak IL-10

-0.786
(0.021)

-

-

-

Peak TNF-α

-

-0.714
(0.047)

-

-
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and for the first 19 minutes of each curve. Area under the curve values provide an estimation of
insulin sensitivity, and have been shown to increase in insulin-resistant horses.254 Examination
of insulin responses during the first 19 minutes of the FSIGTT procedure (before administration
of exogenous insulin) provides information on the pancreatic response to a glucose challenge,
and increased insulin secretion suggests pancreatic compensation for peripheral IR.
Minimal model analysis was the other method used in this study.

This is a

compartmental model of glucose and insulin dynamics that partitions glucose disposal into
glucose-dependent and insulin-dependent components.221,232,233 The SI parameter is an index of
peripheral insulin sensitivity and describes the ability of insulin to mediate glucose disposal.
Glucose effectiveness describes the ability of glucose to stimulate its own disposal through mass
effect, and becomes increasingly important to glucose homeostasis when insulin-dependent
glucose disposal is impaired.234,235 The AIRg parameter assesses the pancreatic response to a
glucose challenge, and is calculated from values obtained in the first 10 min, prior to
administration of exogenous insulin. Disposition index is an assessment of whether pancreatic
insulin secretion is adequately compensating for alterations in peripheral insulin sensitivity and is
calculated by multiplying SI with AIRg.580
Mean baseline SI values for normal horses in this study compared favorably to previously
reported values in lean light-breed horses.225,232,327,354,577,581 Baseline SI values for horses with
EMS, however, did not differ from normal animals and were higher than the means of 0.39 to
0.62 × 10-4 L × min-1 × mU-1 previously reported for a cohort of Arabian and Arabian-cross
geldings in which obesity was induced through dietary manipulation.581 Values were also higher
than those reported for obese thoroughbred geldings (mean SI of 0.37 × 10-4 L × min-1 × mU-1 ),
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but were comparable to values obtained in moderately obese animals (mean SI of 1.47 × 10 -4 L ×
min-1 × mU-1).232
One reason for this discrepancy is that horses with EMS were part of an intensively
managed research herd and several animals had lost weight prior to enrollment in this study.
Weight loss has previously been shown to improve insulin sensitivity in horses and ponies.582-584
Although a cut-off value for determining IR in horses has not been established, SI values less
than 0.78 × 10-4 L × min-1 × mU-1 correspond to the lowest quintile reported in a group of 46
healthy horses and can be used as a guideline for interpreting results.225 Variability in baseline
SI was seen in both normal and EMS horses between the first and second weeks of the study.
This could represent inherent variability in glucose and insulin homeostasis due to factors such
as stress. Although mean baseline SI values did not differ between normal and EMS horses, a
significant group effect was detected, indicating that SI was lower overall in horses with EMS as
treatments were administered and procedures performed.
Area under the insulin curve (0 to 180 min) increased and SI values decreased in both
normal and EMS horses 21 hours after LPS infusion. These findings indicate that IR developed
in response to endotoxin infusion and are consistent with previous reports by our research group
demonstrating IR in normal horses 20 to 24 hours after LPS administration at the same
dose.327,354 In those studies, values of 0.9 × 10-4 L × min-1 × mU-1 and 0.63 × 10-4 L × min-1 ×
mU-1 were reported at 20 and 24 hours, respectively. In another report, Vick, et al.269 detected IR
in normal mares 24 hours after endotoxin infusion using a hyperinsulinemic-euglycemic clamp
procedure, and inflammatory cytokine expression also increased in blood and adipose tissue.
Blood cytokine gene expression was also measured for 4 hours following LPS administration in
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this study (refer to chapter 4), and negative correlations were detected between peak cytokine
expression and indices of glucose and insulin homeostasis at 24 hours.
Development of IR following LPS administration can be explained by the cross-talk that
occurs between inflammatory cytokine and

insulin signaling pathways, such that

insulin

sensitivity decreases during systemic inflammation.91 Serine kinases such as protein kinase C, cJun NH2-terminal kinase, and inhibitor of κB kinase are integral to inflammatory signaling, and
also phosphorylate key components of the insulin signaling pathway on serine residues, which
induces IR.88,114 Although systemic inflammation might be expected to affect insulin sensitivity
to a greater extent in horses with EMS, differences in SI did not reach statistical significance.
However, resting hyperinsulinemia was detected in all EMS horses following LPS infusion,
whereas only one normal horse became hyperinsulinemic, and AUCg (0 to 180 min) was
significantly higher 21 hours after LPS in affected horses.
Insulin sensitivity decreased over time in horses with EMS independent of treatment.
Stress from hospitalization and testing procedures could have contributed to IR in these animals
because decreased insulin sensitivity has been attributed to stress in horses during prolonged stall
confinement.354 Stress hormones including glucocorticoids and epinephrine decrease insulin
sensitivity through mechanisms that include down-regulation of proteins in the insulin signaling
cascade and inhibition of glucose uptake and storage.100-103,585-588 In contrast, insulin sensitivity
increased transiently in normal horses at 0.5 hours. Transient increases in insulin sensitivity and
glucose utilization have been described in humans589,590 and horses269 following LPS
administration, but increase in horses receiving saline is difficult to explain. Insulin sensitivity
varied markedly in EMS horses throughout the study and this suggests that stress, diet, housing,
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or other factors influenced this variable. Horses with EMS may therefore be less able to adapt
to situations such as hospitalization, and IR may be exacerbated under these conditions.
Insulin resistance was measured in this study because microvascular dysfunction caused
by IR plays an important role in the pathogenesis of cardiovascular disease in humans, 296 and
could also contribute to development of laminitis in horses with EMS.

Insulin has

vasoregulatory functions in addition to its effects on cellular glucose uptake, and exerts mainly
vasodilatory effects in normal individuals.198,199 Binding of insulin to its receptor activates
multiple intracellular signaling pathway, with phosphoinositide 3-kinase and mitogen activated
protein kinase most important to vasoregulation.198,199 Insulin resistance selectively inhibits the
phosphoinositide 3-kinase pathway of insulin signaling, which is responsible for both insulinmediated glucose uptake and production of the vasodilator nitric oxide by endothelial cells.198,199
Insulin signaling through the mitogen activated protein kinase pathway remains active even in
the insulin-resistant state and leads to endothelial cell production of the potent vasoconstrictor
endothelin-1.198,199 The balance therefore shifts to favor vasoconstriction during IR, an effect
that has been reproduced in vitro in equine digital vessels.591 Compensatory hyperinsulinemia
that develops in response to IR may further exacerbate vasoconstriction.199

Increased

endothelin-1 production occurs in the hoof during the development of acute laminitis,486 so
horses with IR may be at increased risk of developing the disease because their vessels are
already prone to vasoconstriction.
Both AUCi (0 to 19 min) and AIRg assess the pancreatic responses to a glucose
challenge. Increased pancreatic insulin secretion indicates compensation for peripheral IR.327 In
this study, AUCi (0 to 19 min) did not change over time in normal animals with either treatment,
but transiently decreased in EMS horses that received LPS.

This finding suggests that
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pancreatic insulin output is acutely inhibited, and has been documented 12 hours after LPS
administration in rats.592

Horses with EMS horses are more susceptible to suppression of

pancreatic insulin output caused by inflammation.
Values for AIRg in normal horses in this study fell within ranges previously reported for
lean light-breed horses, although considerable variability exists among reports.225,232,327,354,577,581
In previous studies, AIRg in normal horses ranged from a mean value of 206 mU × min × L-1
reported by Carter et al.581 to 520 mU × min × L-1 reported by our research group in a cohort of
16 healthy horses.327 These values overlap with AIRg reported in obese thoroughbred geldings
(mean of 408 mU × min × L-1 ),232 and the upper limit of the range is consistent with baseline
values obtained for EMS horses in the current study. Direct comparisons among studies may be
hampered by variability in study populations or in methodology. Although not statistically
significant, AIRg was approximately 2- to 3-fold higher in EMS than normal horses, suggesting
a degree of compensated IR.183,226,581 In this study, only values for EMS horses 0.5 and 21 hours
after saline infusion were comparable to those previously reported in obese light-breed horses
(means of 804 to 973 mU × min × L-1)581 and this provides further evidence that horses with
EMS are susceptible to IR caused by stress. Of note, AIRg did not increase at 21 hours after
LPS in either normal or EMS horses, which contrasts with the finding from a previous report
that pancreatic compensation occurs 24 hours after LPS administration.327
Glucose effectiveness has been identified as an important determinant of glucose
tolerance in obese horses,232 but baseline values did not differ between groups in this study. A
decrease in Sg was detected at 21 hours in horses with EMS independent of treatment. This
differs from previous reports where Sg remained unaffected in normal horses following LPS
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infusion.327,354 Reductions in Sg are reported in response to epinephrine infusion in dogs,593,594
which supports the hypothesis that horses with EMS are more affected by physiological stress.
Although insulin secretion increased as a result of IR in both normal and EMS horses,
glucose homeostasis was not maintained as effectively in horses with EMS when LPS was
administered. Higher AUCg (0 to 180 min) values were detected in both groups at 21 hours
post-LPS administration, but the magnitude of this increase was greater in EMS horses;
suggesting greater loss of glycemic control. Resting hyperglycemia was also detected in 80% of
EMS horses compared to 17% of normal animals following LPS administration. Changes in DI
also support inadequate pancreatic compensation and loss of glycemic control. Hyperglycemia
can be explained by reduced tissue insulin sensitivity or inadequate pancreatic insulin secretion.
It can also result from increased hepatic glucose production because the major source of glucose
during sepsis is hepatic gluconeogenesis.91,144,292

Insulin normally inhibits hepatic glucose

output, but sepsis hinders this control mechanism by inducing hepatic IR.144,595A recent study by
our research group demonstrated reduced hepatic insulin clearance in horses with EMS, and this
may be a manifestation of hepatic IR.596 Horses with EMS might therefore be more susceptible
to hyperglycemia during systemic illness and this could contribute to the development of
laminitis.
Mild hyperglycemia can cause endothelial damage,573-575 so this may explain why horses
with EMS are at greater risk of developing laminitis during

systemic inflammation .307

Hyperglycemia causes mitochondrial overproduction of reactive oxygen species in endothelial
cells, leading directly to endothelial dysfunction.572 Reactive oxygen species incite inflammation
and the production of inflammatory cytokines.91,572 They also promote vasoconstriction by
reacting with and depleting nitric oxide302,572 and exert pro-thrombotic effects on vessels.91,572

159

Hyperglycemia augments the production of inflammatory cytokines in septic human patients,597
and has been shown to increase matrix metalloproteinase 1, 2 and 9 expression in cultured
endothelial cells and macrophages.401 Inflammation, vascular dysfunction, and increased matrix
metalloproteinase activity are key features of acute laminitis,303,373,598 and might therefore be
exacerbated by hyperglycemia.
Hyperglycemia is also associated with increased mortality in horses with colic288,291,599
and in critically ill neonatal foals.289 In one study, over 50% of horses with acute abdominal
disease were reported to be hyperglycemic at presentation, and higher blood glucose
concentrations were negatively associated with short and long-term survival.288 A well-known
series of studies by Van den Berghe and colleagues331-333

demonstrated that maintaining tight

glycemic control, defined as blood glucose concentrations between 80 and 110 mg/dL,
significantly reduced morbidity and mortality in critically ill humans. Optimal blood glucose
target ranges, however, remain an area of ongoing debate.600-605
Resting hyperinsulinemia was detected in all EMS horses and 1 normal horse after LPS
infusion.

Recent studies have demonstrated that hyperinsulinemia per se is detrimental to

laminar tissues independently of IR.384,385

In these studies, maintaining insulin at

supraphysiologic concentrations for approximately 2 days induced laminitis in normal horses and
ponies. The mechanisms responsible for laminitis development are incompletely understood, but
may include increased glucose delivery to the hoof and localized glucotoxicity as a result of
insulin-induced vasodilation and capillary recruitment.296,299 Mitogenic stimulation by insulin
and abnormal laminar tissue proliferation has also been suggested.387,388 Mean serum insulin
concentrations used to induce laminitis under experimental conditions exceed 1000 µU/mL and
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are not commonly encountered in clinical cases.

However, it is possible that moderate

elevations in insulin adversely affect the laminae with prolonged exposure.
One limitation of this study was that horses in the EMS and normal groups did not differ
with respect to body condition score or baseline insulin sensitivity, although some EMS horses
retained abnormal characteristics such as generalized or regional adiposity. It is possible that
greater differences would have been detected between groups if horses had been in an
exacerbated state of IR or obesity. Small group sizes also limited the power of the study.
Despite these limitations, differences were detected between normal and EMS horses,
particularly with regard to glycemic control and responses to stress.
Syndrome is thought to have an underlying genetic basis226,246

Equine Metabolic

and manifestation of the

syndrome may rely upon interactions between individual horses and their environment. For
example, exaggerated insulin responses and decreased insulin sensitivity occur in response to
high dietary carbohydrate intake in laminitis-prone ponies.256,257 In humans, hyperglycemia
during sepsis is sometime the first indication of occult diabetes mellitus.144 Endotoxin challenge
may therefore have unmasked inherent defects in insulin and glucose regulation in horses with
EMS.
We conclude that EMS modulates glucose and insulin responses and adversely impacts
glycemic control following exposure to LPS. Horses with EMS may also be more susceptible to
derangements in glucose and insulin homeostasis as a result of stress, which could increase the
risk of laminitis in stressful situations such as hospitalization. Further studies are required to
examine the role of stress in the pathogenesis of laminitis.
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CHAPTER 6
Endotoxemia as a predisposing factor for laminitis in horses

6.1 Introduction

An ongoing challenge of laminitis research is to untangle the relationships among
inflammation, endotoxemia, and insulin resistance (IR). Insulin resistance182,226,250 and systemic
inflammation3 are independent risk factor for laminitis; reportedly increasing the odds of
laminitis 10- and 5-fold, respectively.3,226

The role of endotoxin is controversial, because

endotoxin administration alone consistently fails to induce laminitis in the horse.327,354,410,534
That said, laminitis is a common complication of diseases in which endotoxemia occurs,
including gastrointestinal disease, metritis, pneumonia, and Gram-negative septicemia.13,606,607
Endotoxin has also been detected in the blood of horses following experimental laminitis
induction by carbohydrate overload,409,423 and is known to affect digital vascular function403,406
and platelet activation.409 A theoretical basis therefore exists for its role in laminitis, possibly as
a predisposing factor.
Laminitis is frequently observed in insulin-resistant horses after grazing on abundant
pasture with high carbohydrate content, and this is referred to as pasture-associated laminitis.298
Clinical experience suggests that affected horses only develop laminitis after several days of
consuming excessive amounts of grass, which suggests a cumulative process. Most of our
understanding of pasture-associated laminitis comes from carbohydrate overload models.298 In
these models, starch is administered in amounts that exceed small intestinal digestive capacity or
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horses receive oligofructose (OF), which is minimally hydrolyzed within the mammalian
foregut.165,418,499

Rapid fermentation of carbohydrates by lactate-producing Gram-positive

streptococcal species in the hindgut causes a precipitous drop in cecal pH, an increase in mucosal
permeability, and increased cecal endotoxin concentrations.165,420,422,500-505

Gut-derived

endotoxins, exotoxins, and vasoactive amines translocating from the gastrointestinal tract may
directly trigger laminitis or indirectly induce the disease by inciting systemic inflammation. 375
Acute laminitis shares many characteristics with sepsis-associated organ failure, and might be a
manifestation of end-organ damage in the horse.373
Although these carbohydrate overload models are an imperfect method of studying
pasture-associated laminitis because carbohydrate is administered as a single large bolus, grazing
horses can theoretically consume a comparable amount of carbohydrate in one day under certain
pasture conditions.499 It is also conceivable that minor intestinal carbohydrate overload events
occur in grazing horses and trigger laminitis in susceptible animals.298 Systemic inflammation
lowers insulin sensitivity,91 and IR is a known risk factor for laminitis, so these factors may
combine to induce the disease.

Our research group previously examined this situation by

administering lipopolysaccharide (LPS) and OF to horses.164 Lipopolysaccharide lowers insulin
sensitivity in horses269,327,354 and OF administration also affects glucose dynamics,608 so it was
postulated that a combination of these treatments would alter glucose and insulin dynamics to a
greater extent than each factor alone and cause laminitis. Horses received LPS or saline and then
OF, and the incidence and severity of laminitis tended to increase in horses that received both
treatments .164 Both LPS and OF administration lowered insulin sensitivity, but an additive
effect was not documented.

An alternative hypothesis is therefore that initial inflammatory
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events induced by LPS prime the immune system and this results in a more severe inflammatory
reaction following carbohydrate overload.
In what has been termed the “two-hit hypothesis” of organ damage, sequential exposure
to inflammatory stimuli can exacerbate inflammatory responses and increase mortality during
sepsis.440

The initial inflammatory response primes the immune system and causes an

exaggerated response to a second, sometimes innocuous, stimulus.437-439 Animal models have
been developed to examine this phenomenon using combinations of fecal peritonitis, gut
ischemia-reperfusion injury, hemorrhagic shock, burn injury, and LPS administration.442-445
Increased infiltration of the liver and lungs with neutrophils, higher pro-inflammatory cytokine
and chemokine expression, and a greater incidence of acute lung injury have been demonstrated
in animals that receive multiple treatments.442-445 In humans, neutrophils from trauma patients
are primed in vivo by inflammatory mediators and release more superoxide anion than those
from healthy individuals when harvested and stimulated in vitro.446

Trauma patients may

therefore be at increased risk of multiple organ failure in the face of a second inflammatory event
such as hemorrhage or infection.446,609,610

In LPS models, the initially inflammatory event is

thought to enhance Toll-like receptor 4 reactivity and augment pro-inflammatory signaling
pathways, while also disrupting negative regulatory mechanisms.442 Extrapolation of the two-hit
hypothesis to the horse might explain why sequential administration of LPS and OF increased
the severity of laminitis as reported by Tóth, et al.,164 and provides a theory linking multiple
carbohydrate overload events to the pathogenesis of pasture-associated laminitis.
The current study was performed to provide evidence for the two-hit hypothesis in
horses. We hypothesized that that the systemic inflammation induced by intestinal carbohydrate
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overload would be more pronounced in horses that were pre-treated with LPS and horses
receiving both treatments would have a greater incidence and severity of laminitis.

6.2 Materials and methods

Animals – All horses used in this study had chronic diseases or behavioral abnormalities that
warranted euthanasia.

Animals were either donated to the University of Tennessee for

euthanasia by their owners or were purchased for the study. Adult light breed geldings and
nonpregnant mares were accepted, and animals with active laminitis or other lameness severe
enough to interfere with laminitis assessments during the study were excluded.
Twenty-four mares (10) and geldings (14) met the inclusion criteria. Horses ranged in
age from 3 to 25 years (mean 13.3 year; median 13.5 years), weighed between 334 and 555 kg
(mean 402.8 kg; median 385), and had body condition scores of 2 to 8.5 (mean 4.5; median 4) on
the scale of 1 to 9 developed by Henneke, et al.249 Breeds included Tennessee Walking Horses
and Tennessee Walking Horse crosses (8), Quarter Horses (5), Paint Horses (3), American
Saddlebreds and Saddlebred crosses (3), Appaloosas and Appaloosa crosses (2), an Arabian (1),
Morgan cross (1), and Haflinger cross (1). Horses were to be euthanized for the following
reasons: musculoskeletal disease (10), behavioral abnormalities (5), blindness (4), recurrent
uveitis (3), neurological abnormalities (3), unexplained weight loss (2), cardiac disease (1), and
squamous cell carcinoma (1). Multiple problems were present in some animals. The study
protocol was approved by the University of Tennessee Institutional Animal Care and Use
Committee.
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Study Design – Horses were housed in 3.7 m × 3.7 m box stalls in the Veterinary Teaching
Hospital for the duration of the study. Body weight measurements and physical examinations
were performed at the time of arrival. Grass hay and water were provided ad libitum at all times.
Beginning 2 days before testing, all animals received OF (1 g/kg daily) added to the basal ration
and physical examination monitoring was initiated. Baseline blood samples were collected for
analysis of whole blood inflammatory cytokine gene expression and measurement of plasma
glucose and serum insulin concentrations at 0800 on the first day of testing (designated as time =
-24 hours). Baseline blood samples were also submitted for complete blood count (CBC)
analysis. Horses were then randomly assigned to receive an 8-hour continuous rate infusion
(CRI) of either LPS (LPS-OF group, n = 12) or saline (SAL-OF group, n = 12). At 0800 the
next morning (time = 0 hours), OF was administered to all horses via nasogastric tube at a
dosage of 5 g/kg. Animals were monitored for the developments of laminitis over the next 48
hours using the Obel grading scale.508

Horses were euthanized by intravenous barbiturate

overdosea and tissues were harvested within 4 hours of the onset of Obel grade 2 laminitis or at
48 hours if Obel grade 2 laminitis did not develop. Liver biopsies were performed under
standing sedation 24 hours after OF administration in horses that had not developed laminitis by
this time. Physical examinations and lameness evaluations were performed hourly during LPS or
saline infusion, and every 4 hours thereafter. Blood samples were collected for measurement of
inflammatory cytokine gene expression at -24, -20, -16, and -12 hours, then every 4 hours from 0
to 48 hours. Plasma and serum were collected for glucose and insulin measurements every 4
hours from time = -24 to 0 hours, then every 2 hours from 0 to 48 hours. An additional CBC was
submitted at -20 hours.

a

Beuthanasia D, Schering-Plough Animal Health Corp, Union, NJ

166

Lipopolysaccharide and saline administration – A 14-g polypropylene IV catheterb was
aseptically placed in the jugular vein 12 hours prior to LPS or saline administration. Horses in
the LPS-OF group received commercially available Escherichia coli O55:B5 LPS solutionc
infused via the IV catheter at a dose of 5 ng/kg/hr for 8 hours. Lipopolysaccharide was diluted in
sterile saline so that an infusion rate of 100 mL/hr provided the appropriate LPS dose for each
animal. Horses in the SAL-OF group received a CRI of sterile saline at a rate of 100 mL/hr for 8
hours.

Oligofructose administration – Horses received 1 g/kg OFd divided into two daily feedings and
mixed with 0.5 kg of oats for 3 days prior to laminitis induction to adapt the hindgut flora to this
carbohydrate. A laminitis induction dose of 5 g/kg OF was dissolved in 4 L of warm water and
administered via nasogastric intubation at time = 0 hours.

Measurement of blood variables – Blood samples for CBC analysis were collected into
ethylenediaminetetraacetic acid anticoagulant tubes and analyzed by the University of Tennessee
Clinical Pathology laboratory.

Whole blood inflammatory cytokine gene expression – Blood samples for quantitation of
interleukin (IL)-1β, IL-6, IL-8, IL-10, TNF-α, and β-glucuronidase (B-Gus) gene expression
were collected into whole blood RNA collection tubese and allowed to incubate at room
temperature for 8 hours, then stored at – 20 °C until analyzed. Total RNA extraction and real-

b

Abbocath-T 14 G X 140 mm, Abbott Laboratories, North Chicago, IL
Sigma Aldrich, Inc., St Louis, MO
d
Orafti® P95, formerly marketed as Beneo® 95, BENEO-Orafti S.A., Pemuco, Chile
e
PAXgene® blood RNA tubes, Qiagen/PreAnalytiX, Valencia, CA
c
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time polymerase chain reaction were performed as previously described (refer to chapter 2). The
comparative CT (ΔΔCT) method was used to determine fold changes in inflammatory cytokine
gene expression.509 Cytokine expression was normalized to the housekeeping gene B-Gus and
each horse’s baseline value was used as the calibrator. Baseline gene expression was therefore
equal to a 1-fold change for all cytokines.

Plasma glucose and serum insulin concentrations – Plasma and serum samples were collected
into appropriate anticoagulant or serum tubes. Tubes were centrifuged at 1,000 × g for 10
minutes and plasma or serum was harvested and stored at –20 ºC until analyzed. Plasma glucose
and serum insulin concentrations were measured as previously described (refer to chapter 3).

Liver Biopsies – Samples were collected for gene expression analysis and histopathology as
previously described (refer to chapter 4).

Postmortem tissue collection – Approximately 20 g of both liver and lung tissues were harvested
immediately after euthanasia and trimmed into 2 cm × 2 cm × 2 cm blocks. Limbs were
disarticulated at the metacarpophalangeal and metatarsophalangeal joints and laminar tissue
obtained from all four hooves by sectioning with a bandsaw, as previously described.361 Middorsal laminar sections were trimmed into 2 cm × 1 cm × 0.5 cm strips using a scalpel. Two
blocks of each tissue were fixed in 10% neutral buffered formalin, and the rest of the tissue was
immediately placed on dry ice and transported to a -80°C freezer for storage. Cecal and right
ventral colon tissues were also collected and fixed in formalin.
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Histopathology – Routing hematoxylin and eosin staining was performed on all formalin-fixed
tissue samples, and tissue sections (5 µm thickness) were evaluated using light microscopy by
one of two board-certified veterinary pathologists who remained blinded to treatment group
allocations.

Periodic acid-Schiff staining was performed on laminar sections, and laminitis was

graded using a previously described histological scoring system on a scale of 0 (no lesions) to 3
(severe lesions).361

Inflammatory cytokine gene expression in liver, lung, and laminar tissues – Total RNA was
obtained from frozen postmortem liver, lung, and laminar tissue samples using guanidinium
thiocyanate-phenol-chloroform extraction.611,612 Tissue samples (200 mg for laminar tissue and
liver; 500 mg for lung) were disrupted in guanidine thiocyanate-phenol solutionf (1 mL per 100
mg tissue) while still frozen using a rotor-stator homogenizer.g Samples were incubated at room
temperature for 5 minutes. Chloroformh (0.5 ml per 100 mg tissue) was added to each sample,
followed by a 5 minute incubation at room temperature and centrifugation (2,770 × g for 20
minutes at 4°C). The aqueous phase was collected and transferred to a clean tube, and RNA was
precipitated by adding 100% isopropyl alcoholh (0.5 mL per 100 mg tissue). Samples were
incubated at room temperature for 20 minutes, then centrifuged (2,770 × g for 20 minutes at
4°C). The RNA pellet was then resuspended and washed with 70% ethanolh (1 mL per 100 mg
tissue), centrifuged (2,770 × g for 20 minutes at 4°C), and air-dried for 10 minutes at room
temperature. The RNA pellet was resuspended in 100 µL of nuclease-free water and purified
using a commercially available kiti accordingly to the manufacturer’s instructions.

f

TRI Reagent,® Molecular Research Center, Inc., Cincinnati, OH
PowerGen® 700, Fisher Scientific, Pittsburgh, PA
h
Sigma Aldrich, Inc., St Louis, MO
i
RNeasy® Mini Kit, Qiagen, Valencia, CA
g
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A commercially available kitj was used to perform column-based total RNA extraction
from frozen liver biopsy samples accordingly to the protocol provided by the manufacturer. This
method was chosen because it achieved the greatest RNA yield from small samples in
preliminary tests.
Concentration and purity of RNA in each sample was measured via spectrophotometry. k
Reverse transcription was performed using a kitl and 1 μg of RNA was loaded into each reaction.
Complementary DNA was then diluted 1:10 with 180 µL of nuclease-free water.
Real time PCR was performed for IL-1β, IL-6, IL-8, IL-10, TNF-α, and β2 microglobulin
(B2M) as described for whole blood. β2 microglobulin was selected as the housekeeping gene
because B2M expression in tissue was more stable than expression of B-Gus in preliminary tests.
Cytokine expression in each sample was normalized to B2M and ΔΔCT calculations were
performed using a pooled calibrator value that was generated for each cytokine by averaging all
ΔCt values for that gene.

Statistical Analysis – Mixed model analysis of variance (ANOVA) for repeated measures was
performed using computer softwarem to determine effects of treatment, time, and main effect
interactions. Area under the curve (AUC) values for whole blood inflammatory cytokine gene
expression were calculated using the trapezoidal method and computer software. n Blood gene
expression data was available for all horses until 24 hours, after which point some animals were
removed from the study. To maintain consistency among animals, calculations for AUC values
included only points up to 24 hours. Blood gene expression data, plasma glucose, serum insulin,
j

RNeasy® Mini Kit, Qiagen, Valencia, CA
NanoDrop ND-1000, Thermo Fisher Scientific, Wilmington, DE
l
High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor, Applied Biosystems, Foster City, CA
m
PROC MIXED, SAS, version 9.2, SAS Institute, Inc., Cary, NC
n
SAS, version 9.2, SAS Institute, Inc., Cary, NC
k
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and selected tissue gene expression and AUC variables required log transformation to fit
ANOVA normal distribution assumptions. Transformed data are reported as geometric means
with 95% CI. All other data are reported as least squares means ± SEM. The autoregressive
correlation parameter was excluded from the final model for analysis of IL-6 and TNF-α
expression in blood. Mean separation was performed using Fisher’s protected least significant
difference and significance was set at P < 0.05.
Mean blood cytokine expression at each time point was compared to the pre-infusion
baseline using one-sample t-tests with Bonferroni correction for multiple comparisons.
Significance was set at P < 0.0016 after the Bonferroni correction was applied. For all horses
that had liver biopsies performed at 24 hours, gene expression was compared between liver
biopsy and liver necropsy samples using paired t-tests. Two-tailed Fisher’s exact tests were used
to compare the incidence of laminitis and histologic findings between treatment groups. Blood
cytokine AUC values and tissue gene expression results were correlated with time to onset of
Obel grade 1 and 2 laminitis in responders using Spearman’s rank correlation coefficients.
Associations between blood cytokine expression and vital parameters were also assessed using
Spearman’s rank correlation coefficients. Correlation analyses were performed at the level of the
individual animal. Significance was set at P < 0.05 for all correlations.
Treatment was not statistically significant in any analyses, so horses were reclassified as
responder and non-responders based upon the development of clinically detectable laminitis.
Treatment was eliminated from the model and all analyses were repeated. Because responders
were euthanized earlier than non-responders, comparisons were only performed until 28 hours.
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6.3 Results

Clinical signs – Treatment groups did not differ significantly with respect to age, body weight or
body condition score. All horses that received LPS exhibited transient depression, anorexia,
muscle fasciculations, or mild colic signs such as pawing, stretching, or sternal recumbency
during the infusion. Profound depression, anorexia, and/or abdominal discomfort developed in
15/24 horses following OF administration, mild responses were noted in 8/24 horses, and 1 horse
showed no change in demeanor following OF administration. Diarrhea was observed in 21/24
horses between 8 and 32 hours following OF administration and continued in 3 horses until 44 or
48 hours. Cardiovascular compromise developed in 3 animals following the onset of diarrhea,
and each received 10 to 20 L of crystalloids to maintain hemodynamic stability.
Treatment (LPS versus saline) × time effects were significant for mean rectal temperature
(P < 0.001; Figure 6.1A), heart rate (P = 0.003; Figure 6.1B), and respiratory rate (P < 0.001;
Figure 6.1C). Biphasic responses corresponding to LPS infusion and OF administration were
detected for these variables in the LPS-OF group, while single peaks following OF
administration occurred in the SAL-OF group. During LPS infusion, mean rectal temperature
and heart rate peaked from -22 to -16 hours. In contrast, there was an initial decrease in
respiratory rate, followed by an increase during the same time period. Mean rectal temperature
and heart rate increased in both groups approximately 12 to 24 hours after OF administration,
and respiratory rate increased at 8 hours in the SAL-OF group and from 20 to 24 hours in both
groups. Peaks following OF administration did not differ in magnitude between groups.
When horses were reclassified as responders and non-responders on the basis of whether
laminitis developed, mean heart rate increased in responders from 16 to 24 hours (group × time;
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Figure 6.1 Changes in physical examination parameters of horses receiving either an 8-hour
LPS CRI (5 ng/kg/hr) or saline CRI, followed by administration of OF (5 g/kg). Data are
expressed as means ± SEM.

*LPS-OF:

Significant difference from baseline.

Significant difference from baseline.

†

SAL-OF:

Treatment (LPS versus saline) × time effects were

significant for A) mean rectal temperature (P < 0.001), B) mean heart rate (P = 0.003), and C)
mean respiratory rate (P < 0.001).

The vertical dotted line denotes the time of OF

administration.

173

Figure 6.1, continued.
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Figure 6.1, continued.
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P = 0.008), corresponding to the onset of laminitis (data not shown). Mean rectal temperature
and respiratory rate did not differ between responders and non-responders. All responders
showed clinical signs of systemic inflammation following OF administration, and 13/15 (87%)
had diarrhea. All of the non-responders (n = 9) showed transient clinical signs of systemic
inflammation (n = 8) or diarrhea (n = 8) after OF was administered. One non-responder (from
the SAL-OF group) became acutely recumbent and developed severe metabolic acidosis at 32
hours, and was euthanized early.

Laminitis – Laminitis developed in 8/12 (67%) of horses in the LPS-OF group compared to 7/12
(58%) horses in the SAL-OF group, and this was not significant when analyzed using the
Fisher’s exact test. The overall laminitis induction rate was therefore 63%. In the 15 responders,
Obel grade 2 laminitis developed at 20 hours (3 horses), 24 hours (8 horses), and 28 hours (4
horses), and 4 horses continued to deteriorate rapidly before euthanasia was performed. No more
than 12 hours elapsed from the time laminitis was first detected to the onset of Obel grade 2 in
any animal. Neither time to onset of laminitis nor time to onset of Obel grade 2 laminitis
differed between treatment groups.

Hematology – Leukocyte counts were not significantly affected by LPS administration (data not
shown). Leukopenia (reference range = 4.6 – 12 × 103 WBC/μL)o was detected in 3/12 (25%)
horses when measured 4 hours after starting the LPS infusion, but not in horses that received
saline.

o

Reference ranges used by the University of Tennessee Clinical Pathology laboratory
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Whole blood cytokine gene expression – Treatment (LPS versus saline) × time effects were
significant for interleukin (IL)-1β (P < 0.001; Figure 6.2A), IL-6 (P = 0.040; Figure 6.2B), and
tumor necrosis factor-α (TNF-α; P = 0.016; Figure 6.2C). Significant treatment effects were
detected for IL-8 (P = 0.002; Figure 6.2D), and time effects were significant for IL-10 (P <
0.001; Figure 6.2E). During LPS or saline infusion, IL-1β and IL-6 expression differed between
treatment groups from -20 to -12 hours and TNF-α expression differed from -16 to -12 hours.
Differences in inflammatory cytokine expression were detected between treatment groups
on occasion after OF administration, but did not follow a recognizable pattern. Interleukin-1β
expression increased relative to baseline during LPS infusion in the LPS-OF group, and
following OF administration in both groups. Increases in IL-6 and IL-8 expression were also
detected in the LPS-OF group during LPS infusion and after OF administration, while a decrease
in IL-8 expression relative to baseline was noted at -16 hours in the SAL-OF group. Expression
of IL-10 and TNF-α did not differ significantly from baseline in either group, but IL-10
expression increased approximately 16 to 28 hours after OF administration in both treatment
groups.
Area under the curve values for IL-1β (P < 0.001), IL-6 (P < 0.001), and IL-8 (P = 0.002)
expression were higher in the LPS-OF group compared to the SAL-OF group during the time
period from -24 to 0 hours when infusions were performed (Table 6.1). Area under the curve for
IL-8 was also higher in the LPS-OF group after OF administration (P = 0.014).
When responders and non-responders were compared, IL-1β expression remained
elevated for longer relative to baseline in responders after OF administration, but there were no
differences in the magnitude of responses (Figure 6.3). Area under the curve for IL-1β was
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Figure 6.2 Change in whole blood gene expression of IL-1β, IL-6, TNF-α, IL-8, and IL-10 in
horses receiving either an 8-hour LPS CRI (5 ng/kg/hr) or saline CRI, followed by
administration of OF (5 g/kg). Data are expressed as geometric means and 95% CI, and are
displayed on a logarithmic scale. Significance was set at P < 0.0016 for one-sample t-test
comparisons between cytokine expression at each time point, compared to baseline. Significance
for ANOVA main effects and interactions was defined by P < 0.05. *LPS-OF: Significant
difference from baseline.

†

SAL-OF: Significant difference from baseline. Treatment (LPS

versus saline) × time effects were significant for A) IL-1β (P < 0.001), B) IL-6 (P = 0.040), and
C) TNF-α (P = 0.016). D) Treatment effects were significant for IL-8 (P = 0.002). E) Time
effects were significant for IL-10 (P < 0.001). The vertical dotted line denotes the time of OF
administration.
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Table 6.1 Area under the curve values for whole blood inflammatory cytokine expression in
horses receiving either an 8-hour LPS CRI (5 ng/kg/hr) or saline CRI, followed by
administration of OF (5 g/kg). Area under the curve values were also compared between
laminitis responders and non-responders. Comparisons were made during the time period from
-24 to 0 hours when infusions were performed and from 0 to 24 hours after OF administration.
Values for IL-8 and TNF-α (0 to 24 hours) in comparisons of LPS-OF and SAL-OF groups and
TNF-α (0 to 24 hours) in comparisons of responders and non-responders are expressed as means
± SEM. All other data are expressed as geometric means and 95% CI. Significance was set at P
< 0.05.
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Table 6.1, continued.

AUC (fold change × min)

Treatment

Between infusion
After OF
and OF
P value
administration
administration
(0 to 24 hours)
(-24 to 0 hours)
LPS-OF compared to SAL-OF

P value

Interleukin-1β

LPS-OF
SAL-OF

104.5 (75.4 to144.8)a
20.0 (13.7 to 29.2)b

0.001

75.5 (48.7 to 117.1)
71.4 (43.1 to 118.2)

0.869

Interleukin-6

LPS-OF
SAL-OF

70.3 (47.7 to 103.6)a
24.3 (16.8 to 35.1)b

0.001

66.0 (42.8 to 101.7)
45.4 (29.9 to 69.0)

0.228

Interleukin-8

LPS-OF
SAL-OF

127.4 (63.1 to 257.4)a
22.3 (11.8 to 42.0)b

0.002

327.1 ± 87.5c
74.1 ± 23.0d

0.014

Interleukin-10

LPS-OF
SAL-OF

29.8 (16.7 to 53.2)
31.0 (21.1 to 45.5)

0.909

44.3 (22.4 to 87.6)
54.7 (33.9 to 88.0)

0.620

TNF-α

LPS-OF
SAL-OF

40.3 (27.2 to 59.7)
23.6 (15.5 to 35.8)

0.075

36.7 ± 5.4
27.8 ± 5.9

0.275

Responders compared to non-responders
Interleukin-1β

Responder
Non-responder

48.4 (26.6 to 88.0)
41.6 (23.7 to73.0)

0.738

100.4 (67.0 to 150.4)e
43.6 (30.6 to 62.2)f

0.010

Interleukin-6

Responder
Non-responder

37.2 (25.2 to 54.9)
49.2 (25.4 to 95.2)

0.442

59.2 (39.8 to 88.0)
48.1 (29.5 to 78.3)

0.521

Interleukin-8

Responder
Non-responder

50.4 (22.9 to 110.6)
64.0 (24.7 to 165.9)

0.703

114.5 (45.7 to 286.7)
56.4 (28.8 to 110.7)

0.279

Interleukin-10

Responder
Non-responder

30.6 (19.8 to 47.3)
30.0 (16.8 to 53.7)

0.958

61.9 (39.0 to 98.3)
33.6 (16.1 to 70.0)

0.152

TNF-α

Responder
Non-responder

31.0 (20.4 to 47.0)
30.6 (19.7 to 47.5)

0.968

32.9 ± 5.1
31.2 ± 6.9

0.839

a,b

For each variable, letters indicate significant differences between LPS-OF and SAL-OF groups during
LPS or Saline infusion
c,d
Letters indicate significant differences between LPS-OF and SAL-OF groups after OF administration
e,f
Letters indicate significant differences between Responders and Non-responders after OF administration
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Figure 6.3 Whole blood IL-1β expression in laminitis responders and non-responders. Data are
expressed as geometric means and 95% CI, and are displayed on a logarithmic scale.
Significance was set at P < 0.0023 for one-sample t-test comparisons between cytokine
expression at each time point, compared to baseline. Significant ANOVA main effects were not
detected (P > 0.05).

§

Responders: Significant difference from baseline.

Significant difference from baseline.

‡

Non-responders:

The vertical dotted line denotes the time of OF

administration.
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significantly higher in responders than non-responders for the period of time following OF
administration (P = 0.010).

Liver, lung, and laminar tissue cytokine gene expression – Results are summarized in Table 6.2.
No differences were detected between LPS-OF and SAL-OF groups, but significant differences
were detected for all tissues between responders and non-responders. When liver biopsy and
post mortem liver samples were compared in non-responders (n = 9), mean IL-8 expression was
significantly higher (approximately 2.5-fold difference) in post mortem samples.

Histopathology – All liver biopsy specimens obtained at 24 hours from non-responders were of
diagnostic quality.

Mild portal inflammation and/or sinusoidal neutrophil infiltration was

identified in 7/9 (78%) non-responders.
Mild portal inflammation was identified in liver samples from 22/24 (92%) horses at
necropsy. The 2 horses without evidence of portal inflammation were both non-responders.
Nascent microthrombi and/or hemorrhage were noted in medium to large pulmonary arteries in
11/24 (46%) horses, including 5/12 (42%) horses in the LPS-OF group and 6/12 (50%) horse in
the SAL-OF group.

When classified as responders and non-responders, lung lesions were

identified in 8/15 (53%) responders and 3/9 (33%) non-responders. These differences were not
significant when analyzed using the Fisher’s exact test. Significant lesions were not identified in
the colon or cecum.
Gross evidence of mild chronic laminitis (e.g. rotation or remodeling of the distal
phalanx) was seen in 3 horses at necropsy. Laminar histologic scores (calculated as the sum of
the grades for each hoof) did not correspond to Obel scores at the time of euthanasia
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Table 6.2 Tissue gene expression of inflammatory cytokines in laminitis responders and non-responders. Gene expression in post
mortem samples was compared for all tissue types. Post mortem liver samples in responders (obtained at approximately 24 hours)
were also compared to 24-hour liver biopsy samples in non-responders. Values for IL-10 and TNF-α in liver biopsy comparisons and
IL-1β in post mortem liver and lung comparisons are expressed as means ± SEM. All other data are expressed as geometric means
and 95% CI. Significance was set at P < 0.05.

Liver biopsy

Liver

Relative gene expression
Lung
Forelimb

Hind limb

Interleukin-1β

Responder
Non-responder

1.4 (1.0 to 2.0)a
0.6 (0.3 to 1.2)b

1.7 ± 0.2a
0.7 ± 0.2b

1.5 ± 0.2
1.0 ± 0.3

1.3 (0.8 to 2.1)
0.6 (0.4 to 1.1)

1.5 (1.1 to 2.2)a
0.5 (0.3 to 0.8)b

Interleukin-6

Responder
Non-responder

1.4 (0.7 to 2.6)a
0.5 (0.2 to 1.0)b

1.4 (0.7 to 2.6)
0.6 (0.4 to 1.0)

1.3 (0.7 to 2.5)
0.6 (0.3 to 1.2)

1.8 (0.8 to 3.7)a
0.1 (0.1 to 0.3)b

2.0 (1.0 to 3.9)a
0.1 (0.0 to 0.7)b

Interleukin-8

Responder
Non-responder

1.5 (0.9 to 2.3)a
0.2 (0.1 to 0.5)b

1.5 (0.9 to 2.3)a
0.5 (0.2 to 1.2)b

1.5 (1.0 to 2.2)a
0.5 (0.3 to 0.8)b

1.3 (0.9 to 1.9)a
0.6 (0.4 to 1.1)b

1.6 (1.0 to 2.7)a
0.4 (0.2 to 0.7)b

Interleukin-10

Responder
Non-responder

2.6 ± 0.5
1.9 ± 0.6

1.8 (1.0 to 3.1)a
0.4 (0.4 to 1.0)b

1.5 (1.0 to 2.1)a
0.5 (0.3 to 0.9)b

0.8 (0.4 to 1.7)
1.3 (0.5 to 3.0)

1.0 (0.5 to 2.1)
0.9 (0.5 to 1.7)

Responder
1.4 ± 0.1a
1.2 (0.9 to 1.6)
0.8 (0.6 to 1.1)
1.3 (0.8 to 2.2)
1.4 (0.8 to 2.4)
b
Non-responder
0.5 ± 0.1
0.7 (0.5 to 1.2)
1.4 (0.8 to 2.2)
0.6 (0.3 to 1.1)
0.6 (0.2 to 1.4)
a,b
For each variable and tissue type, different letters indicate significant (P < 0.05) differences between responders and non-responders
TNF-α

188

(Spearman’s rho = 0.133; P = 0.536). Changes consistent with laminitis were identified in at
least one hoof from all horses, including non-responders. In individual samples with histologic
laminitis grades of 1 and 2, typically less than 25% of the secondary epidermal laminae were
affected.

Grade 3 lesions involved global changes to the laminae in most specimens.

A

histologic grade of 3 was assigned to at least one hoof from 3 horses. Of these, one had laminitis
that had progressed beyond Obel grade 2 in the short time interval between detection and
euthanasia and 2 were non-responders (including an animal with evidence of mild chronic
laminitis).

Glucose and insulin dynamics – Time effects were detected for plasma glucose (P < 0.001;
Figure 6.4A) and serum insulin (P < 0.001; Figure 6.4B). Time effects remained significant
when horses were grouped as responders and non-responders, and a group effect was detected,
which indicates that glucose concentrations were higher overall in responders (P = 0.012).

Correlations – Cytokine gene expression was positively correlated with rectal temperature, heart
rate, and respiratory rate (Table 6.3).

Positive correlations were also identified among

inflammatory cytokines (data not shown).
Within the responder group, there were no biologically significant correlations detected
between blood and tissue cytokine expression and laminitis.
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Figure 6.4 Plasma glucose and serum insulin concentrations of horses receiving either an 8-hour
LPS CRI (5 ng/kg/hr) or saline CRI, followed by administration of OF (5 g/kg). Data are
¶

expressed as geometric means and 95% CI, and are displayed on a logarithmic scale. Refers to
time effects and denotes points that are significantly different from baseline. Time effects were
detected for A) plasma glucose (P < 0.001) and B) serum insulin (P < 0.001). The vertical
dotted line denotes the time of OF administration.

190

Figure 6.4, continued.
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Table 6.3 Spearman’s rank correlation coefficients for associations among whole blood gene
expression values and physical examination parameters in horses receiving either an 8-hour LPS
CRI (5 ng/kg/hr) or saline CRI, followed by administration of OF (5 g/kg). Significance was set
at P < 0.05 and P values are displayed in parentheses.

Rectal temperature

Heart rate

Respiratory rate

Interleukin-1β

0.532
(0.001)

0.410
(0.001)

-

Interleukin-6

0.234
(0.001)

0.294
(0.001)

-

Interleukin-8

0.271
(0.001)

0.173
(0.003)

0.172
(0.003)

Interleukin-10

0.286
(0.001)

0.210
(0.001)

-

TNF-α

-

0.136
(0.017)

-
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6.4 Discussion

Systemic inflammation developed in response to LPS infusion and alimentary
carbohydrate overload in this study. The magnitude of the systemic inflammatory response to
carbohydrate overload and the incidence of laminitis were not affected by endotoxin
pretreatment, so our hypothesis was not supported. We have, however, provided evidence that
inflammatory responses in tissues such as the liver and lungs may be more severe in horses that
develop carbohydrate overload laminitis when compared to non-responders. Further studies are
needed to confirm these findings and determine the role of specific organs and inflammatory
mediators in carbohydrate overload laminitis.
Increases in rectal temperature, heart rate, and respiratory rate observed during LPS
infusion are consistent with previous studies in which LPS was administered to horses as a CRI
or single bolus, including the studies described in chapters 3 and 4.164,327 When LPS was infused
for 8 hours in a previous study, changes in physical examination variables persisted the duration
of the CRI.164 These variables were also affected by OF administration in the study reported
here, which indicates that systemic inflammation developed in response to intestinal
carbohydrate overload. Oligofructose administration at high doses has also been associated with
clinical signs of systemic inflammation.165,409 It has previously been reported that clinical signs
of systemic inflammation develop approximately 24 hours after OF administration when the
lower 5 g/kg dose is used.164,608 Diarrhea also develops after OF administration, and the timing
and duration observed in this study were consistent with previous reports.164,608 In all studies
performed to date, including this one, laminitis develops approximately 20 to 36 hours after OF
is administered at the low dosage.164,608
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Lipopolysaccharide infusion increased the expression of IL-1β, IL-6, and IL-8 in whole
blood. Although LPS administration altered the expression of TNF-α over time, and IL-10
changed over time in both groups, expression of these cytokines did not differ significantly from
baseline values in either treatment group or when responders and non-responders were
compared. Lipopolysaccharide is recognized by many cell types through the cell-surface pattern
recognition receptor Toll-like receptor 4,13 and stimulates the production of inflammatory
mediators that regulate both the innate and adaptive immune responses.7,11

The pro-

inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α have been shown to increase in response to
LPS administration in horses.269,410,506,534 It is not clear why TNF-α did not increase following
LPS infusion in this study, but the timing of measurements serves as one explanation. Tumor
necrosis factor-α peaks early in the inflammatory response and can decline rapidly within 1-2
hours, even during continuous LPS infusion.18,410,511 The method of LPS administration in this
study may also limit direct comparisons to studies in which LPS was administered as a bolus.
For instance, Nieto, et al.506 described robust increases in inflammatory cytokine gene expression
that declined substantially 3 hours after LPS was administered intravenously as a 30 ng/kg bolus.
A comparable cumulative LPS dose was delivered over 6 hours in the current study, so the lower
cytokine responses observed here reflect the slower rate of administration.

Similarly, in the

study performed by Vick, et al.,269 a higher dosage of 45 ng/kg was used.
Inflammatory gene expression results show that both LPS and intestinal carbohydrate
overload induce systemic inflammation, but there was little evidence that pretreatment with LPS
enhances the inflammatory response to carbohydrate overload.

Only AUC for IL-8 was higher

following OF administration when horses were pretreated with LPS, indicating that endotoxin
had a priming effect on the release of this cytokine. Interleukin-8 was the only cytokine that
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showed this response, so results must be interpreted with caution. However, earlier and more
pronounced expression of cytokine-induced neutrophil chemoattractant, the rat ortholog of IL-8,
has been described in primed alveolar macrophages in a rodent two-hit model.443
Consistent with other reports, peak expression of IL-1β and IL-6 occurred 20 hours
following the administration of OF, while 2 peaks in IL-8 expression were detected at 20 and 44
hours. In a previous study, TNF-α protein plasma concentrations increased12 to 24 hours after
OF was administered at a dosage of 10 g/kg.409 In addition, results reported in chapter 2 show
that IL-1β, IL-6, IL-8, and IL-10 expression increased over the 24 hours that followed OF
administration at the higher dosage.
Blood cytokine responses did not appear to differ markedly when LPS and OF
administration were compared in this study. It has been suggested that the duration of
inflammation is longer with intestinal carbohydrate overload than experimental endotoxemia
because this model is closer to cecal ligation and puncture models in rodents.613 Accordingly,
this might explain why carbohydrate overload induces laminitis whereas short-lived
inflammatory reactions to LPS do not. Lipopolysaccharide induced similar blood cytokine
expression to carbohydrate overload in this study, but laminitis did not develop before OF was
administered.164 One explanation for this finding is that factors other than inflammation are
important to the pathogenesis of laminitis, including the release of vasoactive amines from the
hindgut.375,421 Alternatively, cytokine production in circulating leukocytes may contribute less to
systemic inflammation in this model than cytokine production within tissues such as the liver and
lung.517,519,614

Serial tissue sampling would have been required to assess the duration of

inflammation in tissues, and should be considering in future studies.

Early removal of

responders could conceivably have hindered detection of prolonged cytokine expression in the
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blood following OF administration, but it is unlikely because IL-1β expression declined by 20
hours in this group and other cytokines were not significantly different from non-responders.
Endotoxin tolerance often occurs in circulating leukocytes after repeated LPS
exposures,76,448,517 and we documented this finding in the study described in chapter 3. Previous
studies have also detected endotoxin tolerance in horses.460,461 In this study, cytokine production
increased following carbohydrate overload even though LPS was administered 24 hours
beforehand. This suggests that endotoxin tolerance did not develop in the horses studied here or
that other agents stimulated the immune system during intestinal carbohydrate overload. Both
LPS and Gram-positive bacterial products are expected to escape from the gut following OF
administration. Heterotolerance between different Toll-like receptor agonists occurs,450,615 but
the variety and number of toxins escaping the intestine may stimulate multiple signalling
pathways.
Tumor necrosis factor-α gene expression did not increase in blood following
carbohydrate overload in this study despite the fact that OF administration has previously been
associated with higher TNF-α protein concentrations.409 This is consistent with our previous
findings that TNF-α gene expression failed to increase in blood following 10 g/kg OF
administration (refer to chapter 2). It is possible that organs such as the liver and lungs, rather
than circulating leukocytes, are the primary source of circulating TNF-α protein following
carbohydrate overload.

These organs are thought to be major contributors to systemic

inflammation through their release of inflammatory mediators.517,519,614

Some studies even

suggest that leukocytes are not the primary source of cytokines such as IL-6 during sepsis, and
organs are responsible for the majority of detectable protein in circulation.517 In the current
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study, expression of TNF-α was increased in 24-hour liver biopsy samples from responders,
supporting the theory that organs are the primary source of this mediator.
One important finding from this study is that responders demonstrated prolonged IL-1β
expression in the blood and increased AUC values when compared to non-responders.
Interluekin-1β is a major regulator of the innate immune response, with multiple functions
including stimulation of other cytokines and activation of neutrophils and macrophages. 18,19,511
Sepsis-associated organ failure in humans is the result of an overwhelming inflammatory
response and the excessive release of cytokines that result in endothelial injury, infiltration of
leukocytes into tissues, and ultimately parenchymal damage.21,511,616

The release of

inflammatory cytokines from distant locations is responsible for initiating this cascade, while
local mediator production plays a significant role in the later phases of organ damage. 616
Increased circulating IL-1β concentrations correlate with the severity of sepsis in humans,
although IL-1β does not appear to be a reliable predictor of mortality.511 In contrast, increased
plasma IL-1β concentrations predict mortality in humans with acute respiratory distress
syndrome,28 and show promise as a prognostic indicator for septic cats.617 The utility of IL-1β as
a prognostic indicator for laminitis in horses therefore warrants further consideration.
Perhaps the most important finding from this study is that inflammatory cytokine gene
expression increased in the liver and lungs of responders when compared to non-responders.
The liver and lungs are actively participants in the inflammatory response.517,519,614 Increased IL6, IL-8, and TNF-α expression has been detected in both liver and lung of horses during the
developmental stage of black-walnut extract-induced laminitis.427

However, the question

remains as to whether systemic inflammation is simply a comorbid condition, or directly causes
laminitis. In this study, 4 of the 5 cytokines measured were higher in liver samples from
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responders 24 hours after OF administration. This evidence of inflammation was also found in
liver samples taken at necropsy.
In the current study, cytokine expression in liver tissue was compared at 24 hours in both
groups, and both liver and lung samples were compared at the time of necropsy. Most horses in
the responder group were euthanized at approximately 24 hours, while non-responders were
euthanized at 48 hours. It is possible that differences in liver and lung gene expression between
groups at necropsy were a result of the 24-hour intervening period in non-responders. However
gene expression was compared between liver biopsy and necropsy samples from non-responders
and, with the exception of IL-8, did not change over time. Inflammatory cytokine expression
was also higher in lung tissues from responders. Although, lung biopsies at the 24-hour time
point were not performed in non-responders for logistical reasons, it is unlikely that
inflammation would have subsided by the time of necropsy, and results suggest that pulmonary
inflammation plays a role in laminitis induced by carbohydrate overload. Furthermore, in a
species such as the horse that possesses pulmonary intravascular macrophages, the lungs might
be expected to play a sizable role in the systemic inflammatory response.519 Euthanizing all
horses 24 hours following OF administration was considered, but it was decided that nonresponders should be monitored for 48 hours to ensure that laminitis did not develop at a later
time in these animals.
Histological examination of liver and lung samples supports a role for these organs in the
inflammatory response. Although findings did not differ between groups, approximately 50% of
all horses had pulmonary microthrombi. These lesions are characteristic of acute lung injury,618
although other findings consistent with this problem, including neutrophilic infiltration were not
observed. Portal inflammation was also identified in most horses following the administration of
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OF. Mixed and lymphohistiocytic portal inflammation, as well as lobular inflammation, have
been described in human patients with fatal sepsis,619 however a certain amount of inflammation
might be expected in normal horses given the role of the liver in removing gut-derived toxins
from the portal circulation. Because samples were not obtained prior to the administration of
OF, it is not possible to determine whether inflammation was already present or occurred in
response to carbohydrate overload.
Results of this study suggest that production of inflammatory mediators in tissues such as
the liver and lung may be more important to the pathogenesis of laminitis than release of
cytokines from circulating leukocytes. Compartmentalization of inflammatory response is a
common feature in sepsis.517 Opposite inflammatory responses can even be detected in different
organs within the same animal.520,620,621 Factors including local tissue microenvironment and
inherent differences in mononuclear phagocyte and endothelial cell populations contribute to
compartmentalization, and the largest discrepancies are often seen between tissues and blood.517
Leukocytes from various tissues and blood can show different responses to sepsis and two-hit
models, with decreased, enhanced, or unchanged production of inflammatory cytokines
possible.517
Expression of IL-1β, IL-6, and IL-8 was higher in laminar tissues from responders in this
study. These cytokines have previously been shown to increase in both black walnut extract and
carbohydrate overload models of laminitis,

429-431,493,622

and our results provide further support

for these mediators playing a role in the pathogenesis of laminitis. Laminar expression of IL-10
and TNF-α did not differ between responders and non-responders in this study and these
cytokines consistently remain unaffected in the laminitic hoof, suggesting that local production
of these cytokines is not important in the pathogenesis of this disease.429,430,493
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Laminar histologic scores did not agree with severity of laminitis based on clinical
assessments, and the reason for this finding is unclear. Although the exclusion criteria used in
this study only applied to horses with active laminitis or morphological evidence of past
episodes, it is unlikely that residual damage from chronic laminitis affected results of lesions
post mortem because laminar pathology differs markedly in the chronic and acute phases.623
Histological laminitis scores correlated well with clinical severity in the report that established
this scoring method, but abnormal histologic grades were also assigned to samples from 2/8
sound horses,361 so some lesions may be incidental findings. Histological scoring results in this
study suggest that subclinical laminitis developed in all animals, which significantly impacts the
concept of responders and non-responders. For the purposes of this study, laminitis was defined
by clinical signs rather than histologic score.
Glucose and insulin responses changed over time in this study, but differences were not
detected between treatment groups.

Inflammation induces IR through the release of

inflammatory cytokines and counter-regulatory hormones such as glucocorticoids and
catecholamines.91

Serum insulin concentrations typically increase to compensate for IR in

horses, but this was not observed in the current study. Glucose concentrations increased over
time, however, suggesting some loss of glycemic control. Glucose concentrations were higher
overall in responders, and may reflect a difference in the magnitude of systemic inflammation
compared to non-responders.
A certain percentage of horses fail to develop laminitis following carbohydrate overload,
with laminitis previously reported in approximately 50% of horses that receive OF at the 5 g/kg
dose.164,608 Even at higher doses, the response rate is 80 to 100% with OF administration165,409,417
and approximately 75% in the starch overload model.493,624 It is not clear why some horses
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develop laminitis whereas others do not. Studies to date suggest that the gut microflora does not
differ between laminitis-prone and normal ponies,295 but this question has not been explored
during laminitis induction models.

In horses, factors such as polymorphisms in proximal

components of the LPS signalling cascade have not explained inter-individual variability in the
response to endotoxin,625 but more work is required in this area. Recently, Leise, et al.493 found
that non-responders in a starch overload model of laminitis failed to develop a febrile response,
indicating that systemic inflammation was absent in these animals. In contrast, assessment of
physical examination parameters and blood cytokine expression in the current study indicates
that inflammation also developed in non-responders after OF administration. However, changes
in demeanor were milder in many of these animals.

It is also conceivable that local protective

mechanisms in the hoof prevent laminitis from developing in some animals, but these
mechanisms must still be identified.
One drawback of this study is the heterogeneous population of horses studied. This
approach was selected for ethical reasons to reduce the number of healthy animals euthanized for
research purposes. Although variability among animals may have decreased the power of the
study, examining a diverse group of animals allows us to extrapolate findings to the general
horse population.
We conclude that repeated inflammatory events over the course of two days do not
exacerbate the systemic inflammatory responses induced by intestinal carbohydrate overload or
increase the incidence of laminitis in horses. Our hypothesis was not supported. However, we
have demonstrated that laminitis following intestinal carbohydrate overload is associated with
the development of systemic inflammation, and results of this study suggest that inflammation in
tissues such as the liver and lungs may pose a greater risk. Future studies should assess the
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contributions of tissue-generated inflammatory mediators to the pathogenesis of laminitis. The
use of IL-1β as a prognostic indicator for the development of laminitis also warrants further
consideration.
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CHAPTER 7
Conclusions and future directions

Studies presented in this dissertation serve to further characterize the role of systemic
inflammation in the development of equine laminitis.
A series of studies were performed to test the overall hypothesis that endotoxin causes
laminitis if endotoxemia is induced in a manner that approximates naturally occurring disease, or
if predisposing factors such as obesity and insulin resistance (IR) are present.

Systemic

inflammation is a known risk factor for laminitis and it is commonly assumed that endotoxemia
is the cause of inflammation, and therefore laminitis.3 This association exists in the veterinary
literature, despite the lack of evidence linking endotoxemia with laminitis or measuring
endotoxin concentrations in clinical cases.
Laminitis often develops several days after the onset of illness, so our first study
examined the relationship between systemic inflammation and laminitis. We used a method of
quantifying gene expression in whole blood samples developed by Rainen, et al.507 to assess
systemic inflammation.

Peripheral blood is easily accessible and circulating leukocytes

continuously survey the body for signs of disease, so blood samples provide useful information
when examining inflammatory conditions.524 However, one disadvantage of using blood is that
only peripheral leukocyte responses are assessed.

Because compartmentalization of the

inflammatory response occurs, blood may not be representative of inflammation in all tissues.517
The method we used to assess cytokine responses in blood minimizes RNA degradation and
changes in the gene expression profile associated with sample collection and storage.507 An
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alternative technique would have been to isolate leukocytes from whole blood samples, which
eliminates contaminating RNA from erythrocytes and reticulocytes and increases the sensitivity
of some gene expression assays.522,523

However, leukocyte isolation must be performed

immediately after sample collection,526,527 which would not have been feasible in our studies, and
the additional processing steps can induce alterations in the gene expression profile.525 Using the
whole blood RNA isolation technique, we demonstrated that carbohydrate overload increases
expression of inflammatory cytokines and is associated with systemic inflammation.
Our second study determined whether prolonged exposure to lipopolysaccharide (LPS)
over 48 hours induced laminitis. Two LPS dosing methods were employed: continuous exposure
and intermittent bolus administration.

Amounts of LPS or other toxins entering systemic

circulation may fluctuate during the course of illness, explaining intermittent episodes of
worsening clinical condition that are sometimes observed in horses with gastrointestinal disease
or infections such as metritis. In what has been termed the “two-hit hypothesis” of organ
damage during sepsis, exposure to an initial inflammatory stimulus can prime the immune
system and cause exaggerated responses to subsequent, sometimes innocuous, stimuli.437-439
Intermittent LPS exposure might therefore be expected to exacerbate inflammation and increase
the risk of laminitis. When this hypothesis was tested, laminitis did not develop, and horses
became tolerant to endotoxin within approximately 24 hours. We can conclude from this study
that exposure to endotoxin alone does not induce laminitis, although it remains conceivable that
endotoxemia combines with other factors to initiate the events of laminitis.
Although endotoxin administered alone did not induce laminitis, it was postulated that
pre-existing conditions such as Equine Metabolic Syndrome (EMS) affect the systemic
inflammatory response.

Previous studies had only examined responses to experimental
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endotoxemia in normal horses,269,327,410,506,534 so this was the first time that horses with EMS had
been evaluated in this way. Endotoxin still did not induce laminitis in horses with EMS, but our
study yielded interesting results. Of note, peripheral leukocyte cytokine expression remained
increased for longer in horses with EMS.

This is a major finding because exaggerated

inflammation might explain why horses with EMS are predisposed to laminitis. Adipose tissue
participates in inflammatory responses,269 so future studies should also assess the contributions
of increased fat mass and abnormal adipose tissue to systemic inflammation in horses with EMS.
This could be accomplished by performing adipose tissue biopsies following the administration
of LPS in affected animals.
We also demonstrated that hepatic inflammation occurs in response to LPS
administration, although differences were not detected between normal and EMS horses. Given
the potentially important role of obesity-related liver dysfunction in systemic inflammation and
IR,109,279 additional studies are needed to characterize liver function in horses with EMS. Our
ability to detect differences between EMS and normal horses was limited by the design of the
study; serial biopsies should be performed in the future to characterize hepatic inflammation in
obese horses as systemic illness progresses.
Examination of glucose and insulin dynamics during systemic inflammation in normal
and EMS horses revealed two major findings. Although resting hyperglycemia is not a feature of
EMS,4 greater loss of glycemic control occurred in affected animals after LPS administration.
Hyperglycemia might increase the risk of laminitis by compromising the vascular
endothelium.190,572 Glucose dysregulation is often detected during the development of
experimental laminitis and it is possible that this factor contributes to the development of the
disease.164,165,608

Glycemic control in EMS horses is a potential target for therapeutic
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intervention during systemic illness, and the role of transient hyperglycemia in pastureassociated laminitis also warrants further consideration.
The second key finding from this study was that insulin sensitivity decreased over time in
horses with EMS after treatment with LPS or saline, but did not decrease after saline infusion in
normal animals. Stress hormones such as glucocorticoids and catecholamines lower insulin
sensitivity,626 and results suggest that horses with EMS are more susceptible to derangements in
glucose and insulin homeostasis under stressful conditions such as hospitalization.
One limitation of the studies involving EMS horses was that animals were part of an
intensively managed research herd, so weight loss may have normalized metabolic functions.
While this limited our ability to detect differences between groups, an interested finding
emerged. Endotoxin challenge appeared to unmask inherent differences in glucose and insulin
homeostasis and inflammatory responses among horses. This supports an underlying genetic
basis for EMS,226,246 and suggests that horses with the condition remain at risk of developing
laminitis, even after weight loss.
Our finding that systemic inflammation is accompanied by loss of glycemic control in
horses with EMS highlights the importance of focusing on microvascular function in the future.
Obesity and IR adversely affect the vascular endothelium, and endothelial dysfunction might be
greatly exacerbated during systemic illness because affected animal are prone to exaggerated
inflammatory responses and hyperglycemia. Studies should be undertaken to assess endothelial
dysfunction in horses with EMS that are experiencing systemic inflammation. These studies
should include investigations of naturally occurring EMS and experimentally induced obesity.
Lipopolysaccharide administration was not sufficient to trigger laminitis in healthy horses
or those with EMS and results of our final study make us question whether endotoxemia should
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even be considered as predisposing factor. Our research group previously reported that the
incidence and severity of laminitis tended to increase in horses pretreated with LPS prior to
oligofructose administration.164 This study was therefore repeated with the aims of examining
more horses and characterizing the systemic inflammatory response.

Our results reveal that

endotoxin pretreatment had little effect on the systemic inflammatory response induced by
intestinal carbohydrate overload. Furthermore, pretreatment with LPS failed to increase the
incidence of laminitis.

These results call into question the role of endotoxemia in the

pathogenesis of laminitis.

Although endotoxin undoubtedly contributes to systemic

inflammation in a number of common equine diseases, it neither causes laminitis when
administered alone nor predisposes horses to the disease.
Results of two of our studies confirm that systemic inflammation occurs during the
development of carbohydrate overload laminitis, as measured by blood inflammatory cytokine
expression. However, this alone does not prove that inflammation directly causes laminitis. It
was also an important finding that expression of inflammatory cytokines was higher in liver and
lung tissues from horses that developed laminitis when compared to non-responders. These
results suggest that tissues, rather than blood leukocytes, are the major source of circulating
protein because the magnitude of peripheral leukocyte responses did not show the same
association with laminitis. In addition, tumor necrosis factor-α gene expression did not increased
in peripheral leukocytes following oligofructose administration, while increases were detected in
liver tissues of responders. These tissues may therefore represent the source of circulating protein
previously reported in horses subjected to this model.409 Future studies should therefore focus on
characterizing the roles of specific organs and inflammatory mediators in carbohydrate overload
laminitis.
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Only one inflammatory cytokine, interleukin-1β, exhibited higher expression in
peripheral leukocytes of laminitis responders compared to non-responders, and its utility as a
prognostic indicator for laminitis should be evaluated.
In conclusion, we have provided evidence that systemic inflammation accompanies the
development of laminitis in horses, and that EMS exacerbates inflammatory responses.
Additionally, horses with EMS may experience greater alterations in glucose and insulin
homeostasis during systemic illness, which would be expected to increase the risk of laminitis.
Our results do not support a role for LPS as the causal agent of laminitis or for endotoxemia as a
predisposing factor for the disease. Results also suggest that tissue-generated inflammatory
mediators may be of greatest importance to the development of laminitis. These findings are
important because they provide potential targets for therapeutic intervention in animals at risk of
developing laminitis.
To further investigate these questions, a number of studies should be performed. The
first study would be designed to assess inflammatory responses to carbohydrate overload in
horses with EMS. Results to date suggest that LPS-induced inflammation is prolonged in
affected animals, and it is also possible that hepatic and adipose tissue inflammation contribute
significantly to the risk of laminitis in obese horses following intestinal carbohydrate overload.
A study should therefore be conducted in which blood and tissue inflammatory responses are
measured following carbohydrate overload in horses with EMS.
A series of studies could be performed to test the hypothesis that EMS is associated with
microvascular dysfunction, and that endothelial function is further compromised during systemic
inflammation. Techniques including in vitro evaluation of endothelium-dependent vasodilation,
assessment of microvascular blood flow, and gene expression and immunohistochemistry studies
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of adhesion molecule expression by endothelial cells could be employed to evaluated
microvascular function in digital and laminar vessels. Endothelial function should first be
assessed in horses with naturally occurring EMS and compared to normal animals following
experimental induction of obesity. Subsequently, systemic inflammation should be induced in
obese animals using LPS infusion or carbohydrate overload to evaluate the combined effects of
obesity and inflammation on the endothelium.
Finally, additional studies are indicated to elucidate the role of inflammation in organs
such as the liver and lung during laminitis. Production of inflammatory mediators in these
tissues should be evaluated at multiple time points during the onset of experimental laminitis,
and a broader panel of mediators must be examined. Although studies of naturally occurring
laminitis are logistically more difficult to perform, inflammation in organs also warrants
consideration in these cases. Additionally, the role of hepatic dysfunction in horses with EMS
requires further study.

The prevalence of hepatic lipidosis in this population could be

determined through post mortem evaluation of naturally occurring cases, and abnormal hepatic
lipid metabolism might be detected using gene expression techniques. Studies could also be
undertaken to evaluate Kupffer cell functions in horses with EMS because abnormalities such as
decreased phagocytic activity or exaggerated production of inflammatory cytokines could
increase the risk of laminitis in affected animals.
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